{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[42], line 98\u001b[0m\n\u001b[0;32m     95\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m updated_data\n\u001b[0;32m     97\u001b[0m \u001b[38;5;66;03m# Execute a simple request (no Excel file used)\u001b[39;00m\n\u001b[1;32m---> 98\u001b[0m result \u001b[38;5;241m=\u001b[39m \u001b[43mupdate_row\u001b[49m\u001b[43m(\u001b[49m\u001b[43m{\u001b[49m\u001b[43m}\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m     99\u001b[0m \u001b[38;5;28mprint\u001b[39m(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mResult:\u001b[39m\u001b[38;5;124m\"\u001b[39m, result)\n",
      "Cell \u001b[1;32mIn[42], line 67\u001b[0m, in \u001b[0;36mupdate_row\u001b[1;34m(row_dict)\u001b[0m\n\u001b[0;32m     61\u001b[0m headers \u001b[38;5;241m=\u001b[39m {\n\u001b[0;32m     62\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mAuthorization\u001b[39m\u001b[38;5;124m\"\u001b[39m: \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mBearer \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mPERPLEXITY_API_KEY\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m,\n\u001b[0;32m     63\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mContent-Type\u001b[39m\u001b[38;5;124m\"\u001b[39m: \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mapplication/json\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m     64\u001b[0m }\n\u001b[0;32m     66\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m---> 67\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[43mrequests\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mpost\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m     68\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mhttps://api.perplexity.ai/chat/completions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     69\u001b[0m \u001b[43m        \u001b[49m\u001b[43mjson\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mpayload\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     70\u001b[0m \u001b[43m        \u001b[49m\u001b[43mheaders\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mheaders\u001b[49m\n\u001b[0;32m     71\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m     72\u001b[0m     response\u001b[38;5;241m.\u001b[39mraise_for_status()\n\u001b[0;32m     73\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m requests\u001b[38;5;241m.\u001b[39mRequestException \u001b[38;5;28;01mas\u001b[39;00m e:\n",
      "File \u001b[1;32mc:\\Users\\FahRe\\AppData\\Local\\Programs\\Python\\Python39\\lib\\site-packages\\requests\\api.py:115\u001b[0m, in \u001b[0;36mpost\u001b[1;34m(url, data, json, **kwargs)\u001b[0m\n\u001b[0;32m    103\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21mpost\u001b[39m(url, data\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mNone\u001b[39;00m, json\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mNone\u001b[39;00m, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs):\n\u001b[0;32m    104\u001b[0m \u001b[38;5;250m    \u001b[39m\u001b[38;5;124mr\u001b[39m\u001b[38;5;124;03m\"\"\"Sends a POST request.\u001b[39;00m\n\u001b[0;32m    105\u001b[0m \n\u001b[0;32m    106\u001b[0m \u001b[38;5;124;03m    :param url: URL for the new :class:`Request` object.\u001b[39;00m\n\u001b[1;32m   (...)\u001b[0m\n\u001b[0;32m    112\u001b[0m \u001b[38;5;124;03m    :rtype: requests.Response\u001b[39;00m\n\u001b[0;32m    113\u001b[0m \u001b[38;5;124;03m    \"\"\"\u001b[39;00m\n\u001b[1;32m--> 115\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m request(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mpost\u001b[39m\u001b[38;5;124m\"\u001b[39m, url, data\u001b[38;5;241m=\u001b[39mdata, json\u001b[38;5;241m=\u001b[39mjson, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n",
      "File \u001b[1;32mc:\\Users\\FahRe\\AppData\\Local\\Programs\\Python\\Python39\\lib\\site-packages\\requests\\api.py:59\u001b[0m, in \u001b[0;36mrequest\u001b[1;34m(method, url, **kwargs)\u001b[0m\n\u001b[0;32m     55\u001b[0m \u001b[38;5;66;03m# By using the 'with' statement we are sure the session is closed, thus we\u001b[39;00m\n\u001b[0;32m     56\u001b[0m \u001b[38;5;66;03m# avoid leaving sockets open which can trigger a ResourceWarning in some\u001b[39;00m\n\u001b[0;32m     57\u001b[0m \u001b[38;5;66;03m# cases, and look like a memory leak in others.\u001b[39;00m\n\u001b[0;32m     58\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m sessions\u001b[38;5;241m.\u001b[39mSession() \u001b[38;5;28;01mas\u001b[39;00m session:\n\u001b[1;32m---> 59\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m session\u001b[38;5;241m.\u001b[39mrequest(method\u001b[38;5;241m=\u001b[39mmethod, url\u001b[38;5;241m=\u001b[39murl, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n",
      "File \u001b[1;32mc:\\Users\\FahRe\\AppData\\Local\\Programs\\Python\\Python39\\lib\\site-packages\\requests\\sessions.py:589\u001b[0m, in \u001b[0;36mSession.request\u001b[1;34m(self, method, url, params, data, headers, cookies, files, auth, timeout, allow_redirects, proxies, hooks, stream, verify, cert, json)\u001b[0m\n\u001b[0;32m    584\u001b[0m send_kwargs \u001b[38;5;241m=\u001b[39m {\n\u001b[0;32m    585\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mtimeout\u001b[39m\u001b[38;5;124m\"\u001b[39m: timeout,\n\u001b[0;32m    586\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mallow_redirects\u001b[39m\u001b[38;5;124m\"\u001b[39m: allow_redirects,\n\u001b[0;32m    587\u001b[0m }\n\u001b[0;32m    588\u001b[0m send_kwargs\u001b[38;5;241m.\u001b[39mupdate(settings)\n\u001b[1;32m--> 589\u001b[0m resp \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39msend(prep, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39msend_kwargs)\n\u001b[0;32m    591\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m resp\n",
      "File \u001b[1;32mc:\\Users\\FahRe\\AppData\\Local\\Programs\\Python\\Python39\\lib\\site-packages\\requests\\sessions.py:703\u001b[0m, in \u001b[0;36mSession.send\u001b[1;34m(self, request, **kwargs)\u001b[0m\n\u001b[0;32m    700\u001b[0m start \u001b[38;5;241m=\u001b[39m preferred_clock()\n\u001b[0;32m    702\u001b[0m \u001b[38;5;66;03m# Send the request\u001b[39;00m\n\u001b[1;32m--> 703\u001b[0m r \u001b[38;5;241m=\u001b[39m adapter\u001b[38;5;241m.\u001b[39msend(request, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n\u001b[0;32m    705\u001b[0m \u001b[38;5;66;03m# Total elapsed time of the request (approximately)\u001b[39;00m\n\u001b[0;32m    706\u001b[0m elapsed \u001b[38;5;241m=\u001b[39m preferred_clock() \u001b[38;5;241m-\u001b[39m start\n",
      "File \u001b[1;32mc:\\Users\\FahRe\\AppData\\Local\\Programs\\Python\\Python39\\lib\\site-packages\\requests\\adapters.py:667\u001b[0m, in \u001b[0;36mHTTPAdapter.send\u001b[1;34m(self, request, stream, timeout, verify, cert, proxies)\u001b[0m\n\u001b[0;32m    664\u001b[0m     timeout \u001b[38;5;241m=\u001b[39m TimeoutSauce(connect\u001b[38;5;241m=\u001b[39mtimeout, read\u001b[38;5;241m=\u001b[39mtimeout)\n\u001b[0;32m    666\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m--> 667\u001b[0m     resp \u001b[38;5;241m=\u001b[39m \u001b[43mconn\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43murlopen\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m    668\u001b[0m \u001b[43m        \u001b[49m\u001b[43mmethod\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mmethod\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    669\u001b[0m \u001b[43m        \u001b[49m\u001b[43murl\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43murl\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    670\u001b[0m \u001b[43m        \u001b[49m\u001b[43mbody\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mbody\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    671\u001b[0m \u001b[43m        \u001b[49m\u001b[43mheaders\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mheaders\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    672\u001b[0m \u001b[43m        \u001b[49m\u001b[43mredirect\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[0;32m    673\u001b[0m \u001b[43m        \u001b[49m\u001b[43massert_same_host\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[0;32m    674\u001b[0m \u001b[43m        \u001b[49m\u001b[43mpreload_content\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[0;32m    675\u001b[0m \u001b[43m        \u001b[49m\u001b[43mdecode_content\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[0;32m    676\u001b[0m \u001b[43m        \u001b[49m\u001b[43mretries\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mmax_retries\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    677\u001b[0m \u001b[43m        \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtimeout\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    678\u001b[0m \u001b[43m        \u001b[49m\u001b[43mchunked\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mchunked\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    679\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    681\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m (ProtocolError, \u001b[38;5;167;01mOSError\u001b[39;00m) \u001b[38;5;28;01mas\u001b[39;00m err:\n\u001b[0;32m    682\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mConnectionError\u001b[39;00m(err, request\u001b[38;5;241m=\u001b[39mrequest)\n",
      "File \u001b[1;32mc:\\Users\\FahRe\\AppData\\Local\\Programs\\Python\\Python39\\lib\\site-packages\\urllib3\\connectionpool.py:787\u001b[0m, in \u001b[0;36mHTTPConnectionPool.urlopen\u001b[1;34m(self, method, url, body, headers, retries, redirect, assert_same_host, timeout, pool_timeout, release_conn, chunked, body_pos, preload_content, decode_content, **response_kw)\u001b[0m\n\u001b[0;32m    784\u001b[0m response_conn \u001b[38;5;241m=\u001b[39m conn \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m release_conn \u001b[38;5;28;01melse\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[0;32m    786\u001b[0m \u001b[38;5;66;03m# Make the request on the HTTPConnection object\u001b[39;00m\n\u001b[1;32m--> 787\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_make_request(\n\u001b[0;32m    788\u001b[0m     conn,\n\u001b[0;32m    789\u001b[0m     method,\n\u001b[0;32m    790\u001b[0m     url,\n\u001b[0;32m    791\u001b[0m     timeout\u001b[38;5;241m=\u001b[39mtimeout_obj,\n\u001b[0;32m    792\u001b[0m     body\u001b[38;5;241m=\u001b[39mbody,\n\u001b[0;32m    793\u001b[0m     headers\u001b[38;5;241m=\u001b[39mheaders,\n\u001b[0;32m    794\u001b[0m     chunked\u001b[38;5;241m=\u001b[39mchunked,\n\u001b[0;32m    795\u001b[0m     retries\u001b[38;5;241m=\u001b[39mretries,\n\u001b[0;32m    796\u001b[0m     response_conn\u001b[38;5;241m=\u001b[39mresponse_conn,\n\u001b[0;32m    797\u001b[0m     preload_content\u001b[38;5;241m=\u001b[39mpreload_content,\n\u001b[0;32m    798\u001b[0m     decode_content\u001b[38;5;241m=\u001b[39mdecode_content,\n\u001b[0;32m    799\u001b[0m     \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mresponse_kw,\n\u001b[0;32m    800\u001b[0m )\n\u001b[0;32m    802\u001b[0m \u001b[38;5;66;03m# Everything went great!\u001b[39;00m\n\u001b[0;32m    803\u001b[0m clean_exit \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mTrue\u001b[39;00m\n",
      "File \u001b[1;32mc:\\Users\\FahRe\\AppData\\Local\\Programs\\Python\\Python39\\lib\\site-packages\\urllib3\\connectionpool.py:534\u001b[0m, in \u001b[0;36mHTTPConnectionPool._make_request\u001b[1;34m(self, conn, method, url, body, headers, retries, timeout, chunked, response_conn, preload_content, decode_content, enforce_content_length)\u001b[0m\n\u001b[0;32m    532\u001b[0m \u001b[38;5;66;03m# Receive the response from the server\u001b[39;00m\n\u001b[0;32m    533\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m--> 534\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[43mconn\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mgetresponse\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    535\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m (BaseSSLError, \u001b[38;5;167;01mOSError\u001b[39;00m) \u001b[38;5;28;01mas\u001b[39;00m e:\n\u001b[0;32m    536\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_raise_timeout(err\u001b[38;5;241m=\u001b[39me, url\u001b[38;5;241m=\u001b[39murl, timeout_value\u001b[38;5;241m=\u001b[39mread_timeout)\n",
      "File \u001b[1;32mc:\\Users\\FahRe\\AppData\\Local\\Programs\\Python\\Python39\\lib\\site-packages\\urllib3\\connection.py:516\u001b[0m, in \u001b[0;36mHTTPConnection.getresponse\u001b[1;34m(self)\u001b[0m\n\u001b[0;32m    513\u001b[0m _shutdown \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mgetattr\u001b[39m(\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39msock, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mshutdown\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;28;01mNone\u001b[39;00m)\n\u001b[0;32m    515\u001b[0m \u001b[38;5;66;03m# Get the response from http.client.HTTPConnection\u001b[39;00m\n\u001b[1;32m--> 516\u001b[0m httplib_response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43msuper\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mgetresponse\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    518\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m    519\u001b[0m     assert_header_parsing(httplib_response\u001b[38;5;241m.\u001b[39mmsg)\n",
      "File \u001b[1;32mc:\\Users\\FahRe\\AppData\\Local\\Programs\\Python\\Python39\\lib\\http\\client.py:1347\u001b[0m, in \u001b[0;36mHTTPConnection.getresponse\u001b[1;34m(self)\u001b[0m\n\u001b[0;32m   1345\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m   1346\u001b[0m     \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m-> 1347\u001b[0m         \u001b[43mresponse\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mbegin\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m   1348\u001b[0m     \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mConnectionError\u001b[39;00m:\n\u001b[0;32m   1349\u001b[0m         \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mclose()\n",
      "File \u001b[1;32mc:\\Users\\FahRe\\AppData\\Local\\Programs\\Python\\Python39\\lib\\http\\client.py:307\u001b[0m, in \u001b[0;36mHTTPResponse.begin\u001b[1;34m(self)\u001b[0m\n\u001b[0;32m    305\u001b[0m \u001b[38;5;66;03m# read until we get a non-100 response\u001b[39;00m\n\u001b[0;32m    306\u001b[0m \u001b[38;5;28;01mwhile\u001b[39;00m \u001b[38;5;28;01mTrue\u001b[39;00m:\n\u001b[1;32m--> 307\u001b[0m     version, status, reason \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_read_status\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    308\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m status \u001b[38;5;241m!=\u001b[39m CONTINUE:\n\u001b[0;32m    309\u001b[0m         \u001b[38;5;28;01mbreak\u001b[39;00m\n",
      "File \u001b[1;32mc:\\Users\\FahRe\\AppData\\Local\\Programs\\Python\\Python39\\lib\\http\\client.py:268\u001b[0m, in \u001b[0;36mHTTPResponse._read_status\u001b[1;34m(self)\u001b[0m\n\u001b[0;32m    267\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21m_read_status\u001b[39m(\u001b[38;5;28mself\u001b[39m):\n\u001b[1;32m--> 268\u001b[0m     line \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mstr\u001b[39m(\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mfp\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mreadline\u001b[49m\u001b[43m(\u001b[49m\u001b[43m_MAXLINE\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m+\u001b[39;49m\u001b[43m \u001b[49m\u001b[38;5;241;43m1\u001b[39;49m\u001b[43m)\u001b[49m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124miso-8859-1\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[0;32m    269\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mlen\u001b[39m(line) \u001b[38;5;241m>\u001b[39m _MAXLINE:\n\u001b[0;32m    270\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m LineTooLong(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mstatus line\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n",
      "File \u001b[1;32mc:\\Users\\FahRe\\AppData\\Local\\Programs\\Python\\Python39\\lib\\socket.py:704\u001b[0m, in \u001b[0;36mSocketIO.readinto\u001b[1;34m(self, b)\u001b[0m\n\u001b[0;32m    702\u001b[0m \u001b[38;5;28;01mwhile\u001b[39;00m \u001b[38;5;28;01mTrue\u001b[39;00m:\n\u001b[0;32m    703\u001b[0m     \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m--> 704\u001b[0m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_sock\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrecv_into\u001b[49m\u001b[43m(\u001b[49m\u001b[43mb\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    705\u001b[0m     \u001b[38;5;28;01mexcept\u001b[39;00m timeout:\n\u001b[0;32m    706\u001b[0m         \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_timeout_occurred \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mTrue\u001b[39;00m\n",
      "File \u001b[1;32mc:\\Users\\FahRe\\AppData\\Local\\Programs\\Python\\Python39\\lib\\ssl.py:1241\u001b[0m, in \u001b[0;36mSSLSocket.recv_into\u001b[1;34m(self, buffer, nbytes, flags)\u001b[0m\n\u001b[0;32m   1237\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m flags \u001b[38;5;241m!=\u001b[39m \u001b[38;5;241m0\u001b[39m:\n\u001b[0;32m   1238\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\n\u001b[0;32m   1239\u001b[0m           \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mnon-zero flags not allowed in calls to recv_into() on \u001b[39m\u001b[38;5;132;01m%s\u001b[39;00m\u001b[38;5;124m\"\u001b[39m \u001b[38;5;241m%\u001b[39m\n\u001b[0;32m   1240\u001b[0m           \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m\u001b[38;5;18m__class__\u001b[39m)\n\u001b[1;32m-> 1241\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mread\u001b[49m\u001b[43m(\u001b[49m\u001b[43mnbytes\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mbuffer\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m   1242\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[0;32m   1243\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28msuper\u001b[39m()\u001b[38;5;241m.\u001b[39mrecv_into(buffer, nbytes, flags)\n",
      "File \u001b[1;32mc:\\Users\\FahRe\\AppData\\Local\\Programs\\Python\\Python39\\lib\\ssl.py:1099\u001b[0m, in \u001b[0;36mSSLSocket.read\u001b[1;34m(self, len, buffer)\u001b[0m\n\u001b[0;32m   1097\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m   1098\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m buffer \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[1;32m-> 1099\u001b[0m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_sslobj\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mread\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mlen\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mbuffer\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m   1100\u001b[0m     \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[0;32m   1101\u001b[0m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_sslobj\u001b[38;5;241m.\u001b[39mread(\u001b[38;5;28mlen\u001b[39m)\n",
      "\u001b[1;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "import json\n",
    "import re\n",
    "import requests\n",
    "import yaml\n",
    "import time\n",
    "\n",
    "# Load configuration (ensure config.yaml has your Perplexity key under \"Perplexity\")\n",
    "with open(\"config.yaml\", \"r\") as file:\n",
    "    config = yaml.safe_load(file)\n",
    "\n",
    "PERPLEXITY_API_KEY = config[\"Perplexity\"]\n",
    "def robust_extract_json(response_text):\n",
    "    code_block_match = re.search(r\"```(?:json)?\\s*([\\s\\S]+?)\\s*```\", response_text)\n",
    "    if code_block_match:\n",
    "        candidate = code_block_match.group(1)\n",
    "        try:\n",
    "            return json.loads(candidate)\n",
    "        except json.JSONDecodeError:\n",
    "            pass\n",
    "    start = response_text.find(\"{\")\n",
    "    end = response_text.rfind(\"}\")\n",
    "    if start != -1 and end != -1 and end > start:\n",
    "        candidate = response_text[start:end+1]\n",
    "        try:\n",
    "            return json.loads(candidate)\n",
    "        except json.JSONDecodeError:\n",
    "            return None\n",
    "\n",
    "    return None\n",
    "\n",
    "def update_row(row_dict):\n",
    "    prompt = \"how is the weather in solothurn today?\"\n",
    "    payload = {\n",
    "        \"model\": \"sonar-reasoning-pro\",\n",
    "        \"messages\": [\n",
    "            {\n",
    "                \"role\": \"system\",\n",
    "                \"content\": \"you are very ironic and sarcastic, but you are also very helpful.\"\n",
    "            },\n",
    "            {\n",
    "                \"role\": \"user\",\n",
    "                \"content\": prompt\n",
    "            }\n",
    "        ],\n",
    "        \"max_tokens\": 1000\n",
    "    }\n",
    "    headers = { \"Authorization\": f\"Bearer {PERPLEXITY_API_KEY}\", \"Content-Type\": \"application/json\"}\n",
    "    try:\n",
    "        response = requests.post(\n",
    "            \"https://api.perplexity.ai/chat/completions\",\n",
    "            json=payload,\n",
    "            headers=headers\n",
    "        )\n",
    "        response.raise_for_status()\n",
    "    except requests.RequestException as e:\n",
    "        print(f\"Request error: {e}\")\n",
    "        return row_dict\n",
    "\n",
    "    try:\n",
    "        response_data = response.json()\n",
    "    except json.JSONDecodeError as e:\n",
    "        print(f\"JSON decode error in response: {e}\")\n",
    "        return row_dict\n",
    "\n",
    "    if \"choices\" not in response_data or not response_data[\"choices\"]:\n",
    "        print(\"No choices found in response.\")\n",
    "        return row_dict\n",
    "\n",
    "    raw_reply = response_data[\"choices\"][0][\"message\"][\"content\"]\n",
    "    print(\"Raw reply:\", raw_reply)  # For debugging\n",
    "\n",
    "    updated_data = robust_extract_json(raw_reply)\n",
    "    if updated_data is None:\n",
    "        print(\"Could not extract valid JSON; returning original data.\")\n",
    "        return row_dict\n",
    "\n",
    "    return updated_data\n",
    "\n",
    "result = update_row({})\n",
    "print(\"Result:\", result)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Processing row 1/1...\n",
      "Processing row 2/1...\n",
      "Processing row 3/1...\n",
      "Processing row 4/1...\n",
      "Processing row 5/1...\n",
      "Processing row 6/1...\n",
      "Processing row 7/1...\n",
      "Processing row 8/1...\n",
      "Processing row 9/1...\n",
      "Processing row 10/1...\n",
      "Updated data saved to updated_Pipeline_tabelle_LE2_sonar_pro_highsearch.xlsx\n"
     ]
    }
   ],
   "source": [
    "import json\n",
    "import re\n",
    "import requests\n",
    "import pandas as pd\n",
    "import time\n",
    "import yaml\n",
    "import os\n",
    "\n",
    "with open(\"config.yaml\", \"r\") as file:\n",
    "    config = yaml.safe_load(file)\n",
    "\n",
    "PERPLEXITY_API_KEY = config[\"Perplexity\"]\n",
    "def robust_extract_json(response_text):\n",
    "    code_block_match = re.search(r\"```(?:json)?\\s*([\\s\\S]+?)\\s*```\", response_text)\n",
    "    if code_block_match:\n",
    "        candidate = code_block_match.group(1)\n",
    "        try:\n",
    "            return json.loads(candidate)\n",
    "        except json.JSONDecodeError:\n",
    "            pass\n",
    "\n",
    "    start = response_text.find(\"{\")\n",
    "    end = response_text.rfind(\"}\")\n",
    "    if start != -1 and end != -1 and end > start:\n",
    "        candidate = response_text[start:end+1]\n",
    "        try:\n",
    "            return json.loads(candidate)\n",
    "        except json.JSONDecodeError:\n",
    "            return None\n",
    "\n",
    "    return None\n",
    "\n",
    "def update_row(row_dict):\n",
    "    prompt = ( \"You are an expert in verifying pharmaceutical data, especially for the German market. \"\n",
    "        \"Your task is to verify and update each field of the given row using the most current online information from reliable sources. \"\n",
    "        \"Please check every column (e.g., Therapiegebiet, Indikation, Verabreichung, Firma, Wirkstoff, Markennamen, \"\n",
    "        \"EMEA / FDA Registered, Registrierung CH erwartet im, etc.) using authoritative websites such as compendium.ch, Swissmedic, \"\n",
    "        \"and other trusted sources. \\n\\n\"\n",
    "        \"Hinweis: Die Excel-Daten sind in deutscher Sprache. Bitte nutzen Sie auch deutschsprachige Quellen, wo angebracht. \\n\\n\"\n",
    "        \"IMPORTANT: If you use any online source to verify or update a field, include the URL (source link) in the 'Website' column and make sure these URLs actually exist and not outdated. \"\n",
    "        \"If multiple sources are used, separate them with a semicolon and two blank spaces for its readablility. If no source was used or no update was made, leave the field unchanged. \\n\\n\"\n",
    "        \"Only update a field if you have confirmed new, reliable information. Otherwise, return the original value. \"\n",
    "        \"Return the updated row as a JSON object with the same keys and no additional commentary or text. \\n\\n\"\n",
    "        \"Row data:\\n\" + json.dumps(row_dict, indent=2, default=str))\n",
    "    payload = {\n",
    "        \"model\": \"sonar-pro\", # cost for 10 rows: 0.5 USD\n",
    "        \"web_search_options\": {\"search_context_size\": \"high\"},\n",
    "        \"temperature\": 0.0,\n",
    "        \n",
    "        \"messages\": [ { \"role\": \"system\",\"content\": (\n",
    "                    \"You are a highly knowledgeable and diligent expert in pharmaceutical data verification. \"\n",
    "                    \"Your role is to verify each field of the given German data using up-to-date online sources. \"\n",
    "                    \"Double-check every column, and only update fields when you are certain about the new data via your extensive research. \"\n",
    "                    \"If you cannot verify a field, return the original value. Do not include any commentary in your reply.\" )},\n",
    "            {\"role\": \"user\", \"content\": prompt }],\n",
    "        \"max_tokens\": 8000}\n",
    "\n",
    "    headers = {\"Authorization\": f\"Bearer {PERPLEXITY_API_KEY}\",\"Content-Type\": \"application/json\"}\n",
    "\n",
    "    try:\n",
    "        response = requests.post(\n",
    "            \"https://api.perplexity.ai/chat/completions\",\n",
    "            json=payload,\n",
    "            headers=headers\n",
    "        )\n",
    "        response.raise_for_status()  # Raises an HTTPError if the status is 4xx, 5xx\n",
    "    except requests.RequestException as e:\n",
    "        print(f\"Request error: {e}\")\n",
    "        return row_dict\n",
    "\n",
    "    try:\n",
    "        response_data = response.json()\n",
    "    except json.JSONDecodeError as e:\n",
    "        print(f\"JSON decode error in response: {e}\")\n",
    "        return row_dict\n",
    "\n",
    "    if \"choices\" not in response_data or not response_data[\"choices\"]:\n",
    "        print(\"No choices found in response.\")\n",
    "        return row_dict\n",
    "\n",
    "    raw_reply = response_data[\"choices\"][0][\"message\"][\"content\"]\n",
    "    #print(\"Raw reply:\", raw_reply)\n",
    "\n",
    "    updated_data = robust_extract_json(raw_reply)\n",
    "    if updated_data is None:\n",
    "        print(\"Could not extract valid JSON; returning original row.\")\n",
    "        return row_dict\n",
    "\n",
    "    return updated_data\n",
    "\n",
    "input_filename = \"Pipeline.xlsx\"\n",
    "output_filename = \"updated_Pipeline_tabelle_LE2_sonar_pro_highsearch.xlsx\"\n",
    "sheet_name = \"Tabelle für LE2 2022\"\n",
    "\n",
    "df = pd.read_excel(input_filename, sheet_name=sheet_name)\n",
    "updated_rows = []\n",
    "\n",
    "for index, row in df.head(10).iterrows():\n",
    "    row_dict = row.to_dict()\n",
    "    print(f\"Processing row {index+1}/{len(df.head(1))}...\")\n",
    "    updated_data = update_row(row_dict)\n",
    "    updated_rows.append(updated_data)\n",
    "    time.sleep(1)\n",
    "\n",
    "updated_df = pd.DataFrame(updated_rows)\n",
    "updated_df.to_excel(output_filename, index=False)\n",
    "print(f\"Updated data saved to {output_filename}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Processing row 1/264...\n",
      "Processing row 2/264...\n",
      "Processing row 3/264...\n",
      "Updated data saved to updated_data.xlsx\n"
     ]
    }
   ],
   "source": [
    "import json\n",
    "import re\n",
    "import pandas as pd\n",
    "import openai\n",
    "import time\n",
    "import os\n",
    "from openai import OpenAI\n",
    "import yaml\n",
    "\n",
    "with open(\"config.yaml\", \"r\") as file:\n",
    "    config = yaml.safe_load(file)\n",
    "\n",
    "client = OpenAI(api_key=config[\"OPENAI_KEY_TEST\"],)\n",
    "\n",
    "def extract_json(reply):\n",
    "    match = re.search(r\"```(?:json)?\\s*([\\s\\S]*?)\\s*```\", reply)\n",
    "    if match:\n",
    "        return match.group(1)\n",
    "    return reply\n",
    "\n",
    "def update_row(row_dict):\n",
    "    prompt = (\n",
    "        \"You are an expert in verifying and analyzing pharmaceutical data, specializing in identifying active pharmaceutical ingredients (Wirkstoffe) in Phase 3 clinical trials and updating pipeline products. \"\n",
    "        \"Your task is to perform a comprehensive market analysis by processing the provided Excel row and verifying its information using only trusted, reliable sources. \"\n",
    "        \"These sources include, but are not limited to, ClinicalTrials.gov, EMA, Swissmedic, FirstWord Pharma, Evaluate Pharma, Fierce Pharma, DAZ, and official manufacturer websites. \"\n",
    "        \"Focus on checking for any updates in clinical trial phases, approvals, or other key changes. \"\n",
    "        \"Add additional information if available, but do not remove any existing data. \"\n",
    "        \" Please ensure that the format of the data remains consistent, especially for dates (dd/mm/yyyy). \"\n",
    "        \"Return ONLY the updated row as a JSON object with the same keys, with no additional text or explanation. \"\n",
    "        \"For every online resource/link used, include the URL in the 'Website' column (if multiple sources are used, separate them with a '&') - moreover please in brackets give the date of the webpage like for example: wwww.pharmazie/news/acti.com (2025). \"\n",
    "        \"If no update is needed for a field, retain the original value.\\n\\n\"\n",
    "        \"Row data:\\n\" + json.dumps(row_dict, indent=2, default=str))\n",
    "    try:\n",
    "        response = client.chat.completions.create(\n",
    "            model=\"gpt-4o-mini-search-preview\",\n",
    "            messages=[\n",
    "                {\"role\": \"system\", \"content\": \"You are an expert in pharmaceutical market analysis specializing in active pharmaceutical ingredients in Phase 3 clinical trials. You verify and update pipeline product data by cross-checking reliable and trusted online sources such as ClinicalTrials.gov, EMA, Swissmedic, FirstWord Pharma, Evaluate Pharma, Fierce Pharma, DAZ, and manufacturer websites. Your analysis should be thorough, focused on current approvals and phase updates, and must rely solely on verified sources.\"},\n",
    "                {\"role\": \"user\", \"content\": prompt}\n",
    "            ],max_tokens=5000)\n",
    "        reply = response.choices[0].message.content.strip()\n",
    "        json_content = extract_json(reply)\n",
    "        try:\n",
    "            updated_row = json.loads(json_content)\n",
    "        except json.JSONDecodeError as e:\n",
    "            print(\"JSON decode error:\", e)\n",
    "            return row_dict \n",
    "        return updated_row\n",
    "\n",
    "    except Exception as e:\n",
    "        print(\"Error updating row:\", e)\n",
    "        return row_dict  \n",
    "input_filename = \"Pipeline.xlsx\"\n",
    "output_filename = \"updated_data.xlsx\"\n",
    "sheet_name = \"Tabelle für LE2 2022\"  \n",
    "df = pd.read_excel(input_filename, sheet_name=sheet_name)\n",
    "updated_rows = []\n",
    "for index, row in df.head(3).iterrows():\n",
    "    row_dict = row.to_dict()\n",
    "    print(f\"Processing row {index+1}/{len(df)}...\")\n",
    "    updated_data = update_row(row_dict)\n",
    "    updated_rows.append(updated_data)\n",
    "    time.sleep(1) \n",
    "updated_df = pd.DataFrame(updated_rows)\n",
    "updated_df.to_excel(output_filename, index=False)\n",
    "print(f\"Updated data saved to {output_filename}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [],
   "source": [
    "from openai import OpenAI\n",
    "import pandas as pd\n",
    "import json\n",
    "import os\n",
    "from utils import extract_table_from_text\n",
    "import yaml\n",
    "\n",
    "with open(\"config.yaml\", \"r\") as file:\n",
    "    config = yaml.safe_load(file)\n",
    "client = OpenAI(api_key=config[\"OPENAI_KEY_TEST\"],)\n",
    "response = client.responses.create(model=\"gpt-4o\",\n",
    "  input = [\n",
    "    {\n",
    "        \"role\": \"system\",\n",
    "        \"content\":  [\n",
    "        {\"type\": \"input_text\",\n",
    "         \"text\":\n",
    "            \"Du bist ein Assistent, der aus einem gegebenen Prompt eine Excel-Tabelle generiert und bist bei jeder Spalte und jeder Reihe sehr präzise und überprüfst deine Antwort selbständig. \"\n",
    "            \"Du kannst eine vollständige Liste aller Moleküle und deren Indikationen erstellen und repetierst dich nicht sondern überprüfst immer wieder auf die Korrektheit deiner Antwort. \"\n",
    "            \"eine FDA-Entscheidung (inklusive FDA Priority Review) erwartet wird. Die Liste soll nach Indikation \"\n",
    "            \"und erwarteten Zulassungsdatum sortiert sein und die folgenden Spalten enthalten: Brandname, Wirkstoff, \"\n",
    "            \"Produkteigenschaften, Applikationsformen (inkl. Darreichungsformen wie Pen, Fertigspritze, Filmtablette, Kapsel usw.), \"\n",
    "            \"Lagerungsbedingungen (insbesondere ob Kühlung erforderlich ist), spezielle Patientengruppen, Informationen für \"\n",
    "            \"Ärzte/Apotheken/Patienten, Wirkmechanismus, Kontraindikationen, Nebenwirkungen, Interaktionen, Schulungshinweise, \"\n",
    "            \"und zugelassene Konkurrenzprodukte und die wichtigsten Webseiten die du zur erstellung der Tabelle genommen hast (in Abständen falls mehrere).\" \n",
    "            \"Du lieferst die Antwort ausschliesslich einer geordneten Tabelle - es ist auch oke wenn du zu etwas keine Informationen findest - bitte erwähne dies aber.\"\n",
    "            \" Zudem schaust du immer wieder nach ob deine Tabelle Duplikationen enthält und entfernst diese - wir wollen keine Duplikationen in der Tabelle haben.\"\n",
    "            \"Die Tabelle soll mindestens 50 Moleküle und deren Indikationen umfassen, die im Jahr 2025 eine FDA-Entscheidung erwarten - nur die Interessanten.\"}]\n",
    "    }, {\n",
    "        \"role\": \"user\",\n",
    "        \"content\":[\n",
    "        {\n",
    "          \"type\": \"input_text\",\n",
    "          \"text\": \n",
    "            \"Erstelle vollständige Liste aller Moleküle von allen Indikationen für die im Jahr 2025 eine Entscheidung der US-amerikanischen \"\n",
    "            \"Food and Drug Administration (FDA) erwartet wird inklusive FDA Priority Review. Die Liste ist nach Indikation und erwartetem Zulassungsdatum sortiert. \"\n",
    "            \"Die Liste umfasst im Weiteren: Brandname, Wirkstoff, Produkteigenschaften, Applikationsformen (einschließlich Darreichungsformen wie Pen, Fertigspritze, \"\n",
    "            \"Filmtablette, Kapsel usw.), Lagerungsbedingungen (insbesondere ob eine Kühlung erforderlich ist), spezielle Patientengruppen, Informationen für Ärzte, \"\n",
    "            \"Apotheken und Patienten, inklusive Wirkmechanismus, Kontraindikationen, Nebenwirkungen, Interaktionen und Schulungshinweisen, zugelassene Konkurrenzprodukte, Wichtigste Webseiten.\"\n",
    "            \"Gib mir mindestens 50 Moleküle und deren Indikationen, die im Jahr 2025 eine FDA-Entscheidung erwarten, wenn bereits (heute; 8.April.2025) zugelassen oder nicht- bitte erwähne dies in einer seperaten Spalte (Zulassungsstatus). \"\n",
    "            \"Bitte liefere als Antwort ausschliesslich einer geordneten Tabelle - es ist auch oke wenn du zu etwas keine Informationen findest - bitte erwähne dies aber.\"\n",
    "            \"Bitte foukussiere dich nur auf HOCH-Interessante Moleküle und deren Indikationen - und überprüfe auch Online deren Zulassungsstatus\"}]\n",
    "    }\n",
    "],\n",
    "text={\"format\": {\"type\": \"text\"}},\n",
    "reasoning={},\n",
    "tools=[{\"type\": \"web_search_preview\",\n",
    "        \"search_context_size\": \"high\"}],\n",
    "temperature=0.1,\n",
    "max_output_tokens=12000,\n",
    "top_p=1,\n",
    "store=False\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {},
   "outputs": [],
   "source": [
    "from openai import OpenAI\n",
    "import pandas as pd\n",
    "import json\n",
    "import os\n",
    "from utils import extract_table_from_text\n",
    "import yaml\n",
    "\n",
    "with open(\"config.yaml\", \"r\") as file:\n",
    "    config = yaml.safe_load(file)\n",
    "client = OpenAI(api_key=config[\"OPENAI_KEY_TEST\"],)\n",
    "response = client.responses.create(\n",
    "    model=\"gpt-4o\",\n",
    "    input=[\n",
    "        {\n",
    "            \"role\": \"system\",\n",
    "            \"content\": [\n",
    "                {\"type\": \"input_text\",\n",
    "                 \"text\": (\n",
    "                     \"Du bist ein Experte für pharmazeutische Wirkstoffe und deren regulatorische Prozesse bei der FDA - vorallem Zulassungsdaten oder noch nicht Zulassungen müssen online nachgeschaut werden. \"\n",
    "                     \"Deine Aufgabe ist es, eine sorgfältig recherchierte, präzise und umfassende Excel-Tabelle zu erstellen. \"\n",
    "                     \"Die Tabelle enthält mindestens 50 hochinteressante Moleküle und deren Indikationen, für welche im Jahr 2025 eine Entscheidung \"\n",
    "                     \"der FDA erwartet wird (einschließlich FDA Priority Review). \"\n",
    "                     \"Die Tabelle muss strikt frei von Duplikaten sein, wobei du jeden Eintrag eigenständig auf Genauigkeit und Vollständigkeit prüfst. \"\n",
    "                     \"Sortiere die Tabelle primär nach Indikation und anschließend nach erwartetem Zulassungsdatum. Die Tabelle enthält die folgenden Spalten: \"\n",
    "                     \"Brandname, Wirkstoff, Indikation, Produkteigenschaften, Applikationsformen (inkl. Pen, Fertigspritze, Filmtablette, Kapsel etc.), \"\n",
    "                     \"Lagerungsbedingungen (insbesondere Kühlungsbedarf), spezielle Patientengruppen, Informationen für Ärzte/Apotheken/Patienten, \"\n",
    "                     \"Wirkmechanismus, Kontraindikationen, Nebenwirkungen, Interaktionen, Schulungshinweise,, aktueller Zulassungsstatus,Wichtigste Webseiten (Quelle), zugelassene Konkurrenzprodukte, \"\n",
    "                     \"Falls bestimmte Informationen nicht auffindbar sind, weise dies explizit aus.\"\n",
    "                 )}\n",
    "            ]\n",
    "        },\n",
    "        {\n",
    "            \"role\": \"user\",\n",
    "            \"content\": [\n",
    "                {\"type\": \"input_text\",\n",
    "                 \"text\": (\n",
    "                     \"Bitte erstelle eine sorgfältig recherchierte Excel-Tabelle zu mindestens 50 hochinteressanten Molekülen, deren Indikationen und zugehörigen FDA-Entscheidungen \"\n",
    "                     \"(inklusive FDA Priority Review), die im Jahr 2025 erwartet werden. Die Tabelle soll folgende Details umfassen: Brandname, Wirkstoff, Indikation, Produkteigenschaften, \"\n",
    "                     \"Applikationsformen (Pen, Fertigspritze, Filmtablette, Kapsel usw.), Lagerungsbedingungen (inkl. notwendiger Kühlung), spezielle Patientengruppen, \"\n",
    "                     \"Informationen für Ärzte, Apotheken und Patienten, Wirkmechanismus, Kontraindikationen, Nebenwirkungen, Interaktionen, Schulungshinweise, zugelassene Konkurrenzprodukte, \"\n",
    "                     \"Wichtigste Webseiten (Quellen) und den aktuellen Zulassungsstatus (Stand: 8. April 2025; zugelassen oder nicht). \"\n",
    "                     \"Sortiere die Liste nach Indikation und erwartetem Zulassungsdatum und stelle sicher, dass keinerlei Duplikate vorhanden sind. \"\n",
    "                     \"Überprüfe den Zulassungsstatus und verfügbare Informationen sorgfältig online und weise explizit darauf hin, falls bestimmte Daten nicht gefunden werden können.\"\n",
    "                 )}\n",
    "            ]\n",
    "        }\n",
    "    ],\n",
    "    text={\"format\": {\"type\": \"text\"}},\n",
    "    reasoning={},\n",
    "    tools=[{\"type\": \"web_search_preview\", \"search_context_size\": \"high\"}],\n",
    "    temperature=0,\n",
    "    max_output_tokens=12000,\n",
    "    top_p=1,\n",
    "    store=False\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Brandname</th>\n",
       "      <th>Wirkstoff</th>\n",
       "      <th>Indikation</th>\n",
       "      <th>Produkteigenschaften</th>\n",
       "      <th>Applikationsformen</th>\n",
       "      <th>Lagerungsbedingungen</th>\n",
       "      <th>Spezielle Patientengruppen</th>\n",
       "      <th>Informationen für Ärzte/Apotheken/Patienten</th>\n",
       "      <th>Wirkmechanismus</th>\n",
       "      <th>Kontraindikationen</th>\n",
       "      <th>Nebenwirkungen</th>\n",
       "      <th>Interaktionen</th>\n",
       "      <th>Schulungshinweise</th>\n",
       "      <th>Zugelassene Konkurrenzprodukte</th>\n",
       "      <th>Wichtigste Webseiten (Quelle)</th>\n",
       "      <th>Aktueller Zulassungsstatus</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>**Reproxalap**</td>\n",
       "      <td>Reproxalap</td>\n",
       "      <td>Trockene Augen</td>\n",
       "      <td>Modulator reaktiver Aldehydspezies (RASP)</td>\n",
       "      <td>Augentropfen</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Keine spezifischen Gruppen</td>\n",
       "      <td>Anwendungshinweise für Patienten</td>\n",
       "      <td>Bindet an freie Aldehyde, reduziert RASP-Level</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Augenreizung</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Anwendungstechnik</td>\n",
       "      <td>Künstliche Tränen</td>\n",
       "      <td>[Clinical Advisor](https://www.clinicaladvisor...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: 2. April 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>**Cabometyx**</td>\n",
       "      <td>Cabozantinib</td>\n",
       "      <td>Neuroendokrine Tumoren</td>\n",
       "      <td>Tyrosinkinase-Inhibitor</td>\n",
       "      <td>Tabletten</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Erwachsene und Kinder ab 12 Jahren</td>\n",
       "      <td>Dosierungsanpassungen für Kinder</td>\n",
       "      <td>Hemmt Tyrosinkinasen, reduziert Tumorwachstum</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Diarrhö, Müdigkeit</td>\n",
       "      <td>CYP3A4-Inhibitoren</td>\n",
       "      <td>Überwachung der Leberfunktion</td>\n",
       "      <td>Keine spezifischen</td>\n",
       "      <td>[Wikipedia](https://en.wikipedia.org/wiki/Cabo...</td>\n",
       "      <td>Zugelassen (März 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>**Dupixent**</td>\n",
       "      <td>Dupilumab</td>\n",
       "      <td>Chronische spontane Urtikaria</td>\n",
       "      <td>Monoklonaler Antikörper</td>\n",
       "      <td>Fertigspritze</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Ab 12 Jahren</td>\n",
       "      <td>Schulungsmaterialien für Selbstinjektion</td>\n",
       "      <td>Hemmt IL-4 und IL-13 Signalwege</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Reaktionen an der Injektionsstelle</td>\n",
       "      <td>Lebendimpfstoffe vermeiden</td>\n",
       "      <td>Selbstinjektionstechnik</td>\n",
       "      <td>Omalizumab</td>\n",
       "      <td>[Clinical Advisor](https://www.clinicaladvisor...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: 18. April 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>**Elamipretid**</td>\n",
       "      <td>Elamipretid</td>\n",
       "      <td>Barth-Syndrom</td>\n",
       "      <td>Mitochondriales Peptid</td>\n",
       "      <td>Injektion</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Ärzte</td>\n",
       "      <td>Bindet an Cardiolipin, verbessert Mitochondrie...</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Übelkeit, Kopfschmerzen</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Überwachung der Herzfunktion</td>\n",
       "      <td>Keine spezifischen</td>\n",
       "      <td>[Clinical Advisor](https://www.clinicaladvisor...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: 29. April 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>**STS101**</td>\n",
       "      <td>Dihydroergotamin</td>\n",
       "      <td>Migräne</td>\n",
       "      <td>Nasales Pulver</td>\n",
       "      <td>Nasenspray</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Patienten</td>\n",
       "      <td>Agonist an Serotoninrezeptoren</td>\n",
       "      <td>Überempfindlichkeit, Herz-Kreislauf-Erkrankungen</td>\n",
       "      <td>Übelkeit, Schwindel</td>\n",
       "      <td>CYP3A4-Inhibitoren</td>\n",
       "      <td>Anwendungstechnik</td>\n",
       "      <td>Sumatriptan</td>\n",
       "      <td>[Clinical Advisor](https://www.clinicaladvisor...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: 30. April 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>**Blujepa**</td>\n",
       "      <td>Gepotidacin</td>\n",
       "      <td>Unkomplizierte Harnwegsinfektionen</td>\n",
       "      <td>Triazaacenaphthylen-Antibiotikum</td>\n",
       "      <td>Tabletten</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Frauen ab 12 Jahren</td>\n",
       "      <td>Anwendungshinweise für Patienten</td>\n",
       "      <td>Hemmt bakterielle Topoisomerasen</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Übelkeit, Durchfall</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Einnahmehinweise</td>\n",
       "      <td>Nitrofurantoin</td>\n",
       "      <td>[Wikipedia](https://en.wikipedia.org/wiki/Gepo...</td>\n",
       "      <td>Zugelassen (März 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>**Cardamyst**</td>\n",
       "      <td>Etripamil</td>\n",
       "      <td>Paroxysmale supraventrikuläre Tachykardie</td>\n",
       "      <td>Kalziumkanalblocker</td>\n",
       "      <td>Nasenspray</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Patienten</td>\n",
       "      <td>Blockiert Kalziumkanäle, verlangsamt Herzfrequenz</td>\n",
       "      <td>Überempfindlichkeit, Hypotonie</td>\n",
       "      <td>Nasale Beschwerden, Schwindel</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Anwendungstechnik</td>\n",
       "      <td>Verapamil</td>\n",
       "      <td>[GoodRx](https://www.goodrx.com/drugs/news/upc...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: 27. März 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>**Novavax COVID-19 Vaccine**</td>\n",
       "      <td>NVX-CoV2373</td>\n",
       "      <td>COVID-19</td>\n",
       "      <td>Proteinbasierter Impfstoff</td>\n",
       "      <td>Injektion</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Impfaufklärungsmaterialien</td>\n",
       "      <td>Induziert Immunantwort gegen SARS-CoV-2</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Schmerzen an der Injektionsstelle, Müdigkeit</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Impfstoffhandhabung</td>\n",
       "      <td>mRNA-Impfstoffe</td>\n",
       "      <td>[GoodRx](https://www.goodrx.com/drugs/news/upc...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: April 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>**Gomekli**</td>\n",
       "      <td>Mirdametinib</td>\n",
       "      <td>Neurofibromatose Typ 1</td>\n",
       "      <td>MEK1/2-Inhibitor</td>\n",
       "      <td>Kapseln, Tabletten zur Suspension</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Erwachsene und Kinder ab 2 Jahren</td>\n",
       "      <td>Dosierungsanpassungen für Kinder</td>\n",
       "      <td>Hemmt MEK1/2, reduziert Tumorwachstum</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Hautausschlag, Durchfall</td>\n",
       "      <td>CYP3A4-Inhibitoren</td>\n",
       "      <td>Überwachung der Leberfunktion</td>\n",
       "      <td>Selumetinib</td>\n",
       "      <td>[Wikipedia](https://en.wikipedia.org/wiki/Mird...</td>\n",
       "      <td>Zugelassen (Februar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>**Encelto**</td>\n",
       "      <td>Revakinagene taroretcel</td>\n",
       "      <td>Makuläre Teleangiektasie Typ 2</td>\n",
       "      <td>Gentherapie</td>\n",
       "      <td>Intraokularer Implantat</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Ärzte</td>\n",
       "      <td>Expression von CNTF, schützt Photorezeptoren</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Augenreizung, Entzündung</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Chirurgische Technik</td>\n",
       "      <td>Keine spezifischen</td>\n",
       "      <td>[Wikipedia](https://en.wikipedia.org/wiki/Reva...</td>\n",
       "      <td>Zugelassen (März 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>**Datroway**</td>\n",
       "      <td>Datopotamab deruxtecan</td>\n",
       "      <td>Brustkrebs</td>\n",
       "      <td>Antikörper-Wirkstoff-Konjugat</td>\n",
       "      <td>Injektion</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Ärzte</td>\n",
       "      <td>Bindet an Trop-2, liefert Topoisomerase-Inhibitor</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Stomatitis, Übelkeit</td>\n",
       "      <td>CYP3A4-Inhibitoren</td>\n",
       "      <td>Überwachung der Leberfunktion</td>\n",
       "      <td>Trastuzumab deruxtecan</td>\n",
       "      <td>[Wikipedia](https://en.wikipedia.org/wiki/Dato...</td>\n",
       "      <td>Zugelassen (Januar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>**Journavx**</td>\n",
       "      <td>Suzetrigine</td>\n",
       "      <td>Akute Schmerzen</td>\n",
       "      <td>NaV1.8-Inhibitor</td>\n",
       "      <td>Tabletten</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Patienten</td>\n",
       "      <td>Hemmt NaV1.8, blockiert Schmerzsignale</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Juckreiz, Muskelkrämpfe</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Einnahmehinweise</td>\n",
       "      <td>Opioide</td>\n",
       "      <td>[Wikipedia](https://en.wikipedia.org/wiki/Suze...</td>\n",
       "      <td>Zugelassen (Januar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>**Brensocatib**</td>\n",
       "      <td>Brensocatib</td>\n",
       "      <td>Bronchiektasen</td>\n",
       "      <td>DPP1-Inhibitor</td>\n",
       "      <td>Tabletten</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Patienten</td>\n",
       "      <td>Hemmt DPP1, reduziert Neutrophilenaktivität</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Kopfschmerzen, Übelkeit</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Einnahmehinweise</td>\n",
       "      <td>Keine spezifischen</td>\n",
       "      <td>[COMTEX News](https://pr.comtex.com/2025/02/06...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: 12. August 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>**Ozempic**</td>\n",
       "      <td>Semaglutid</td>\n",
       "      <td>Chronische Nierenerkrankung bei Typ-2-Diabetes</td>\n",
       "      <td>GLP-1-Rezeptor-Agonist</td>\n",
       "      <td>Fertigpen</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Patienten</td>\n",
       "      <td>Stimuliert Insulinfreisetzung, reduziert Glukagon</td>\n",
       "      <td>Überempfindlichkeit, Magen-Darm-Erkrankungen</td>\n",
       "      <td>Übelkeit, Erbrechen</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Selbstinjektionstechnik</td>\n",
       "      <td>Dapagliflozin</td>\n",
       "      <td>[Becker's Hospital Review](https://www.beckers...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: Ende Januar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>**Leqembi**</td>\n",
       "      <td>Lecanemab</td>\n",
       "      <td>Alzheimer-Krankheit</td>\n",
       "      <td>Monoklonaler Antikörper</td>\n",
       "      <td>Infusion</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Ärzte</td>\n",
       "      <td>Bindet an Amyloid-Beta, reduziert Plaques</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Kopfschmerzen, ARIA</td>\n",
       "      <td>Antikoagulanzien</td>\n",
       "      <td>Überwachung auf ARIA</td>\n",
       "      <td>Aducanumab</td>\n",
       "      <td>[Becker's Hospital Review](https://www.beckers...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: 25. Januar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>**Suzetrigine**</td>\n",
       "      <td>Suzetrigine</td>\n",
       "      <td>Akute Schmerzen</td>\n",
       "      <td>NaV1.8-Inhibitor</td>\n",
       "      <td>Tabletten</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Patienten</td>\n",
       "      <td>Hemmt NaV1.8, blockiert Schmerzsignale</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Juckreiz, Muskelkrämpfe</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Einnahmehinweise</td>\n",
       "      <td>Opioide</td>\n",
       "      <td>[Becker's Hospital Review](https://www.beckers...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: 30. Januar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>**Gepotidacin**</td>\n",
       "      <td>Gepotidacin</td>\n",
       "      <td>Unkomplizierte Harnwegsinfektionen</td>\n",
       "      <td>Triazaacenaphthylen-Antibiotikum</td>\n",
       "      <td>Tabletten</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Frauen ab 12 Jahren</td>\n",
       "      <td>Anwendungshinweise für Patienten</td>\n",
       "      <td>Hemmt bakterielle Topoisomerasen</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Übelkeit, Durchfall</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Einnahmehinweise</td>\n",
       "      <td>Nitrofurantoin</td>\n",
       "      <td>[Becker's Hospital Review](https://www.beckers...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: 26. März 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>**Cardamyst**</td>\n",
       "      <td>Etripamil</td>\n",
       "      <td>Paroxysmale supraventrikuläre Tachykardie</td>\n",
       "      <td>Kalziumkanalblocker</td>\n",
       "      <td>Nasenspray</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Patienten</td>\n",
       "      <td>Blockiert Kalziumkanäle, verlangsamt Herzfrequenz</td>\n",
       "      <td>Überempfindlichkeit, Hypotonie</td>\n",
       "      <td>Nasale Beschwerden, Schwindel</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Anwendungstechnik</td>\n",
       "      <td>Verapamil</td>\n",
       "      <td>[Becker's Hospital Review](https://www.beckers...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: 27. März 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>**Novavax COVID-19 Vaccine**</td>\n",
       "      <td>NVX-CoV2373</td>\n",
       "      <td>COVID-19</td>\n",
       "      <td>Proteinbasierter Impfstoff</td>\n",
       "      <td>Injektion</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Impfaufklärungsmaterialien</td>\n",
       "      <td>Induziert Immunantwort gegen SARS-CoV-2</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Schmerzen an der Injektionsstelle, Müdigkeit</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Impfstoffhandhabung</td>\n",
       "      <td>mRNA-Impfstoffe</td>\n",
       "      <td>[Becker's Hospital Review](https://www.beckers...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: Ende April 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>**Sebetralstat**</td>\n",
       "      <td>Sebetralstat</td>\n",
       "      <td>Hereditäres Angioödem</td>\n",
       "      <td>Kallikrein-Inhibitor</td>\n",
       "      <td>Tabletten</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Ab 12 Jahren</td>\n",
       "      <td>Anwendungshinweise für Patienten</td>\n",
       "      <td>Hemmt Plasma-Kallikrein, reduziert Bradykinin</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Kopfschmerzen, Übelkeit</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Einnahmehinweise</td>\n",
       "      <td>Icatibant</td>\n",
       "      <td>[Becker's Hospital Review](https://www.beckers...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: 17. Juni 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>**Brensocatib**</td>\n",
       "      <td>Brensocatib</td>\n",
       "      <td>Bronchiektasen</td>\n",
       "      <td>DPP1-Inhibitor</td>\n",
       "      <td>Tabletten</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Patienten</td>\n",
       "      <td>Hemmt DPP1, reduziert Neutrophilenaktivität</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Kopfschmerzen, Übelkeit</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Einnahmehinweise</td>\n",
       "      <td>Keine spezifischen</td>\n",
       "      <td>[COMTEX News](https://pr.comtex.com/2025/02/06...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: 12. August 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>**Bkemv**</td>\n",
       "      <td>Eculizumab</td>\n",
       "      <td>Paroxysmale nächtliche Hämoglobinurie</td>\n",
       "      <td>Komplementinhibitor</td>\n",
       "      <td>Infusion</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Ärzte</td>\n",
       "      <td>Hemmt Komplementprotein C5</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Kopfschmerzen, Übelkeit</td>\n",
       "      <td>Lebendimpfstoffe vermeiden</td>\n",
       "      <td>Überwachung auf Infektionen</td>\n",
       "      <td>Soliris</td>\n",
       "      <td>[VeganMed](https://www.veganmed.org/post/2025-...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: März 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>**Donanemab**</td>\n",
       "      <td>Donanemab</td>\n",
       "      <td>Alzheimer-Krankheit</td>\n",
       "      <td>Monoklonaler Antikörper</td>\n",
       "      <td>Infusion</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Ärzte</td>\n",
       "      <td>Bindet an Amyloid-Beta, reduziert Plaques</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Kopfschmerzen, ARIA</td>\n",
       "      <td>Antikoagulanzien</td>\n",
       "      <td>Überwachung auf ARIA</td>\n",
       "      <td>Aducanumab</td>\n",
       "      <td>[VeganMed](https://www.veganmed.org/post/2025-...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: Anfang 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>**Tarlatamab**</td>\n",
       "      <td>Tarlatamab</td>\n",
       "      <td>Kleinzelliges Lungenkarzinom</td>\n",
       "      <td>Bispezifischer Antikörper</td>\n",
       "      <td>Infusion</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Ärzte</td>\n",
       "      <td>Bindet an DLL3 und CD3, aktiviert T-Zellen</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Zytokin-Freisetzungssyndrom</td>\n",
       "      <td>Immunsuppressiva</td>\n",
       "      <td>Überwachung auf CRS</td>\n",
       "      <td>Keine spezifischen</td>\n",
       "      <td>[VeganMed](https://www.veganmed.org/post/2025-...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: Mitte 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>**Mavorixafor**</td>\n",
       "      <td>Mavorixafor</td>\n",
       "      <td>WHIM-Syndrom</td>\n",
       "      <td>CXCR4-Antagonist</td>\n",
       "      <td>Kapseln</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Patienten</td>\n",
       "      <td>Blockiert CXCR4, erhöht Leukozytenzahl</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Übelkeit, Kopfschmerzen</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Einnahmehinweise</td>\n",
       "      <td>Keine spezifischen</td>\n",
       "      <td>[VeganMed](https://www.veganmed.org/post/2025-...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: Erstes Halbjahr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>**Elafibranor**</td>\n",
       "      <td>Elafibranor</td>\n",
       "      <td>Primär biliäre Cholangitis</td>\n",
       "      <td>PPAR-Agonist</td>\n",
       "      <td>Tabletten</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Patienten</td>\n",
       "      <td>Aktiviert PPARs, reduziert Entzündung</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Übelkeit, Müdigkeit</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Einnahmehinweise</td>\n",
       "      <td>Ursodeoxycholsäure</td>\n",
       "      <td>[VeganMed](https://www.veganmed.org/post/2025-...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: Mitte 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>**Imetelstat**</td>\n",
       "      <td>Imetelstat</td>\n",
       "      <td>Myelodysplastische Syndrome</td>\n",
       "      <td>Telomerase-Inhibitor</td>\n",
       "      <td>Infusion</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Ärzte</td>\n",
       "      <td>Hemmt Telomerase, reduziert Zellproliferation</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Müdigkeit, Thrombozytopenie</td>\n",
       "      <td>Immunsuppressiva</td>\n",
       "      <td>Überwachung des Blutbildes</td>\n",
       "      <td>Keine spezifischen</td>\n",
       "      <td>[VeganMed](https://www.veganmed.org/post/2025-...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: Zweite Jahreshä...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>**Tirzepatid**</td>\n",
       "      <td>Tirzepatid</td>\n",
       "      <td>Obstruktive Schlafapnoe</td>\n",
       "      <td>GLP-1/GIP-Rezeptor-Agonist</td>\n",
       "      <td>Fertigpen</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Patienten</td>\n",
       "      <td>Stimuliert Insulinfreisetzung, reduziert Gewicht</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Übelkeit, Erbrechen</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Selbstinjektionstechnik</td>\n",
       "      <td>Keine spezifischen</td>\n",
       "      <td>[VeganMed](https://www.veganmed.org/post/2025-...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: Ende 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>**Liraglutid**</td>\n",
       "      <td>Liraglutid</td>\n",
       "      <td>Typ-2-Diabetes und Gewichtsmanagement</td>\n",
       "      <td>GLP-1-Rezeptor-Agonist</td>\n",
       "      <td>Fertigpen</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Patienten</td>\n",
       "      <td>Stimuliert Insulinfreisetzung, reduziert Gewicht</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Übelkeit, Erbrechen</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Selbstinjektionstechnik</td>\n",
       "      <td>Saxenda</td>\n",
       "      <td>[VeganMed](https://www.veganmed.org/post/2025-...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: Ende 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>**Brexpiprazol + Sertralin**</td>\n",
       "      <td>Brexpiprazol + Sertralin</td>\n",
       "      <td>Posttraumatische Belastungsstörung</td>\n",
       "      <td>Atypisches Antipsychotikum + SSRI</td>\n",
       "      <td>Tabletten</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Ärzte</td>\n",
       "      <td>Modulation von Serotonin- und Dopaminrezeptoren</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Übelkeit, Schläfrigkeit</td>\n",
       "      <td>MAO-Hemmer</td>\n",
       "      <td>Überwachung auf Suizidgedanken</td>\n",
       "      <td>Keine spezifischen</td>\n",
       "      <td>[MPR](https://www.empr.com/news/fda-drug-appro...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: 8. Februar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>**MenABCWY-Impfstoff**</td>\n",
       "      <td>Meningokokken-Gruppen A, B, C, W, Y Impfstoff</td>\n",
       "      <td>Meningokokken-Erkrankung</td>\n",
       "      <td>Kombinationsimpfstoff</td>\n",
       "      <td>Injektion</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Ab 10 Jahren</td>\n",
       "      <td>Impfaufklärungsmaterialien</td>\n",
       "      <td>Induziert Immunantwort gegen Meningokokken</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Schmerzen an der Injektionsstelle, Fieber</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Impfstoffhandhabung</td>\n",
       "      <td>Bexsero, Menveo</td>\n",
       "      <td>[MPR](https://www.empr.com/news/fda-drug-appro...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: 14. Februar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>**CHIKV VLP**</td>\n",
       "      <td>Chikungunya-Virus-ähnliches Partikel</td>\n",
       "      <td>Chikungunya-Fieber</td>\n",
       "      <td>Virus-ähnlicher Partikel-Impfstoff</td>\n",
       "      <td>Injektion</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Ab 12 Jahren</td>\n",
       "      <td>Impfaufklärungsmaterialien</td>\n",
       "      <td>Induziert Immunantwort gegen Chikungunya-Virus</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Schmerzen an der Injektionsstelle, Fieber</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Impfstoffhandhabung</td>\n",
       "      <td>Keine spezifischen</td>\n",
       "      <td>[MPR](https://www.empr.com/news/fda-drug-appro...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: 14. Februar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>**Mirdametinib**</td>\n",
       "      <td>Mirdametinib</td>\n",
       "      <td>Neurofibromatose Typ 1</td>\n",
       "      <td>MEK1/2-Inhibitor</td>\n",
       "      <td>Kapseln, Tabletten zur Suspension</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Ab 2 Jahren</td>\n",
       "      <td>Dosierungsanpassungen für Kinder</td>\n",
       "      <td>Hemmt MEK1/2, reduziert Tumorwachstum</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Hautausschlag, Durchfall</td>\n",
       "      <td>CYP3A4-Inhibitoren</td>\n",
       "      <td>Überwachung der Leberfunktion</td>\n",
       "      <td>Selumetinib</td>\n",
       "      <td>[MPR](https://www.empr.com/news/fda-drug-appro...</td>\n",
       "      <td>Nicht zugelassen (PDUFA-Datum: 28. Februar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>**Stoboclo**</td>\n",
       "      <td>Denosumab-bmwo</td>\n",
       "      <td>Osteoporose</td>\n",
       "      <td>RANKL-Inhibitor</td>\n",
       "      <td>Injektion</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Ärzte</td>\n",
       "      <td>Hemmt RANKL, reduziert Knochenresorption</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Rückenschmerzen, Arthralgie</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Überwachung des Kalziumspiegels</td>\n",
       "      <td>Prolia</td>\n",
       "      <td>[Drugs.com](https://www.drugs.com/newdrugs.html)</td>\n",
       "      <td>Zugelassen (28. Februar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>**Osenvelt**</td>\n",
       "      <td>Denosumab-bmwo</td>\n",
       "      <td>Osteolytische Knochenläsionen</td>\n",
       "      <td>RANKL-Inhibitor</td>\n",
       "      <td>Injektion</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Ärzte</td>\n",
       "      <td>Hemmt RANKL, reduziert Knochenresorption</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Rückenschmerzen, Arthralgie</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Überwachung des Kalziumspiegels</td>\n",
       "      <td>Xgeva</td>\n",
       "      <td>[Drugs.com](https://www.drugs.com/newdrugs.html)</td>\n",
       "      <td>Zugelassen (28. Februar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>**Miudella**</td>\n",
       "      <td>Kupfer</td>\n",
       "      <td>Empfängnisverhütung</td>\n",
       "      <td>Intrauterines System</td>\n",
       "      <td>Intrauterines Gerät</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Frauen im gebärfähigen Alter</td>\n",
       "      <td>Anwendungshinweise für Ärzte</td>\n",
       "      <td>Freisetzung von Kupferionen, verhindert Befruc...</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Dysmenorrhö, Menorrhagie</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Einlage- und Entfernungstechnik</td>\n",
       "      <td>Paragard</td>\n",
       "      <td>[Drugs.com](https://www.drugs.com/newdrugs.html)</td>\n",
       "      <td>Zugelassen (24. Februar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>**Ctexli**</td>\n",
       "      <td>Chenodiol</td>\n",
       "      <td>Cerebrotendinöse Xanthomatose</td>\n",
       "      <td>Gallensäure</td>\n",
       "      <td>Tabletten</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Ärzte</td>\n",
       "      <td>Reduziert Cholesterinbiosynthese</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Durchfall, Leberfunktionsstörungen</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Überwachung der Leberfunktion</td>\n",
       "      <td>Keine spezifischen</td>\n",
       "      <td>[Drugs.com](https://www.drugs.com/newdrugs.html)</td>\n",
       "      <td>Zugelassen (21. Februar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>**Romvimza**</td>\n",
       "      <td>Vimseltinib</td>\n",
       "      <td>Tenosynoviale Riesenzelltumoren</td>\n",
       "      <td>CSF1R-Inhibitor</td>\n",
       "      <td>Kapseln</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Ärzte</td>\n",
       "      <td>Hemmt CSF1R, reduziert Tumorwachstum</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Müdigkeit, Übelkeit</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Überwachung der Leberfunktion</td>\n",
       "      <td>Pexidartinib</td>\n",
       "      <td>[Drugs.com](https://www.drugs.com/newdrugs.html)</td>\n",
       "      <td>Zugelassen (14. Februar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>**Penmenvy**</td>\n",
       "      <td>Meningokokken-Gruppen A, B, C, W, Y Impfstoff</td>\n",
       "      <td>Meningokokken-Erkrankung</td>\n",
       "      <td>Kombinationsimpfstoff</td>\n",
       "      <td>Injektion</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Ab 10 Jahren</td>\n",
       "      <td>Impfaufklärungsmaterialien</td>\n",
       "      <td>Induziert Immunantwort gegen Meningokokken</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Schmerzen an der Injektionsstelle, Fieber</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Impfstoffhandhabung</td>\n",
       "      <td>Bexsero, Menveo</td>\n",
       "      <td>[Drugs.com](https://www.drugs.com/newdrugs.html)</td>\n",
       "      <td>Zugelassen (14. Februar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>**Vimkunya**</td>\n",
       "      <td>Chikungunya-Impfstoff</td>\n",
       "      <td>Chikungunya-Fieber</td>\n",
       "      <td>Rekombinanter Impfstoff</td>\n",
       "      <td>Injektion</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Ab 12 Jahren</td>\n",
       "      <td>Impfaufklärungsmaterialien</td>\n",
       "      <td>Induziert Immunantwort gegen Chikungunya-Virus</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Schmerzen an der Injektionsstelle, Fieber</td>\n",
       "      <td>Keine signifikanten bekannt</td>\n",
       "      <td>Impfstoffhandhabung</td>\n",
       "      <td>Keine spezifischen</td>\n",
       "      <td>[Drugs.com](https://www.drugs.com/newdrugs.html)</td>\n",
       "      <td>Zugelassen (14. Februar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>**Merilog**</td>\n",
       "      <td>Insulin aspart-szjj</td>\n",
       "      <td>Diabetes mellitus</td>\n",
       "      <td>Schnell wirkendes Insulin</td>\n",
       "      <td>Injektion</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Erwachsene und Kinder</td>\n",
       "      <td>Anwendungshinweise für Patienten</td>\n",
       "      <td>Senkt Blutzuckerspiegel</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Hypoglykämie, Gewichtszunahme</td>\n",
       "      <td>Beta-Blocker</td>\n",
       "      <td>Selbstinjektionstechnik</td>\n",
       "      <td>NovoLog</td>\n",
       "      <td>[Drugs.com](https://www.drugs.com/newdrugs.html)</td>\n",
       "      <td>Zugelassen (14. Februar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>**Gomekli**</td>\n",
       "      <td>Mirdametinib</td>\n",
       "      <td>Neurofibromatose Typ 1</td>\n",
       "      <td>MEK1/2-Inhibitor</td>\n",
       "      <td>Kapseln, Tabletten zur Suspension</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Ab 2 Jahren</td>\n",
       "      <td>Dosierungsanpassungen für Kinder</td>\n",
       "      <td>Hemmt MEK1/2, reduziert Tumorwachstum</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Hautausschlag, Durchfall</td>\n",
       "      <td>CYP3A4-Inhibitoren</td>\n",
       "      <td>Überwachung der Leberfunktion</td>\n",
       "      <td>Selumetinib</td>\n",
       "      <td>[Drugs.com](https://www.drugs.com/newdrugs.html)</td>\n",
       "      <td>Zugelassen (11. Februar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>**Emblaveo**</td>\n",
       "      <td>Avibactam und Aztreonam</td>\n",
       "      <td>Komplizierte intraabdominelle Infektionen</td>\n",
       "      <td>Beta-Lactamase-Inhibitor + Monobactam</td>\n",
       "      <td>Injektion</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Ärzte</td>\n",
       "      <td>Hemmt Beta-Lactamasen, stört Zellwandsynthese</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Übelkeit, Durchfall</td>\n",
       "      <td>Probenecid</td>\n",
       "      <td>Überwachung der Nierenfunktion</td>\n",
       "      <td>Meropenem</td>\n",
       "      <td>[Drugs.com](https://www.drugs.com/newdrugs.html)</td>\n",
       "      <td>Zugelassen (7. Februar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>**Symbravo**</td>\n",
       "      <td>Meloxicam und Rizatriptan</td>\n",
       "      <td>Migräne</td>\n",
       "      <td>NSAID + Triptan</td>\n",
       "      <td>Tabletten</td>\n",
       "      <td>Raumtemperatur</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Patienten</td>\n",
       "      <td>Hemmt COX, Agonist an Serotoninrezeptoren</td>\n",
       "      <td>Überempfindlichkeit, Herz-Kreislauf-Erkrankungen</td>\n",
       "      <td>Übelkeit, Schwindel</td>\n",
       "      <td>SSRIs</td>\n",
       "      <td>Einnahmehinweise</td>\n",
       "      <td>Sumatriptan</td>\n",
       "      <td>[Drugs.com](https://www.drugs.com/newdrugs.html)</td>\n",
       "      <td>Zugelassen (30. Januar 2025)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>**Avtozma**</td>\n",
       "      <td>Tocilizumab-anoh</td>\n",
       "      <td>Rheumatoide Arthritis</td>\n",
       "      <td>IL-6-Rezeptor-Antagonist</td>\n",
       "      <td>Injektion</td>\n",
       "      <td>Kühlschrank (2-8°C)</td>\n",
       "      <td>Erwachsene</td>\n",
       "      <td>Anwendungshinweise für Ärzte</td>\n",
       "      <td>Hemmt IL-6, reduziert Entzündung</td>\n",
       "      <td>Überempfindlichkeit</td>\n",
       "      <td>Infektionen der oberen Atemwege</td>\n",
       "      <td>Lebendimpfstoffe vermeiden</td>\n",
       "      <td>Überwachung auf Infektionen</td>\n",
       "      <td>Actemra</td>\n",
       "      <td>[Drugs.com](https://www.drugs.com/newdrugs.html)</td>\n",
       "      <td>Zugelassen (24. Januar 2025)</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                       Brandname  \\\n",
       "0                 **Reproxalap**   \n",
       "1                  **Cabometyx**   \n",
       "2                   **Dupixent**   \n",
       "3                **Elamipretid**   \n",
       "4                     **STS101**   \n",
       "5                    **Blujepa**   \n",
       "6                  **Cardamyst**   \n",
       "7   **Novavax COVID-19 Vaccine**   \n",
       "8                    **Gomekli**   \n",
       "9                    **Encelto**   \n",
       "10                  **Datroway**   \n",
       "11                  **Journavx**   \n",
       "12               **Brensocatib**   \n",
       "13                   **Ozempic**   \n",
       "14                   **Leqembi**   \n",
       "15               **Suzetrigine**   \n",
       "16               **Gepotidacin**   \n",
       "17                 **Cardamyst**   \n",
       "18  **Novavax COVID-19 Vaccine**   \n",
       "19              **Sebetralstat**   \n",
       "20               **Brensocatib**   \n",
       "21                     **Bkemv**   \n",
       "22                 **Donanemab**   \n",
       "23                **Tarlatamab**   \n",
       "24               **Mavorixafor**   \n",
       "25               **Elafibranor**   \n",
       "26                **Imetelstat**   \n",
       "27                **Tirzepatid**   \n",
       "28                **Liraglutid**   \n",
       "29  **Brexpiprazol + Sertralin**   \n",
       "30        **MenABCWY-Impfstoff**   \n",
       "31                 **CHIKV VLP**   \n",
       "32              **Mirdametinib**   \n",
       "33                  **Stoboclo**   \n",
       "34                  **Osenvelt**   \n",
       "35                  **Miudella**   \n",
       "36                    **Ctexli**   \n",
       "37                  **Romvimza**   \n",
       "38                  **Penmenvy**   \n",
       "39                  **Vimkunya**   \n",
       "40                   **Merilog**   \n",
       "41                   **Gomekli**   \n",
       "42                  **Emblaveo**   \n",
       "43                  **Symbravo**   \n",
       "44                   **Avtozma**   \n",
       "\n",
       "                                        Wirkstoff  \\\n",
       "0                                      Reproxalap   \n",
       "1                                    Cabozantinib   \n",
       "2                                       Dupilumab   \n",
       "3                                     Elamipretid   \n",
       "4                                Dihydroergotamin   \n",
       "5                                     Gepotidacin   \n",
       "6                                       Etripamil   \n",
       "7                                     NVX-CoV2373   \n",
       "8                                    Mirdametinib   \n",
       "9                         Revakinagene taroretcel   \n",
       "10                         Datopotamab deruxtecan   \n",
       "11                                    Suzetrigine   \n",
       "12                                    Brensocatib   \n",
       "13                                     Semaglutid   \n",
       "14                                      Lecanemab   \n",
       "15                                    Suzetrigine   \n",
       "16                                    Gepotidacin   \n",
       "17                                      Etripamil   \n",
       "18                                    NVX-CoV2373   \n",
       "19                                   Sebetralstat   \n",
       "20                                    Brensocatib   \n",
       "21                                     Eculizumab   \n",
       "22                                      Donanemab   \n",
       "23                                     Tarlatamab   \n",
       "24                                    Mavorixafor   \n",
       "25                                    Elafibranor   \n",
       "26                                     Imetelstat   \n",
       "27                                     Tirzepatid   \n",
       "28                                     Liraglutid   \n",
       "29                       Brexpiprazol + Sertralin   \n",
       "30  Meningokokken-Gruppen A, B, C, W, Y Impfstoff   \n",
       "31           Chikungunya-Virus-ähnliches Partikel   \n",
       "32                                   Mirdametinib   \n",
       "33                                 Denosumab-bmwo   \n",
       "34                                 Denosumab-bmwo   \n",
       "35                                         Kupfer   \n",
       "36                                      Chenodiol   \n",
       "37                                    Vimseltinib   \n",
       "38  Meningokokken-Gruppen A, B, C, W, Y Impfstoff   \n",
       "39                          Chikungunya-Impfstoff   \n",
       "40                            Insulin aspart-szjj   \n",
       "41                                   Mirdametinib   \n",
       "42                        Avibactam und Aztreonam   \n",
       "43                      Meloxicam und Rizatriptan   \n",
       "44                               Tocilizumab-anoh   \n",
       "\n",
       "                                        Indikation  \\\n",
       "0                                   Trockene Augen   \n",
       "1                           Neuroendokrine Tumoren   \n",
       "2                    Chronische spontane Urtikaria   \n",
       "3                                    Barth-Syndrom   \n",
       "4                                          Migräne   \n",
       "5               Unkomplizierte Harnwegsinfektionen   \n",
       "6        Paroxysmale supraventrikuläre Tachykardie   \n",
       "7                                         COVID-19   \n",
       "8                           Neurofibromatose Typ 1   \n",
       "9                   Makuläre Teleangiektasie Typ 2   \n",
       "10                                      Brustkrebs   \n",
       "11                                 Akute Schmerzen   \n",
       "12                                  Bronchiektasen   \n",
       "13  Chronische Nierenerkrankung bei Typ-2-Diabetes   \n",
       "14                             Alzheimer-Krankheit   \n",
       "15                                 Akute Schmerzen   \n",
       "16              Unkomplizierte Harnwegsinfektionen   \n",
       "17       Paroxysmale supraventrikuläre Tachykardie   \n",
       "18                                        COVID-19   \n",
       "19                           Hereditäres Angioödem   \n",
       "20                                  Bronchiektasen   \n",
       "21           Paroxysmale nächtliche Hämoglobinurie   \n",
       "22                             Alzheimer-Krankheit   \n",
       "23                    Kleinzelliges Lungenkarzinom   \n",
       "24                                    WHIM-Syndrom   \n",
       "25                      Primär biliäre Cholangitis   \n",
       "26                     Myelodysplastische Syndrome   \n",
       "27                         Obstruktive Schlafapnoe   \n",
       "28           Typ-2-Diabetes und Gewichtsmanagement   \n",
       "29              Posttraumatische Belastungsstörung   \n",
       "30                        Meningokokken-Erkrankung   \n",
       "31                              Chikungunya-Fieber   \n",
       "32                          Neurofibromatose Typ 1   \n",
       "33                                     Osteoporose   \n",
       "34                   Osteolytische Knochenläsionen   \n",
       "35                             Empfängnisverhütung   \n",
       "36                   Cerebrotendinöse Xanthomatose   \n",
       "37                 Tenosynoviale Riesenzelltumoren   \n",
       "38                        Meningokokken-Erkrankung   \n",
       "39                              Chikungunya-Fieber   \n",
       "40                               Diabetes mellitus   \n",
       "41                          Neurofibromatose Typ 1   \n",
       "42       Komplizierte intraabdominelle Infektionen   \n",
       "43                                         Migräne   \n",
       "44                           Rheumatoide Arthritis   \n",
       "\n",
       "                         Produkteigenschaften  \\\n",
       "0   Modulator reaktiver Aldehydspezies (RASP)   \n",
       "1                     Tyrosinkinase-Inhibitor   \n",
       "2                     Monoklonaler Antikörper   \n",
       "3                      Mitochondriales Peptid   \n",
       "4                              Nasales Pulver   \n",
       "5            Triazaacenaphthylen-Antibiotikum   \n",
       "6                         Kalziumkanalblocker   \n",
       "7                  Proteinbasierter Impfstoff   \n",
       "8                            MEK1/2-Inhibitor   \n",
       "9                                 Gentherapie   \n",
       "10              Antikörper-Wirkstoff-Konjugat   \n",
       "11                           NaV1.8-Inhibitor   \n",
       "12                             DPP1-Inhibitor   \n",
       "13                     GLP-1-Rezeptor-Agonist   \n",
       "14                    Monoklonaler Antikörper   \n",
       "15                           NaV1.8-Inhibitor   \n",
       "16           Triazaacenaphthylen-Antibiotikum   \n",
       "17                        Kalziumkanalblocker   \n",
       "18                 Proteinbasierter Impfstoff   \n",
       "19                       Kallikrein-Inhibitor   \n",
       "20                             DPP1-Inhibitor   \n",
       "21                        Komplementinhibitor   \n",
       "22                    Monoklonaler Antikörper   \n",
       "23                  Bispezifischer Antikörper   \n",
       "24                           CXCR4-Antagonist   \n",
       "25                               PPAR-Agonist   \n",
       "26                       Telomerase-Inhibitor   \n",
       "27                 GLP-1/GIP-Rezeptor-Agonist   \n",
       "28                     GLP-1-Rezeptor-Agonist   \n",
       "29          Atypisches Antipsychotikum + SSRI   \n",
       "30                      Kombinationsimpfstoff   \n",
       "31         Virus-ähnlicher Partikel-Impfstoff   \n",
       "32                           MEK1/2-Inhibitor   \n",
       "33                            RANKL-Inhibitor   \n",
       "34                            RANKL-Inhibitor   \n",
       "35                       Intrauterines System   \n",
       "36                                Gallensäure   \n",
       "37                            CSF1R-Inhibitor   \n",
       "38                      Kombinationsimpfstoff   \n",
       "39                    Rekombinanter Impfstoff   \n",
       "40                  Schnell wirkendes Insulin   \n",
       "41                           MEK1/2-Inhibitor   \n",
       "42      Beta-Lactamase-Inhibitor + Monobactam   \n",
       "43                            NSAID + Triptan   \n",
       "44                   IL-6-Rezeptor-Antagonist   \n",
       "\n",
       "                   Applikationsformen Lagerungsbedingungen  \\\n",
       "0                        Augentropfen       Raumtemperatur   \n",
       "1                           Tabletten       Raumtemperatur   \n",
       "2                       Fertigspritze  Kühlschrank (2-8°C)   \n",
       "3                           Injektion  Kühlschrank (2-8°C)   \n",
       "4                          Nasenspray       Raumtemperatur   \n",
       "5                           Tabletten       Raumtemperatur   \n",
       "6                          Nasenspray       Raumtemperatur   \n",
       "7                           Injektion  Kühlschrank (2-8°C)   \n",
       "8   Kapseln, Tabletten zur Suspension       Raumtemperatur   \n",
       "9             Intraokularer Implantat  Kühlschrank (2-8°C)   \n",
       "10                          Injektion  Kühlschrank (2-8°C)   \n",
       "11                          Tabletten       Raumtemperatur   \n",
       "12                          Tabletten       Raumtemperatur   \n",
       "13                          Fertigpen  Kühlschrank (2-8°C)   \n",
       "14                           Infusion  Kühlschrank (2-8°C)   \n",
       "15                          Tabletten       Raumtemperatur   \n",
       "16                          Tabletten       Raumtemperatur   \n",
       "17                         Nasenspray       Raumtemperatur   \n",
       "18                          Injektion  Kühlschrank (2-8°C)   \n",
       "19                          Tabletten       Raumtemperatur   \n",
       "20                          Tabletten       Raumtemperatur   \n",
       "21                           Infusion  Kühlschrank (2-8°C)   \n",
       "22                           Infusion  Kühlschrank (2-8°C)   \n",
       "23                           Infusion  Kühlschrank (2-8°C)   \n",
       "24                            Kapseln       Raumtemperatur   \n",
       "25                          Tabletten       Raumtemperatur   \n",
       "26                           Infusion  Kühlschrank (2-8°C)   \n",
       "27                          Fertigpen  Kühlschrank (2-8°C)   \n",
       "28                          Fertigpen  Kühlschrank (2-8°C)   \n",
       "29                          Tabletten       Raumtemperatur   \n",
       "30                          Injektion  Kühlschrank (2-8°C)   \n",
       "31                          Injektion  Kühlschrank (2-8°C)   \n",
       "32  Kapseln, Tabletten zur Suspension       Raumtemperatur   \n",
       "33                          Injektion  Kühlschrank (2-8°C)   \n",
       "34                          Injektion  Kühlschrank (2-8°C)   \n",
       "35                Intrauterines Gerät       Raumtemperatur   \n",
       "36                          Tabletten       Raumtemperatur   \n",
       "37                            Kapseln       Raumtemperatur   \n",
       "38                          Injektion  Kühlschrank (2-8°C)   \n",
       "39                          Injektion  Kühlschrank (2-8°C)   \n",
       "40                          Injektion  Kühlschrank (2-8°C)   \n",
       "41  Kapseln, Tabletten zur Suspension       Raumtemperatur   \n",
       "42                          Injektion  Kühlschrank (2-8°C)   \n",
       "43                          Tabletten       Raumtemperatur   \n",
       "44                          Injektion  Kühlschrank (2-8°C)   \n",
       "\n",
       "            Spezielle Patientengruppen  \\\n",
       "0           Keine spezifischen Gruppen   \n",
       "1   Erwachsene und Kinder ab 12 Jahren   \n",
       "2                         Ab 12 Jahren   \n",
       "3                           Erwachsene   \n",
       "4                           Erwachsene   \n",
       "5                  Frauen ab 12 Jahren   \n",
       "6                           Erwachsene   \n",
       "7                           Erwachsene   \n",
       "8    Erwachsene und Kinder ab 2 Jahren   \n",
       "9                           Erwachsene   \n",
       "10                          Erwachsene   \n",
       "11                          Erwachsene   \n",
       "12                          Erwachsene   \n",
       "13                          Erwachsene   \n",
       "14                          Erwachsene   \n",
       "15                          Erwachsene   \n",
       "16                 Frauen ab 12 Jahren   \n",
       "17                          Erwachsene   \n",
       "18                          Erwachsene   \n",
       "19                        Ab 12 Jahren   \n",
       "20                          Erwachsene   \n",
       "21                          Erwachsene   \n",
       "22                          Erwachsene   \n",
       "23                          Erwachsene   \n",
       "24                          Erwachsene   \n",
       "25                          Erwachsene   \n",
       "26                          Erwachsene   \n",
       "27                          Erwachsene   \n",
       "28                          Erwachsene   \n",
       "29                          Erwachsene   \n",
       "30                        Ab 10 Jahren   \n",
       "31                        Ab 12 Jahren   \n",
       "32                         Ab 2 Jahren   \n",
       "33                          Erwachsene   \n",
       "34                          Erwachsene   \n",
       "35        Frauen im gebärfähigen Alter   \n",
       "36                          Erwachsene   \n",
       "37                          Erwachsene   \n",
       "38                        Ab 10 Jahren   \n",
       "39                        Ab 12 Jahren   \n",
       "40               Erwachsene und Kinder   \n",
       "41                         Ab 2 Jahren   \n",
       "42                          Erwachsene   \n",
       "43                          Erwachsene   \n",
       "44                          Erwachsene   \n",
       "\n",
       "   Informationen für Ärzte/Apotheken/Patienten  \\\n",
       "0             Anwendungshinweise für Patienten   \n",
       "1             Dosierungsanpassungen für Kinder   \n",
       "2     Schulungsmaterialien für Selbstinjektion   \n",
       "3                 Anwendungshinweise für Ärzte   \n",
       "4             Anwendungshinweise für Patienten   \n",
       "5             Anwendungshinweise für Patienten   \n",
       "6             Anwendungshinweise für Patienten   \n",
       "7                   Impfaufklärungsmaterialien   \n",
       "8             Dosierungsanpassungen für Kinder   \n",
       "9                 Anwendungshinweise für Ärzte   \n",
       "10                Anwendungshinweise für Ärzte   \n",
       "11            Anwendungshinweise für Patienten   \n",
       "12            Anwendungshinweise für Patienten   \n",
       "13            Anwendungshinweise für Patienten   \n",
       "14                Anwendungshinweise für Ärzte   \n",
       "15            Anwendungshinweise für Patienten   \n",
       "16            Anwendungshinweise für Patienten   \n",
       "17            Anwendungshinweise für Patienten   \n",
       "18                  Impfaufklärungsmaterialien   \n",
       "19            Anwendungshinweise für Patienten   \n",
       "20            Anwendungshinweise für Patienten   \n",
       "21                Anwendungshinweise für Ärzte   \n",
       "22                Anwendungshinweise für Ärzte   \n",
       "23                Anwendungshinweise für Ärzte   \n",
       "24            Anwendungshinweise für Patienten   \n",
       "25            Anwendungshinweise für Patienten   \n",
       "26                Anwendungshinweise für Ärzte   \n",
       "27            Anwendungshinweise für Patienten   \n",
       "28            Anwendungshinweise für Patienten   \n",
       "29                Anwendungshinweise für Ärzte   \n",
       "30                  Impfaufklärungsmaterialien   \n",
       "31                  Impfaufklärungsmaterialien   \n",
       "32            Dosierungsanpassungen für Kinder   \n",
       "33                Anwendungshinweise für Ärzte   \n",
       "34                Anwendungshinweise für Ärzte   \n",
       "35                Anwendungshinweise für Ärzte   \n",
       "36                Anwendungshinweise für Ärzte   \n",
       "37                Anwendungshinweise für Ärzte   \n",
       "38                  Impfaufklärungsmaterialien   \n",
       "39                  Impfaufklärungsmaterialien   \n",
       "40            Anwendungshinweise für Patienten   \n",
       "41            Dosierungsanpassungen für Kinder   \n",
       "42                Anwendungshinweise für Ärzte   \n",
       "43            Anwendungshinweise für Patienten   \n",
       "44                Anwendungshinweise für Ärzte   \n",
       "\n",
       "                                      Wirkmechanismus  \\\n",
       "0      Bindet an freie Aldehyde, reduziert RASP-Level   \n",
       "1       Hemmt Tyrosinkinasen, reduziert Tumorwachstum   \n",
       "2                     Hemmt IL-4 und IL-13 Signalwege   \n",
       "3   Bindet an Cardiolipin, verbessert Mitochondrie...   \n",
       "4                      Agonist an Serotoninrezeptoren   \n",
       "5                    Hemmt bakterielle Topoisomerasen   \n",
       "6   Blockiert Kalziumkanäle, verlangsamt Herzfrequenz   \n",
       "7             Induziert Immunantwort gegen SARS-CoV-2   \n",
       "8               Hemmt MEK1/2, reduziert Tumorwachstum   \n",
       "9        Expression von CNTF, schützt Photorezeptoren   \n",
       "10  Bindet an Trop-2, liefert Topoisomerase-Inhibitor   \n",
       "11             Hemmt NaV1.8, blockiert Schmerzsignale   \n",
       "12        Hemmt DPP1, reduziert Neutrophilenaktivität   \n",
       "13  Stimuliert Insulinfreisetzung, reduziert Glukagon   \n",
       "14          Bindet an Amyloid-Beta, reduziert Plaques   \n",
       "15             Hemmt NaV1.8, blockiert Schmerzsignale   \n",
       "16                   Hemmt bakterielle Topoisomerasen   \n",
       "17  Blockiert Kalziumkanäle, verlangsamt Herzfrequenz   \n",
       "18            Induziert Immunantwort gegen SARS-CoV-2   \n",
       "19      Hemmt Plasma-Kallikrein, reduziert Bradykinin   \n",
       "20        Hemmt DPP1, reduziert Neutrophilenaktivität   \n",
       "21                         Hemmt Komplementprotein C5   \n",
       "22          Bindet an Amyloid-Beta, reduziert Plaques   \n",
       "23         Bindet an DLL3 und CD3, aktiviert T-Zellen   \n",
       "24             Blockiert CXCR4, erhöht Leukozytenzahl   \n",
       "25              Aktiviert PPARs, reduziert Entzündung   \n",
       "26      Hemmt Telomerase, reduziert Zellproliferation   \n",
       "27   Stimuliert Insulinfreisetzung, reduziert Gewicht   \n",
       "28   Stimuliert Insulinfreisetzung, reduziert Gewicht   \n",
       "29    Modulation von Serotonin- und Dopaminrezeptoren   \n",
       "30         Induziert Immunantwort gegen Meningokokken   \n",
       "31     Induziert Immunantwort gegen Chikungunya-Virus   \n",
       "32              Hemmt MEK1/2, reduziert Tumorwachstum   \n",
       "33           Hemmt RANKL, reduziert Knochenresorption   \n",
       "34           Hemmt RANKL, reduziert Knochenresorption   \n",
       "35  Freisetzung von Kupferionen, verhindert Befruc...   \n",
       "36                   Reduziert Cholesterinbiosynthese   \n",
       "37               Hemmt CSF1R, reduziert Tumorwachstum   \n",
       "38         Induziert Immunantwort gegen Meningokokken   \n",
       "39     Induziert Immunantwort gegen Chikungunya-Virus   \n",
       "40                            Senkt Blutzuckerspiegel   \n",
       "41              Hemmt MEK1/2, reduziert Tumorwachstum   \n",
       "42      Hemmt Beta-Lactamasen, stört Zellwandsynthese   \n",
       "43          Hemmt COX, Agonist an Serotoninrezeptoren   \n",
       "44                   Hemmt IL-6, reduziert Entzündung   \n",
       "\n",
       "                                  Kontraindikationen  \\\n",
       "0                                Überempfindlichkeit   \n",
       "1                                Überempfindlichkeit   \n",
       "2                                Überempfindlichkeit   \n",
       "3                                Überempfindlichkeit   \n",
       "4   Überempfindlichkeit, Herz-Kreislauf-Erkrankungen   \n",
       "5                                Überempfindlichkeit   \n",
       "6                     Überempfindlichkeit, Hypotonie   \n",
       "7                                Überempfindlichkeit   \n",
       "8                                Überempfindlichkeit   \n",
       "9                                Überempfindlichkeit   \n",
       "10                               Überempfindlichkeit   \n",
       "11                               Überempfindlichkeit   \n",
       "12                               Überempfindlichkeit   \n",
       "13      Überempfindlichkeit, Magen-Darm-Erkrankungen   \n",
       "14                               Überempfindlichkeit   \n",
       "15                               Überempfindlichkeit   \n",
       "16                               Überempfindlichkeit   \n",
       "17                    Überempfindlichkeit, Hypotonie   \n",
       "18                               Überempfindlichkeit   \n",
       "19                               Überempfindlichkeit   \n",
       "20                               Überempfindlichkeit   \n",
       "21                               Überempfindlichkeit   \n",
       "22                               Überempfindlichkeit   \n",
       "23                               Überempfindlichkeit   \n",
       "24                               Überempfindlichkeit   \n",
       "25                               Überempfindlichkeit   \n",
       "26                               Überempfindlichkeit   \n",
       "27                               Überempfindlichkeit   \n",
       "28                               Überempfindlichkeit   \n",
       "29                               Überempfindlichkeit   \n",
       "30                               Überempfindlichkeit   \n",
       "31                               Überempfindlichkeit   \n",
       "32                               Überempfindlichkeit   \n",
       "33                               Überempfindlichkeit   \n",
       "34                               Überempfindlichkeit   \n",
       "35                               Überempfindlichkeit   \n",
       "36                               Überempfindlichkeit   \n",
       "37                               Überempfindlichkeit   \n",
       "38                               Überempfindlichkeit   \n",
       "39                               Überempfindlichkeit   \n",
       "40                               Überempfindlichkeit   \n",
       "41                               Überempfindlichkeit   \n",
       "42                               Überempfindlichkeit   \n",
       "43  Überempfindlichkeit, Herz-Kreislauf-Erkrankungen   \n",
       "44                               Überempfindlichkeit   \n",
       "\n",
       "                                  Nebenwirkungen                Interaktionen  \\\n",
       "0                                   Augenreizung  Keine signifikanten bekannt   \n",
       "1                             Diarrhö, Müdigkeit           CYP3A4-Inhibitoren   \n",
       "2             Reaktionen an der Injektionsstelle   Lebendimpfstoffe vermeiden   \n",
       "3                        Übelkeit, Kopfschmerzen  Keine signifikanten bekannt   \n",
       "4                            Übelkeit, Schwindel           CYP3A4-Inhibitoren   \n",
       "5                            Übelkeit, Durchfall  Keine signifikanten bekannt   \n",
       "6                  Nasale Beschwerden, Schwindel  Keine signifikanten bekannt   \n",
       "7   Schmerzen an der Injektionsstelle, Müdigkeit  Keine signifikanten bekannt   \n",
       "8                       Hautausschlag, Durchfall           CYP3A4-Inhibitoren   \n",
       "9                       Augenreizung, Entzündung  Keine signifikanten bekannt   \n",
       "10                          Stomatitis, Übelkeit           CYP3A4-Inhibitoren   \n",
       "11                       Juckreiz, Muskelkrämpfe  Keine signifikanten bekannt   \n",
       "12                       Kopfschmerzen, Übelkeit  Keine signifikanten bekannt   \n",
       "13                           Übelkeit, Erbrechen  Keine signifikanten bekannt   \n",
       "14                           Kopfschmerzen, ARIA             Antikoagulanzien   \n",
       "15                       Juckreiz, Muskelkrämpfe  Keine signifikanten bekannt   \n",
       "16                           Übelkeit, Durchfall  Keine signifikanten bekannt   \n",
       "17                 Nasale Beschwerden, Schwindel  Keine signifikanten bekannt   \n",
       "18  Schmerzen an der Injektionsstelle, Müdigkeit  Keine signifikanten bekannt   \n",
       "19                       Kopfschmerzen, Übelkeit  Keine signifikanten bekannt   \n",
       "20                       Kopfschmerzen, Übelkeit  Keine signifikanten bekannt   \n",
       "21                       Kopfschmerzen, Übelkeit   Lebendimpfstoffe vermeiden   \n",
       "22                           Kopfschmerzen, ARIA             Antikoagulanzien   \n",
       "23                   Zytokin-Freisetzungssyndrom             Immunsuppressiva   \n",
       "24                       Übelkeit, Kopfschmerzen  Keine signifikanten bekannt   \n",
       "25                           Übelkeit, Müdigkeit  Keine signifikanten bekannt   \n",
       "26                   Müdigkeit, Thrombozytopenie             Immunsuppressiva   \n",
       "27                           Übelkeit, Erbrechen  Keine signifikanten bekannt   \n",
       "28                           Übelkeit, Erbrechen  Keine signifikanten bekannt   \n",
       "29                       Übelkeit, Schläfrigkeit                   MAO-Hemmer   \n",
       "30     Schmerzen an der Injektionsstelle, Fieber  Keine signifikanten bekannt   \n",
       "31     Schmerzen an der Injektionsstelle, Fieber  Keine signifikanten bekannt   \n",
       "32                      Hautausschlag, Durchfall           CYP3A4-Inhibitoren   \n",
       "33                   Rückenschmerzen, Arthralgie  Keine signifikanten bekannt   \n",
       "34                   Rückenschmerzen, Arthralgie  Keine signifikanten bekannt   \n",
       "35                      Dysmenorrhö, Menorrhagie  Keine signifikanten bekannt   \n",
       "36            Durchfall, Leberfunktionsstörungen  Keine signifikanten bekannt   \n",
       "37                           Müdigkeit, Übelkeit  Keine signifikanten bekannt   \n",
       "38     Schmerzen an der Injektionsstelle, Fieber  Keine signifikanten bekannt   \n",
       "39     Schmerzen an der Injektionsstelle, Fieber  Keine signifikanten bekannt   \n",
       "40                 Hypoglykämie, Gewichtszunahme                 Beta-Blocker   \n",
       "41                      Hautausschlag, Durchfall           CYP3A4-Inhibitoren   \n",
       "42                           Übelkeit, Durchfall                   Probenecid   \n",
       "43                           Übelkeit, Schwindel                        SSRIs   \n",
       "44               Infektionen der oberen Atemwege   Lebendimpfstoffe vermeiden   \n",
       "\n",
       "                  Schulungshinweise Zugelassene Konkurrenzprodukte  \\\n",
       "0                 Anwendungstechnik              Künstliche Tränen   \n",
       "1     Überwachung der Leberfunktion             Keine spezifischen   \n",
       "2           Selbstinjektionstechnik                     Omalizumab   \n",
       "3      Überwachung der Herzfunktion             Keine spezifischen   \n",
       "4                 Anwendungstechnik                    Sumatriptan   \n",
       "5                  Einnahmehinweise                 Nitrofurantoin   \n",
       "6                 Anwendungstechnik                      Verapamil   \n",
       "7               Impfstoffhandhabung                mRNA-Impfstoffe   \n",
       "8     Überwachung der Leberfunktion                    Selumetinib   \n",
       "9              Chirurgische Technik             Keine spezifischen   \n",
       "10    Überwachung der Leberfunktion         Trastuzumab deruxtecan   \n",
       "11                 Einnahmehinweise                        Opioide   \n",
       "12                 Einnahmehinweise             Keine spezifischen   \n",
       "13          Selbstinjektionstechnik                  Dapagliflozin   \n",
       "14             Überwachung auf ARIA                     Aducanumab   \n",
       "15                 Einnahmehinweise                        Opioide   \n",
       "16                 Einnahmehinweise                 Nitrofurantoin   \n",
       "17                Anwendungstechnik                      Verapamil   \n",
       "18              Impfstoffhandhabung                mRNA-Impfstoffe   \n",
       "19                 Einnahmehinweise                      Icatibant   \n",
       "20                 Einnahmehinweise             Keine spezifischen   \n",
       "21      Überwachung auf Infektionen                        Soliris   \n",
       "22             Überwachung auf ARIA                     Aducanumab   \n",
       "23              Überwachung auf CRS             Keine spezifischen   \n",
       "24                 Einnahmehinweise             Keine spezifischen   \n",
       "25                 Einnahmehinweise             Ursodeoxycholsäure   \n",
       "26       Überwachung des Blutbildes             Keine spezifischen   \n",
       "27          Selbstinjektionstechnik             Keine spezifischen   \n",
       "28          Selbstinjektionstechnik                        Saxenda   \n",
       "29   Überwachung auf Suizidgedanken             Keine spezifischen   \n",
       "30              Impfstoffhandhabung                Bexsero, Menveo   \n",
       "31              Impfstoffhandhabung             Keine spezifischen   \n",
       "32    Überwachung der Leberfunktion                    Selumetinib   \n",
       "33  Überwachung des Kalziumspiegels                         Prolia   \n",
       "34  Überwachung des Kalziumspiegels                          Xgeva   \n",
       "35  Einlage- und Entfernungstechnik                       Paragard   \n",
       "36    Überwachung der Leberfunktion             Keine spezifischen   \n",
       "37    Überwachung der Leberfunktion                   Pexidartinib   \n",
       "38              Impfstoffhandhabung                Bexsero, Menveo   \n",
       "39              Impfstoffhandhabung             Keine spezifischen   \n",
       "40          Selbstinjektionstechnik                        NovoLog   \n",
       "41    Überwachung der Leberfunktion                    Selumetinib   \n",
       "42   Überwachung der Nierenfunktion                      Meropenem   \n",
       "43                 Einnahmehinweise                    Sumatriptan   \n",
       "44      Überwachung auf Infektionen                        Actemra   \n",
       "\n",
       "                        Wichtigste Webseiten (Quelle)  \\\n",
       "0   [Clinical Advisor](https://www.clinicaladvisor...   \n",
       "1   [Wikipedia](https://en.wikipedia.org/wiki/Cabo...   \n",
       "2   [Clinical Advisor](https://www.clinicaladvisor...   \n",
       "3   [Clinical Advisor](https://www.clinicaladvisor...   \n",
       "4   [Clinical Advisor](https://www.clinicaladvisor...   \n",
       "5   [Wikipedia](https://en.wikipedia.org/wiki/Gepo...   \n",
       "6   [GoodRx](https://www.goodrx.com/drugs/news/upc...   \n",
       "7   [GoodRx](https://www.goodrx.com/drugs/news/upc...   \n",
       "8   [Wikipedia](https://en.wikipedia.org/wiki/Mird...   \n",
       "9   [Wikipedia](https://en.wikipedia.org/wiki/Reva...   \n",
       "10  [Wikipedia](https://en.wikipedia.org/wiki/Dato...   \n",
       "11  [Wikipedia](https://en.wikipedia.org/wiki/Suze...   \n",
       "12  [COMTEX News](https://pr.comtex.com/2025/02/06...   \n",
       "13  [Becker's Hospital Review](https://www.beckers...   \n",
       "14  [Becker's Hospital Review](https://www.beckers...   \n",
       "15  [Becker's Hospital Review](https://www.beckers...   \n",
       "16  [Becker's Hospital Review](https://www.beckers...   \n",
       "17  [Becker's Hospital Review](https://www.beckers...   \n",
       "18  [Becker's Hospital Review](https://www.beckers...   \n",
       "19  [Becker's Hospital Review](https://www.beckers...   \n",
       "20  [COMTEX News](https://pr.comtex.com/2025/02/06...   \n",
       "21  [VeganMed](https://www.veganmed.org/post/2025-...   \n",
       "22  [VeganMed](https://www.veganmed.org/post/2025-...   \n",
       "23  [VeganMed](https://www.veganmed.org/post/2025-...   \n",
       "24  [VeganMed](https://www.veganmed.org/post/2025-...   \n",
       "25  [VeganMed](https://www.veganmed.org/post/2025-...   \n",
       "26  [VeganMed](https://www.veganmed.org/post/2025-...   \n",
       "27  [VeganMed](https://www.veganmed.org/post/2025-...   \n",
       "28  [VeganMed](https://www.veganmed.org/post/2025-...   \n",
       "29  [MPR](https://www.empr.com/news/fda-drug-appro...   \n",
       "30  [MPR](https://www.empr.com/news/fda-drug-appro...   \n",
       "31  [MPR](https://www.empr.com/news/fda-drug-appro...   \n",
       "32  [MPR](https://www.empr.com/news/fda-drug-appro...   \n",
       "33   [Drugs.com](https://www.drugs.com/newdrugs.html)   \n",
       "34   [Drugs.com](https://www.drugs.com/newdrugs.html)   \n",
       "35   [Drugs.com](https://www.drugs.com/newdrugs.html)   \n",
       "36   [Drugs.com](https://www.drugs.com/newdrugs.html)   \n",
       "37   [Drugs.com](https://www.drugs.com/newdrugs.html)   \n",
       "38   [Drugs.com](https://www.drugs.com/newdrugs.html)   \n",
       "39   [Drugs.com](https://www.drugs.com/newdrugs.html)   \n",
       "40   [Drugs.com](https://www.drugs.com/newdrugs.html)   \n",
       "41   [Drugs.com](https://www.drugs.com/newdrugs.html)   \n",
       "42   [Drugs.com](https://www.drugs.com/newdrugs.html)   \n",
       "43   [Drugs.com](https://www.drugs.com/newdrugs.html)   \n",
       "44   [Drugs.com](https://www.drugs.com/newdrugs.html)   \n",
       "\n",
       "                           Aktueller Zulassungsstatus  \n",
       "0       Nicht zugelassen (PDUFA-Datum: 2. April 2025)  \n",
       "1                              Zugelassen (März 2025)  \n",
       "2      Nicht zugelassen (PDUFA-Datum: 18. April 2025)  \n",
       "3      Nicht zugelassen (PDUFA-Datum: 29. April 2025)  \n",
       "4      Nicht zugelassen (PDUFA-Datum: 30. April 2025)  \n",
       "5                              Zugelassen (März 2025)  \n",
       "6       Nicht zugelassen (PDUFA-Datum: 27. März 2025)  \n",
       "7          Nicht zugelassen (PDUFA-Datum: April 2025)  \n",
       "8                           Zugelassen (Februar 2025)  \n",
       "9                              Zugelassen (März 2025)  \n",
       "10                           Zugelassen (Januar 2025)  \n",
       "11                           Zugelassen (Januar 2025)  \n",
       "12    Nicht zugelassen (PDUFA-Datum: 12. August 2025)  \n",
       "13   Nicht zugelassen (PDUFA-Datum: Ende Januar 2025)  \n",
       "14    Nicht zugelassen (PDUFA-Datum: 25. Januar 2025)  \n",
       "15    Nicht zugelassen (PDUFA-Datum: 30. Januar 2025)  \n",
       "16      Nicht zugelassen (PDUFA-Datum: 26. März 2025)  \n",
       "17      Nicht zugelassen (PDUFA-Datum: 27. März 2025)  \n",
       "18    Nicht zugelassen (PDUFA-Datum: Ende April 2025)  \n",
       "19      Nicht zugelassen (PDUFA-Datum: 17. Juni 2025)  \n",
       "20    Nicht zugelassen (PDUFA-Datum: 12. August 2025)  \n",
       "21          Nicht zugelassen (PDUFA-Datum: März 2025)  \n",
       "22        Nicht zugelassen (PDUFA-Datum: Anfang 2025)  \n",
       "23         Nicht zugelassen (PDUFA-Datum: Mitte 2025)  \n",
       "24  Nicht zugelassen (PDUFA-Datum: Erstes Halbjahr...  \n",
       "25         Nicht zugelassen (PDUFA-Datum: Mitte 2025)  \n",
       "26  Nicht zugelassen (PDUFA-Datum: Zweite Jahreshä...  \n",
       "27          Nicht zugelassen (PDUFA-Datum: Ende 2025)  \n",
       "28          Nicht zugelassen (PDUFA-Datum: Ende 2025)  \n",
       "29    Nicht zugelassen (PDUFA-Datum: 8. Februar 2025)  \n",
       "30   Nicht zugelassen (PDUFA-Datum: 14. Februar 2025)  \n",
       "31   Nicht zugelassen (PDUFA-Datum: 14. Februar 2025)  \n",
       "32   Nicht zugelassen (PDUFA-Datum: 28. Februar 2025)  \n",
       "33                      Zugelassen (28. Februar 2025)  \n",
       "34                      Zugelassen (28. Februar 2025)  \n",
       "35                      Zugelassen (24. Februar 2025)  \n",
       "36                      Zugelassen (21. Februar 2025)  \n",
       "37                      Zugelassen (14. Februar 2025)  \n",
       "38                      Zugelassen (14. Februar 2025)  \n",
       "39                      Zugelassen (14. Februar 2025)  \n",
       "40                      Zugelassen (14. Februar 2025)  \n",
       "41                      Zugelassen (11. Februar 2025)  \n",
       "42                       Zugelassen (7. Februar 2025)  \n",
       "43                       Zugelassen (30. Januar 2025)  \n",
       "44                       Zugelassen (24. Januar 2025)  "
      ]
     },
     "execution_count": 71,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from utils import extract_table_from_text\n",
    "df = extract_table_from_text(response.output_text)\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(45, 16)\n",
      "(41, 16)\n"
     ]
    }
   ],
   "source": [
    "# drop duplicates\n",
    "df = df.drop_duplicates(subset=[\"Brandname\", \"Wirkstoff\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [],
   "source": [
    "df\n",
    "# save to excel\n",
    "df.to_excel(\"output6.xlsx\", index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "import yaml\n",
    "from pydantic import BaseModel\n",
    "from typing import List, Optional\n",
    "\n",
    "from typing import List\n",
    "from pydantic import BaseModel\n",
    "\n",
    "class AnswerFormat(BaseModel):\n",
    "    brand_name: str\n",
    "    active_ingredient: str\n",
    "    therapy_area: str\n",
    "    indication: str\n",
    "    product_properties: str\n",
    "    application_forms: List[str]\n",
    "    storage_conditions: str\n",
    "    special_patient_groups: Optional[str]\n",
    "    information_for_doctors: str\n",
    "    information_for_pharmacies: str\n",
    "    information_for_patients: str\n",
    "    mechanism_of_action: str\n",
    "    contraindications: str\n",
    "    side_effects: str\n",
    "    interactions: str\n",
    "    training_notes: str\n",
    "    approved_competitor_products: List[str]\n",
    "    important_websites: List[str]\n",
    "    current_approval_status: str\n",
    "    expected_approval_date: Optional[str]\n",
    "\n",
    "class MoleculeList(BaseModel):\n",
    "    molecules: List[AnswerFormat]\n",
    "\n",
    "\n",
    "    \n",
    "with open(\"config.yaml\", \"r\") as file:\n",
    "    config = yaml.safe_load(file)\n",
    "token = config[\"Perplexity\"]\n",
    "url = \"https://api.perplexity.ai/chat/completions\"\n",
    "\n",
    "payload = {\n",
    "    \"model\": \"sonar-deep-research\",  # sonar #sonar-deep-research\n",
    "    \"messages\": [\n",
    "        {\n",
    "            \"role\": \"user\",\n",
    "            \"content\": (\n",
    "                \"Bitte erstelle eine sorgfältig recherchierte Tabelle mit mindestens 10 hochinteressanten Molekülen, deren Indikationen und zugehörigen FDA-Entscheidungen \"\n",
    "                \"(inklusive FDA Priority Review), die im Jahr 2025 erwartet werden. Die Tabelle soll folgende Details umfassen:\"\n",
    "                \"Brandname, Wirkstoff, Therapiegebiet, Indikation, Produkteigenschaften, Applikationsformen (Pen, Fertigspritze, Filmtablette, Kapsel usw.), Lagerungsbedingungen \"\n",
    "                \"(inkl. notwendiger Kühlung), spezielle Patientengruppen, Informationen für Ärzte, Apotheken und Patienten, Wirkmechanismus, Kontraindikationen, \"\n",
    "                \"Nebenwirkungen, Interaktionen, Schulungshinweise, zugelassene Konkurrenzprodukte, wichtigste Webseiten (Quellen) und den aktuellen Zulassungsstatus \"\n",
    "                \"(Stand: 8. April 2025; zugelassen oder nicht). Sortiere die Liste nach Indikation und erwartetem Zulassungsdatum und stelle sicher, dass \"\n",
    "                \"keinerlei Duplikate vorhanden sind. Überprüfe den Zulassungsstatus und verfügbare Informationen sorgfältig online und weise explizit darauf hin, wenn \"\n",
    "                \"bestimmte Daten nicht gefunden werden können.\"\n",
    "            )}],\n",
    "    \"max_tokens\": 8000,\n",
    "    \"temperature\": 0.2,\n",
    "    \"web_search_options\": {\"search_context_size\": \"medium\"},\n",
    "    \"search_domain_filter\": [\"swissmedic.ch\", \"firstwordpharma.com\", \"evaluatepharma.com\",\"fiercepharma.com\", #\"ema.europa.eu\"\"compendium.ch\"\n",
    "                             \"daz.online\", \"pharmazeutische-zeitung.de\",\"-drugs.com\",  \"-fda.gov\", \"clinicaltrials.gov\"],\n",
    "    \"response_format\": {\n",
    "        \"type\": \"json_schema\",\n",
    "        \"json_schema\": {\"schema\": MoleculeList.schema()},\n",
    "    },\n",
    "\n",
    "}\n",
    "\n",
    "headers = {\n",
    "    \"Authorization\": f\"Bearer {token}\",\n",
    "    \"Content-Type\": \"application/json\"\n",
    "}\n",
    "\n",
    "response = requests.post(url, json=payload, headers=headers)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>brand_name</th>\n",
       "      <th>active_ingredient</th>\n",
       "      <th>therapy_area</th>\n",
       "      <th>indication</th>\n",
       "      <th>product_properties</th>\n",
       "      <th>application_forms</th>\n",
       "      <th>storage_conditions</th>\n",
       "      <th>special_patient_groups</th>\n",
       "      <th>information_for_doctors</th>\n",
       "      <th>information_for_pharmacies</th>\n",
       "      <th>information_for_patients</th>\n",
       "      <th>mechanism_of_action</th>\n",
       "      <th>contraindications</th>\n",
       "      <th>side_effects</th>\n",
       "      <th>interactions</th>\n",
       "      <th>training_notes</th>\n",
       "      <th>approved_competitor_products</th>\n",
       "      <th>important_websites</th>\n",
       "      <th>current_approval_status</th>\n",
       "      <th>expected_approval_date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Alyftrek</td>\n",
       "      <td>Vanzacaftor/Tezacaftor/Deutivacaftor</td>\n",
       "      <td>Cystische Fibrose</td>\n",
       "      <td>CFTR-mutationsbedingte zystische Fibrose (ab 6...</td>\n",
       "      <td>Erstes einmal täglich einzunehmendes CFTR-Modu...</td>\n",
       "      <td>[Filmtablette]</td>\n",
       "      <td>Raumtemperatur (15-30°C), vor Feuchtigkeit sch...</td>\n",
       "      <td>Kinder ≥6 Jahre, CF-Patienten mit 31 zusätzlic...</td>\n",
       "      <td>Switch-Option von Trikafta bei besserer Verträ...</td>\n",
       "      <td>Genetischer Test zur Mutationsbestimmung erfor...</td>\n",
       "      <td>Einnahme unabhängig von Mahlzeiten möglich</td>\n",
       "      <td>CFTR-Kanal-Modulation durch Triple-Kombination</td>\n",
       "      <td>Schwere Leberfunktionsstörungen</td>\n",
       "      <td>Kopfschmerzen, nasopharyngeale Entzündung (≥10%)</td>\n",
       "      <td>CYP3A4-Induktoren (Dosisanpassung erforderlich)</td>\n",
       "      <td>Schulung zur Atemwegsclearance begleiten</td>\n",
       "      <td>[Trikafta, Symdeko]</td>\n",
       "      <td>[https://www.fiercepharma.com/marketing/top-10...</td>\n",
       "      <td>Zugelassen am 15.12.2024 (vorverlegt)</td>\n",
       "      <td>2024-12-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Datroway</td>\n",
       "      <td>Datopotamab Deruxtecan</td>\n",
       "      <td>Onkologie</td>\n",
       "      <td>NSCLC (nicht-kleinzelliges Lungenkarzinom)</td>\n",
       "      <td>TROP2-gerichtetes ADC mit Topoisomerase-I-Inhi...</td>\n",
       "      <td>[Intravenöse Infusion]</td>\n",
       "      <td>2-8°C (Originalverpackung), lichtgeschützt</td>\n",
       "      <td>EGFR-mutierte Patienten, Zweitlinientherapie</td>\n",
       "      <td>OS-Vorteil von 15.6 vs. 11.8 Monaten vs. Docet...</td>\n",
       "      <td>Spezialisierte Zytostatika-Herstellung erforde...</td>\n",
       "      <td>Regelmäßige Lungenfunktionskontrollen empfohlen</td>\n",
       "      <td>Antikörper-Wirkstoff-Konjugat (ADC)</td>\n",
       "      <td>Schwere interstitielle Lungenerkrankung</td>\n",
       "      <td>Stomatitis (67%), Alopezie (45%)</td>\n",
       "      <td>Keine bekannten pharmakokinetischen Interaktionen</td>\n",
       "      <td>Schulung zur Erkennung von Pneumonitis-Symptomen</td>\n",
       "      <td>[Trodelvy]</td>\n",
       "      <td>[https://www.fiercepharma.com/marketing/top-10...</td>\n",
       "      <td>Zugelassen für Brustkrebs am 17.01.2025; NSCLC...</td>\n",
       "      <td>2025-07-12</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Journavx</td>\n",
       "      <td>Suzetrigin</td>\n",
       "      <td>Schmerztherapie</td>\n",
       "      <td>Mittelstarke bis starke akute Schmerzen</td>\n",
       "      <td>Erster selektiver NaV1.8-Inhibitor</td>\n",
       "      <td>[Filmtablette]</td>\n",
       "      <td>Raumtemperatur, Originalblister</td>\n",
       "      <td>Patienten mit Opioid-Kontraindikationen</td>\n",
       "      <td>Keine Atemdepression, geringeres Abhängigkeits...</td>\n",
       "      <td>CYP3A4-Interaktionen beachten (Grapefruitsaft-...</td>\n",
       "      <td>Startdosis 100mg, dann 50mg alle 12h</td>\n",
       "      <td>Peripherer Natriumkanal-Blocker (NaV1.8)</td>\n",
       "      <td>Gleichzeitige Einnahme starker CYP3A4-Hemmer</td>\n",
       "      <td>Juckreiz (15%), CK-Erhöhung (8%)</td>\n",
       "      <td>CYP3A4-Inhibitoren erhöhen Exposition um 300%</td>\n",
       "      <td>Schulung zur differenzierten Schmerzdokumentation</td>\n",
       "      <td>[Hydrocodon/Paracetamol]</td>\n",
       "      <td>[https://www.pharmazeutische-zeitung.de/us-zul...</td>\n",
       "      <td>Zugelassen am 03.02.2025</td>\n",
       "      <td>2025-02-03</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Tolebrutinib</td>\n",
       "      <td>Tolebrutinib</td>\n",
       "      <td>Neurologie</td>\n",
       "      <td>Nicht-relabierende sekundär progrediente MS</td>\n",
       "      <td>Erster BTK-Inhibitor für MS</td>\n",
       "      <td>[Filmtablette]</td>\n",
       "      <td>15-30°C, trocken lagern</td>\n",
       "      <td>SPMS-Patienten ohne Schübe</td>\n",
       "      <td>31% Reduktion der Behinderungsprogression</td>\n",
       "      <td>Therapiekontinuität sicherstellen (tägl. Einna...</td>\n",
       "      <td>Regelmäßige Leberwertkontrollen erforderlich</td>\n",
       "      <td>Bruton-Tyrosinkinase-Hemmung</td>\n",
       "      <td>Aktive Hepatitis</td>\n",
       "      <td>Leberenzymerhöhung (4.2%)</td>\n",
       "      <td>CYP3A4-Substrate (Dosisanpassung)</td>\n",
       "      <td>Patientenmonitoring auf hepatische Symptome</td>\n",
       "      <td>[Ocrevus]</td>\n",
       "      <td>[https://www.fiercepharma.com/marketing/top-10...</td>\n",
       "      <td>Breakthrough-Designation 12/2024; Erwartete Zu...</td>\n",
       "      <td>2025-09-30</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Mazdutide</td>\n",
       "      <td>Mazdutide</td>\n",
       "      <td>Endokrinologie</td>\n",
       "      <td>Adipositas/ Typ-2-Diabetes</td>\n",
       "      <td>Erster dualer GLP-1/Glucagon-Rezeptoragonist</td>\n",
       "      <td>[Fertigpen]</td>\n",
       "      <td>2-8°C (ungeöffnet), Raumtemp. bis 4 Wochen</td>\n",
       "      <td>BMI ≥30 oder ≥27 mit Komorbiditäten</td>\n",
       "      <td>Phase-3-Daten: 15.4% Gewichtsreduktion über 52...</td>\n",
       "      <td>Kühlkette beim Transport beachten</td>\n",
       "      <td>Selbstinjektionstechnik schulen</td>\n",
       "      <td>Duale Rezeptoragonismus</td>\n",
       "      <td>MEN-2-Syndrom</td>\n",
       "      <td>Übelkeit (33%), Diarrhö (21%)</td>\n",
       "      <td>Verzögerte Magenentleerung (orale Medikation)</td>\n",
       "      <td>Schulung zur Injektionstechnik und Nebenwirkun...</td>\n",
       "      <td>[Semaglutid, Tirzepatid]</td>\n",
       "      <td>[https://www.fiercepharma.com/marketing/top-10...</td>\n",
       "      <td>Phase-3 abgeschlossen; Erwartete FDA-Zulassung...</td>\n",
       "      <td>2025-12-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Nipocalimab</td>\n",
       "      <td>Nipocalimab</td>\n",
       "      <td>Neurologie</td>\n",
       "      <td>Generalisierte Myasthenia gravis (gMG)</td>\n",
       "      <td>Neonatal-Fc-Rezeptor (FcRn)-Antikörper</td>\n",
       "      <td>[Intravenöse Infusion]</td>\n",
       "      <td>2-8°C, vor Licht schützen</td>\n",
       "      <td>Refraktäre gMG-Patienten</td>\n",
       "      <td>Reduktion MG-ADL-Score um 4.2 Punkte vs. Placebo</td>\n",
       "      <td>Infusionslösung ex tempore herstellen</td>\n",
       "      <td>Monatliche Infusionen erforderlich</td>\n",
       "      <td>IgG-Antikörper-Clearance über FcRn-Blockade</td>\n",
       "      <td>Aktive Infektionen</td>\n",
       "      <td>Infusionsreaktionen (18%)</td>\n",
       "      <td>Live-Impfungen kontraindiziert</td>\n",
       "      <td>Infusionsprotokoll und Prämedikation beachten</td>\n",
       "      <td>[Efgartigimod]</td>\n",
       "      <td>[https://www.fiercepharma.com/marketing/top-10...</td>\n",
       "      <td>Priority Review mit PDUFA 30.06.2025</td>\n",
       "      <td>2025-06-30</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Lenacapavir</td>\n",
       "      <td>Lenacapavir</td>\n",
       "      <td>Infektiologie</td>\n",
       "      <td>Prä-Expositionsprophylaxe (PrEP) bei HIV</td>\n",
       "      <td>Erstes subkutanes Depot-PrEP</td>\n",
       "      <td>[Subkutane Injektion]</td>\n",
       "      <td>2-8°C (vor Gebrauch), Raumtemp. bis 3 Monate</td>\n",
       "      <td>Hochrisiko-Personen</td>\n",
       "      <td>Halbjährliche Applikation</td>\n",
       "      <td>Kühlkettenüberwachung erforderlich</td>\n",
       "      <td>Selbstinjektion nach Training möglich</td>\n",
       "      <td>Kapsidinhibitor</td>\n",
       "      <td>Akute HIV-Infektion</td>\n",
       "      <td>Injektionsstellenreaktionen (23%)</td>\n",
       "      <td>Keine relevanten CYP-Interaktionen</td>\n",
       "      <td>Schulung zur korrekten Injektionstechnik</td>\n",
       "      <td>[Emtricitabin/Tenofovir]</td>\n",
       "      <td>[https://www.fiercepharma.com/pharma/fierce-ph...</td>\n",
       "      <td>Priority Review mit PDUFA 19.06.2025</td>\n",
       "      <td>2025-06-19</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Filspari</td>\n",
       "      <td>Sparsentan</td>\n",
       "      <td>Nephrologie</td>\n",
       "      <td>Fokal segmentale Glomerulosklerose (FSGS)</td>\n",
       "      <td>Dualer Endothelin-Angiotensin-Rezeptorantagonist</td>\n",
       "      <td>[Tablette]</td>\n",
       "      <td>Raumtemperatur, originalverpackt</td>\n",
       "      <td>Proteinurie ≥1.5g/Tag</td>\n",
       "      <td>41% Proteinurie-Reduktion vs. Irbesartan</td>\n",
       "      <td>Teratogenitätsrisiko - Schwangerschaftstest er...</td>\n",
       "      <td>Strenge Kontrazeption notwendig</td>\n",
       "      <td>Duale Rezeptorblockade</td>\n",
       "      <td>Schwangerschaft</td>\n",
       "      <td>Hyperkaliämie (12%), Ödeme (9%)</td>\n",
       "      <td>NSAIDs (Nierenfunktionsverschlechterung)</td>\n",
       "      <td>Risikomanagement bei Frauen im gebärfähigen Alter</td>\n",
       "      <td>[Irbesartan]</td>\n",
       "      <td>[https://www.fiercepharma.com/pharma/fierce-ph...</td>\n",
       "      <td>Priority Review eingereicht; Entscheidung Q4 2025</td>\n",
       "      <td>2025-11-30</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Kerendia</td>\n",
       "      <td>Finerenon</td>\n",
       "      <td>Kardiologie</td>\n",
       "      <td>Herzinsuffizienz mit erhaltener Ejektionsfraktion</td>\n",
       "      <td>Nicht-steroidaler MRA</td>\n",
       "      <td>[Tablette]</td>\n",
       "      <td>15-30°C, trocken lagern</td>\n",
       "      <td>HFpEF-Patienten mit Diabetes</td>\n",
       "      <td>16% Risikoreduktion kardiovaskulärer Ereignisse</td>\n",
       "      <td>Serumkalium regelmäßig kontrollieren</td>\n",
       "      <td>Tägliche Einnahme zur gleichen Uhrzeit</td>\n",
       "      <td>Mineralocorticoid-Rezeptorantagonismus</td>\n",
       "      <td>Hyperkaliämie &gt;5.0 mmol/l</td>\n",
       "      <td>Hyperkaliämie (14%)</td>\n",
       "      <td>Kaliumsparende Diuretika</td>\n",
       "      <td>Patientenmonitoring auf Kaliumspiegel</td>\n",
       "      <td>[Spironolacton]</td>\n",
       "      <td>[https://www.fiercepharma.com/pharma/fierce-ph...</td>\n",
       "      <td>Priority Review mit PDUFA 19.06.2025</td>\n",
       "      <td>2025-06-19</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Zilucoplan</td>\n",
       "      <td>Zilucoplan</td>\n",
       "      <td>Neurologie</td>\n",
       "      <td>Myasthenia gravis</td>\n",
       "      <td>C5-Komplementinhibitor</td>\n",
       "      <td>[Subkutane Fertigspritze]</td>\n",
       "      <td>2-8°C, vor Gebrauch auf Raumtemp. bringen</td>\n",
       "      <td>Anti-AChR-Antikörper-positive Patienten</td>\n",
       "      <td>Tägliche subkutane Selbstinjektion</td>\n",
       "      <td>Kühlkettenmanagement erforderlich</td>\n",
       "      <td>Injektionsstellenrotation beachten</td>\n",
       "      <td>Komplement-C5-Hemmung</td>\n",
       "      <td>Meningokokken-Infektionen</td>\n",
       "      <td>Kopfschmerzen (22%), Injektionsreaktionen (15%)</td>\n",
       "      <td>Keine bekannten pharmakokinetischen Interaktionen</td>\n",
       "      <td>Meningokokken-Impfung vor Therapiebeginn</td>\n",
       "      <td>[Eculizumab]</td>\n",
       "      <td>[https://www.pharmazeutische-zeitung.de/hoch-w...</td>\n",
       "      <td>Phase III abgeschlossen; Erwartete Einreichung...</td>\n",
       "      <td>2025-12-01</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     brand_name                     active_ingredient       therapy_area  \\\n",
       "0      Alyftrek  Vanzacaftor/Tezacaftor/Deutivacaftor  Cystische Fibrose   \n",
       "1      Datroway                Datopotamab Deruxtecan          Onkologie   \n",
       "2      Journavx                            Suzetrigin    Schmerztherapie   \n",
       "3  Tolebrutinib                          Tolebrutinib         Neurologie   \n",
       "4     Mazdutide                             Mazdutide     Endokrinologie   \n",
       "5   Nipocalimab                           Nipocalimab         Neurologie   \n",
       "6   Lenacapavir                           Lenacapavir      Infektiologie   \n",
       "7      Filspari                            Sparsentan        Nephrologie   \n",
       "8      Kerendia                             Finerenon        Kardiologie   \n",
       "9    Zilucoplan                            Zilucoplan         Neurologie   \n",
       "\n",
       "                                          indication  \\\n",
       "0  CFTR-mutationsbedingte zystische Fibrose (ab 6...   \n",
       "1         NSCLC (nicht-kleinzelliges Lungenkarzinom)   \n",
       "2            Mittelstarke bis starke akute Schmerzen   \n",
       "3        Nicht-relabierende sekundär progrediente MS   \n",
       "4                         Adipositas/ Typ-2-Diabetes   \n",
       "5             Generalisierte Myasthenia gravis (gMG)   \n",
       "6           Prä-Expositionsprophylaxe (PrEP) bei HIV   \n",
       "7          Fokal segmentale Glomerulosklerose (FSGS)   \n",
       "8  Herzinsuffizienz mit erhaltener Ejektionsfraktion   \n",
       "9                                  Myasthenia gravis   \n",
       "\n",
       "                                  product_properties  \\\n",
       "0  Erstes einmal täglich einzunehmendes CFTR-Modu...   \n",
       "1  TROP2-gerichtetes ADC mit Topoisomerase-I-Inhi...   \n",
       "2                 Erster selektiver NaV1.8-Inhibitor   \n",
       "3                        Erster BTK-Inhibitor für MS   \n",
       "4       Erster dualer GLP-1/Glucagon-Rezeptoragonist   \n",
       "5             Neonatal-Fc-Rezeptor (FcRn)-Antikörper   \n",
       "6                       Erstes subkutanes Depot-PrEP   \n",
       "7   Dualer Endothelin-Angiotensin-Rezeptorantagonist   \n",
       "8                              Nicht-steroidaler MRA   \n",
       "9                             C5-Komplementinhibitor   \n",
       "\n",
       "           application_forms  \\\n",
       "0             [Filmtablette]   \n",
       "1     [Intravenöse Infusion]   \n",
       "2             [Filmtablette]   \n",
       "3             [Filmtablette]   \n",
       "4                [Fertigpen]   \n",
       "5     [Intravenöse Infusion]   \n",
       "6      [Subkutane Injektion]   \n",
       "7                 [Tablette]   \n",
       "8                 [Tablette]   \n",
       "9  [Subkutane Fertigspritze]   \n",
       "\n",
       "                                  storage_conditions  \\\n",
       "0  Raumtemperatur (15-30°C), vor Feuchtigkeit sch...   \n",
       "1         2-8°C (Originalverpackung), lichtgeschützt   \n",
       "2                    Raumtemperatur, Originalblister   \n",
       "3                            15-30°C, trocken lagern   \n",
       "4         2-8°C (ungeöffnet), Raumtemp. bis 4 Wochen   \n",
       "5                          2-8°C, vor Licht schützen   \n",
       "6       2-8°C (vor Gebrauch), Raumtemp. bis 3 Monate   \n",
       "7                   Raumtemperatur, originalverpackt   \n",
       "8                            15-30°C, trocken lagern   \n",
       "9          2-8°C, vor Gebrauch auf Raumtemp. bringen   \n",
       "\n",
       "                              special_patient_groups  \\\n",
       "0  Kinder ≥6 Jahre, CF-Patienten mit 31 zusätzlic...   \n",
       "1       EGFR-mutierte Patienten, Zweitlinientherapie   \n",
       "2            Patienten mit Opioid-Kontraindikationen   \n",
       "3                         SPMS-Patienten ohne Schübe   \n",
       "4                BMI ≥30 oder ≥27 mit Komorbiditäten   \n",
       "5                           Refraktäre gMG-Patienten   \n",
       "6                                Hochrisiko-Personen   \n",
       "7                              Proteinurie ≥1.5g/Tag   \n",
       "8                       HFpEF-Patienten mit Diabetes   \n",
       "9            Anti-AChR-Antikörper-positive Patienten   \n",
       "\n",
       "                             information_for_doctors  \\\n",
       "0  Switch-Option von Trikafta bei besserer Verträ...   \n",
       "1  OS-Vorteil von 15.6 vs. 11.8 Monaten vs. Docet...   \n",
       "2  Keine Atemdepression, geringeres Abhängigkeits...   \n",
       "3          31% Reduktion der Behinderungsprogression   \n",
       "4  Phase-3-Daten: 15.4% Gewichtsreduktion über 52...   \n",
       "5   Reduktion MG-ADL-Score um 4.2 Punkte vs. Placebo   \n",
       "6                          Halbjährliche Applikation   \n",
       "7           41% Proteinurie-Reduktion vs. Irbesartan   \n",
       "8    16% Risikoreduktion kardiovaskulärer Ereignisse   \n",
       "9                 Tägliche subkutane Selbstinjektion   \n",
       "\n",
       "                          information_for_pharmacies  \\\n",
       "0  Genetischer Test zur Mutationsbestimmung erfor...   \n",
       "1  Spezialisierte Zytostatika-Herstellung erforde...   \n",
       "2  CYP3A4-Interaktionen beachten (Grapefruitsaft-...   \n",
       "3  Therapiekontinuität sicherstellen (tägl. Einna...   \n",
       "4                  Kühlkette beim Transport beachten   \n",
       "5              Infusionslösung ex tempore herstellen   \n",
       "6                 Kühlkettenüberwachung erforderlich   \n",
       "7  Teratogenitätsrisiko - Schwangerschaftstest er...   \n",
       "8               Serumkalium regelmäßig kontrollieren   \n",
       "9                  Kühlkettenmanagement erforderlich   \n",
       "\n",
       "                          information_for_patients  \\\n",
       "0       Einnahme unabhängig von Mahlzeiten möglich   \n",
       "1  Regelmäßige Lungenfunktionskontrollen empfohlen   \n",
       "2             Startdosis 100mg, dann 50mg alle 12h   \n",
       "3     Regelmäßige Leberwertkontrollen erforderlich   \n",
       "4                  Selbstinjektionstechnik schulen   \n",
       "5               Monatliche Infusionen erforderlich   \n",
       "6            Selbstinjektion nach Training möglich   \n",
       "7                  Strenge Kontrazeption notwendig   \n",
       "8           Tägliche Einnahme zur gleichen Uhrzeit   \n",
       "9               Injektionsstellenrotation beachten   \n",
       "\n",
       "                              mechanism_of_action  \\\n",
       "0  CFTR-Kanal-Modulation durch Triple-Kombination   \n",
       "1             Antikörper-Wirkstoff-Konjugat (ADC)   \n",
       "2        Peripherer Natriumkanal-Blocker (NaV1.8)   \n",
       "3                    Bruton-Tyrosinkinase-Hemmung   \n",
       "4                         Duale Rezeptoragonismus   \n",
       "5     IgG-Antikörper-Clearance über FcRn-Blockade   \n",
       "6                                 Kapsidinhibitor   \n",
       "7                          Duale Rezeptorblockade   \n",
       "8          Mineralocorticoid-Rezeptorantagonismus   \n",
       "9                           Komplement-C5-Hemmung   \n",
       "\n",
       "                              contraindications  \\\n",
       "0               Schwere Leberfunktionsstörungen   \n",
       "1       Schwere interstitielle Lungenerkrankung   \n",
       "2  Gleichzeitige Einnahme starker CYP3A4-Hemmer   \n",
       "3                              Aktive Hepatitis   \n",
       "4                                 MEN-2-Syndrom   \n",
       "5                            Aktive Infektionen   \n",
       "6                           Akute HIV-Infektion   \n",
       "7                               Schwangerschaft   \n",
       "8                     Hyperkaliämie >5.0 mmol/l   \n",
       "9                     Meningokokken-Infektionen   \n",
       "\n",
       "                                       side_effects  \\\n",
       "0  Kopfschmerzen, nasopharyngeale Entzündung (≥10%)   \n",
       "1                  Stomatitis (67%), Alopezie (45%)   \n",
       "2                  Juckreiz (15%), CK-Erhöhung (8%)   \n",
       "3                         Leberenzymerhöhung (4.2%)   \n",
       "4                     Übelkeit (33%), Diarrhö (21%)   \n",
       "5                         Infusionsreaktionen (18%)   \n",
       "6                 Injektionsstellenreaktionen (23%)   \n",
       "7                   Hyperkaliämie (12%), Ödeme (9%)   \n",
       "8                               Hyperkaliämie (14%)   \n",
       "9   Kopfschmerzen (22%), Injektionsreaktionen (15%)   \n",
       "\n",
       "                                        interactions  \\\n",
       "0    CYP3A4-Induktoren (Dosisanpassung erforderlich)   \n",
       "1  Keine bekannten pharmakokinetischen Interaktionen   \n",
       "2      CYP3A4-Inhibitoren erhöhen Exposition um 300%   \n",
       "3                  CYP3A4-Substrate (Dosisanpassung)   \n",
       "4      Verzögerte Magenentleerung (orale Medikation)   \n",
       "5                     Live-Impfungen kontraindiziert   \n",
       "6                 Keine relevanten CYP-Interaktionen   \n",
       "7           NSAIDs (Nierenfunktionsverschlechterung)   \n",
       "8                           Kaliumsparende Diuretika   \n",
       "9  Keine bekannten pharmakokinetischen Interaktionen   \n",
       "\n",
       "                                      training_notes  \\\n",
       "0           Schulung zur Atemwegsclearance begleiten   \n",
       "1   Schulung zur Erkennung von Pneumonitis-Symptomen   \n",
       "2  Schulung zur differenzierten Schmerzdokumentation   \n",
       "3        Patientenmonitoring auf hepatische Symptome   \n",
       "4  Schulung zur Injektionstechnik und Nebenwirkun...   \n",
       "5      Infusionsprotokoll und Prämedikation beachten   \n",
       "6           Schulung zur korrekten Injektionstechnik   \n",
       "7  Risikomanagement bei Frauen im gebärfähigen Alter   \n",
       "8              Patientenmonitoring auf Kaliumspiegel   \n",
       "9           Meningokokken-Impfung vor Therapiebeginn   \n",
       "\n",
       "  approved_competitor_products  \\\n",
       "0          [Trikafta, Symdeko]   \n",
       "1                   [Trodelvy]   \n",
       "2     [Hydrocodon/Paracetamol]   \n",
       "3                    [Ocrevus]   \n",
       "4     [Semaglutid, Tirzepatid]   \n",
       "5               [Efgartigimod]   \n",
       "6     [Emtricitabin/Tenofovir]   \n",
       "7                 [Irbesartan]   \n",
       "8              [Spironolacton]   \n",
       "9                 [Eculizumab]   \n",
       "\n",
       "                                  important_websites  \\\n",
       "0  [https://www.fiercepharma.com/marketing/top-10...   \n",
       "1  [https://www.fiercepharma.com/marketing/top-10...   \n",
       "2  [https://www.pharmazeutische-zeitung.de/us-zul...   \n",
       "3  [https://www.fiercepharma.com/marketing/top-10...   \n",
       "4  [https://www.fiercepharma.com/marketing/top-10...   \n",
       "5  [https://www.fiercepharma.com/marketing/top-10...   \n",
       "6  [https://www.fiercepharma.com/pharma/fierce-ph...   \n",
       "7  [https://www.fiercepharma.com/pharma/fierce-ph...   \n",
       "8  [https://www.fiercepharma.com/pharma/fierce-ph...   \n",
       "9  [https://www.pharmazeutische-zeitung.de/hoch-w...   \n",
       "\n",
       "                             current_approval_status expected_approval_date  \n",
       "0              Zugelassen am 15.12.2024 (vorverlegt)             2024-12-15  \n",
       "1  Zugelassen für Brustkrebs am 17.01.2025; NSCLC...             2025-07-12  \n",
       "2                           Zugelassen am 03.02.2025             2025-02-03  \n",
       "3  Breakthrough-Designation 12/2024; Erwartete Zu...             2025-09-30  \n",
       "4  Phase-3 abgeschlossen; Erwartete FDA-Zulassung...             2025-12-15  \n",
       "5               Priority Review mit PDUFA 30.06.2025             2025-06-30  \n",
       "6               Priority Review mit PDUFA 19.06.2025             2025-06-19  \n",
       "7  Priority Review eingereicht; Entscheidung Q4 2025             2025-11-30  \n",
       "8               Priority Review mit PDUFA 19.06.2025             2025-06-19  \n",
       "9  Phase III abgeschlossen; Erwartete Einreichung...             2025-12-01  "
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import json\n",
    "response_json = response.json()\n",
    "raw_content = response_json[\"choices\"][0][\"message\"][\"content\"]\n",
    "cleaned_content = re.sub(r\"<think>.*?</think>\", \"\", raw_content, flags=re.DOTALL).strip()\n",
    "data = json.loads(cleaned_content)\n",
    "molecules = data[\"molecules\"]\n",
    "df = pd.json_normalize(molecules)\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [],
   "source": [
    "df.to_excel(\"output_perplexity_deep_research.xlsx\", index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEBUG: Keine Headerzeile gefunden!\n",
      "DEBUG: Bereinigter Text:\n",
      "\n",
      "{ \"molecules\": [ { \"brand_name\": \"Alyftrek\", \"active_ingredient\": \"Vanza Triple (elexacaftor/tezacaftor/deutivacaftor)\", \"therapy_area\": \"Cystic Fibrosis\", \"indication\": \"Treatment of cystic fibrosis in patients aged 6 years and older\", \"product_properties\": \"CFTR modulator with improved efficacy over previous generations\", \"application_forms\": [\"Film-coated tablet\"], \"storage_conditions\": \"Room temperature (15-30°C)\", \"special_patient_groups\": \"Pediatric patients ≥6 years\", \"information_for_doctors\": \"Monitor liver function tests regularly\", \"information_for_pharmacies\": \"Dispense with patient education materials\", \"information_for_patients\": \"Take with fatty foods for optimal absorption\", \"mechanism_of_action\": \"CFTR protein potentiator/corrector combination\", \"contraindications\": \"Hypersensitivity to components\", \"side_effects\": \"Headache, nasal congestion, elevated liver enzymes\", \"interactions\": \"Strong CYP3A inhibitors require dose adjustment\", \"training_notes\": \"Genetic testing required prior to initiation\", \"approved_competitor_products\": [\"Trikafta\", \"Symdeko\"], \"important_websites\": [\"https://www.vrtx.com\"], \"current_approval_status\": \"Approved (Dec 2024)\", \"expected_approval_date\": \"2024-12-15\" }, { \"brand_name\": \"Datroway\", \"active_ingredient\": \"Datopotamab deruxtecan\", \"therapy_area\": \"Oncology\", \"indication\": \"Non-small cell lung cancer (NSCLC)\", \"product_properties\": \"TROP2-directed antibody-drug conjugate\", \"application_forms\": [\"Intravenous infusion\"], \"storage_conditions\": \"Refrigerated (2-8°C)\", \"special_patient_groups\": \"EGFR-mutated NSCLC patients\", \"information_for_doctors\": \"Monitor for interstitial lung disease\", \"information_for_pharmacies\": \"Reconstitution required before administration\", \"information_for_patients\": \"Report any new respiratory symptoms immediately\", \"mechanism_of_action\": \"Topoisomerase I inhibitor payload delivery\", \"contraindications\": \"Severe pulmonary fibrosis\", \"side_effects\": \"Nausea, alopecia, decreased neutrophil count\", \"interactions\": \"None reported in trials\", \"training_notes\": \"Premedication with corticosteroids required\", \"approved_competitor_products\": [\"Trodelvy\"], \"important_websites\": [\"https://www.daiichisankyo.com\"], \"current_approval_status\": \"Approved for breast cancer (Jan 2025), NSCLC pending\", \"expected_approval_date\": \"2025-07-12\" }, { \"brand_name\": \"Suzetrigine\", \"active_ingredient\": \"Suzetrigine\", \"therapy_area\": \"Pain Management\", \"indication\": \"Chronic neuropathic pain\", \"product_properties\": \"NaV1.8 sodium channel inhibitor\", \"application_forms\": [\"Extended-release tablet\"], \"storage_conditions\": \"Room temperature\", \"special_patient_groups\": \"Patients with opioid tolerance\", \"information_for_doctors\": \"Titrate dose over 4 weeks\", \"information_for_pharmacies\": \"Dispense with medication guide\", \"information_for_patients\": \"Avoid abrupt discontinuation\", \"mechanism_of_action\": \"Voltage-gated sodium channel blockade\", \"contraindications\": \"Concomitant use with MAO inhibitors\", \"side_effects\": \"Dizziness, constipation, dry mouth\", \"interactions\": \"CNS depressants may enhance sedation\", \"training_notes\": \"Requires gradual dose tapering\", \"approved_competitor_products\": [\"Lyrica\", \"Cymbalta\"], \"important_websites\": [\"https://www.vrtx.com\"], \"current_approval_status\": \"Approved (Jan 2025)\", \"expected_approval_date\": \"2025-01-31\" }, { \"brand_name\": \"Tolebrutinib\", \"active_ingredient\": \"Tolebrutinib\", \"therapy_area\": \"Neurology\", \"indication\": \"Non-relapsing secondary progressive multiple sclerosis\", \"product_properties\": \"BTK inhibitor crossing blood-brain barrier\", \"application_forms\": [\"Film-coated tablet\"], \"storage_conditions\": \"Room temperature\", \"special_patient_groups\": \"Patients with progressive MS forms\", \"information_for_doctors\": \"Monitor liver enzymes monthly\", \"information_for_pharmacies\": \"Check for drug-drug interactions\", \"information_for_patients\": \"Take with food to reduce GI upset\", \"mechanism_of_action\": \"Bruton's tyrosine kinase inhibition\", \"contraindications\": \"Active hepatitis\", \"side_effects\": \"Headache, fatigue, transaminase elevation\", \"interactions\": \"Strong CYP3A4 inducers reduce efficacy\", \"training_notes\": \"Requires baseline MRI assessment\", \"approved_competitor_products\": [\"Ocrevus\"], \"important_websites\": [\"https://www.sanofi.com\"], \"current_approval_status\": \"Approved (Mar 2025)\", \"expected_approval_date\": \"2025-03-15\" }, { \"brand_name\": \"Mazdutide\", \"active_ingredient\": \"Mazdutide\", \"therapy_area\": \"Metabolism\", \"indication\": \"Obesity and Type 2 diabetes\", \"product_properties\": \"GLP-1/glucagon receptor dual agonist\", \"application_forms\": [\"Prefilled pen injector\"], \"storage_conditions\": \"Refrigerated (2-8°C)\", \"special_patient_groups\": \"BMI ≥30 or ≥27 with comorbidities\", \"information_for_doctors\": \"Titrate over 16 weeks\", \"information_for_pharmacies\": \"Provide injection training materials\", \"information_for_patients\": \"Rotate injection sites weekly\", \"mechanism_of_action\": \"Dual incretin receptor activation\", \"contraindications\": \"Personal/family history of medullary thyroid carcinoma\", \"side_effects\": \"Nausea, diarrhea, decreased appetite\", \"interactions\": \"May delay gastric emptying affecting oral medications\", \"training_notes\": \"Requires comprehensive lifestyle counseling\", \"approved_competitor_products\": [\"Wegovy\", \"Mounjaro\"], \"important_websites\": [\"https://www.innoventbio.com\"], \"current_approval_status\": \"Approved in China (Feb 2025), US pending\", \"expected_approval_date\": \"2025-09-30\" }, { \"brand_name\": \"Symbravo\", \"active_ingredient\": \"AXS-07\", \"therapy_area\": \"Neurology\", \"indication\": \"Acute migraine treatment\", \"product_properties\": \"Rapid-acting oral combination therapy\", \"application_forms\": [\"Orally disintegrating tablet\"], \"storage_conditions\": \"Room temperature\", \"special_patient_groups\": \"Patients with cardiovascular risk factors\", \"information_for_doctors\": \"Assess cardiovascular risk before prescribing\", \"information_for_pharmacies\": \"Dispense with boxed warning information\", \"information_for_patients\": \"Limit use to 10 days/month\", \"mechanism_of_action\": \"5-HT1B/1D agonist + NSAID combination\", \"contraindications\": \"Coronary artery disease\", \"side_effects\": \"Tingling, dizziness, dry mouth\", \"interactions\": \"MAO inhibitors contraindicated\", \"training_notes\": \"Educate on medication-overuse headache risks\", \"approved_competitor_products\": [\"Ubrelvy\", \"Nurtec\"], \"important_websites\": [\"https://www.axsome.com\"], \"current_approval_status\": \"Approved (Jan 2025)\", \"expected_approval_date\": \"2025-01-31\" }, { \"brand_name\": \"Zynyz\", \"active_ingredient\": \"Retifanlimab\", \"therapy_area\": \"Oncology\", \"indication\": \"Anal cancer (second-line)\", \"product_properties\": \"PD-1 inhibitor\", \"application_forms\": [\"Intravenous infusion\"], \"storage_conditions\": \"Refrigerated (2-8°C)\", \"special_patient_groups\": \"HIV-positive patients\", \"information_for_doctors\": \"Monitor for immune-related adverse events\", \"information_for_pharmacies\": \"Check for proper cold chain maintenance\", \"information_for_patients\": \"Report any signs of infection immediately\", \"mechanism_of_action\": \"Programmed cell death protein 1 blockade\", \"contraindications\": \"Active autoimmune disease\", \"side_effects\": \"Fatigue, rash, colitis\", \"interactions\": \"None significant reported\", \"training_notes\": \"Requires infusion center certification\", \"approved_competitor_products\": [\"Keytruda\"], \"important_websites\": [\"https://www.incyte.com\"], \"current_approval_status\": \"Approved (Sep 2025)\", \"expected_approval_date\": \"2025-09-15\" }, { \"brand_name\": \"Zynquista\", \"active_ingredient\": \"Sotagliflozin\", \"therapy_area\": \"Endocrinology\", \"indication\": \"Type 1 diabetes with chronic kidney disease\", \"product_properties\": \"SGLT1/SGLT2 dual inhibitor\", \"application_forms\": [\"Film-coated tablet\"], \"storage_conditions\": \"Room temperature\", \"special_patient_groups\": \"Patients with eGFR ≥25 mL/min/1.73m²\", \"information_for_doctors\": \"Monitor for diabetic ketoacidosis\", \"information_for_pharmacies\": \"Dispense with ketone testing strips\", \"information_for_patients\": \"Maintain adequate hydration\", \"mechanism_of_action\": \"Sodium-glucose cotransporter inhibition\", \"contraindications\": \"History of Fournier's gangrene\", \"side_effects\": \"Genital mycotic infections, UTIs\", \"interactions\": \"Insulin dose adjustments required\", \"training_notes\": \"Educate on DKA recognition\", \"approved_competitor_products\": [\"Farxiga\"], \"important_websites\": [\"https://www.lexpharma.com\"], \"current_approval_status\": \"Pending (PDUFA Dec 2025)\", \"expected_approval_date\": \"2025-12-20\" }, { \"brand_name\": \"mRNA-1345\", \"active_ingredient\": \"mRNA-1345\", \"therapy_area\": \"Infectious Diseases\", \"indication\": \"RSV prevention in adults ≥60 years\", \"product_properties\": \"mRNA vaccine encoding RSV F protein\", \"application_forms\": [\"Intramuscular injection\"], \"storage_conditions\": \"Frozen (-25°C to -15°C)\", \"special_patient_groups\": \"Immunocompromised individuals\", \"information_for_doctors\": \"Administer pre-filled syringe immediately after thawing\", \"information_for_pharmacies\": \"Maintain cold chain during transport\", \"information_for_patients\": \"Common local reactions expected\", \"mechanism_of_action\": \"Viral surface protein mRNA immunization\", \"contraindications\": \"Severe allergic reaction to previous dose\", \"side_effects\": \"Injection site pain, fatigue, myalgia\", \"interactions\": \"Immunosuppressants may reduce efficacy\", \"training_notes\": \"Requires special thawing equipment\", \"approved_competitor_products\": [\"Arexvy\"], \"important_websites\": [\"https://www.modernatx.com\"], \"current_approval_status\": \"Approved in EU (2024), US pending\", \"expected_approval_date\": \"2025-06-30\" }, { \"brand_name\": \"LX9211\", \"active_ingredient\": \"LX9211\", \"therapy_area\": \"Neurology\", \"indication\": \"Diabetic neuropathic pain\", \"product_properties\": \"AAK1 kinase inhibitor\", \"application_forms\": [\"Oral capsule\"], \"storage_conditions\": \"Room temperature\", \"special_patient_groups\": \"Patients with refractory neuropathic pain\", \"information_for_doctors\": \"Taper existing neuropathic medications gradually\", \"information_for_pharmacies\": \"Monitor for CNS-related adverse effects\", \"information_for_patients\": \"Avoid alcohol consumption\", \"mechanism_of_action\": \"Adaptor-associated kinase 1 inhibition\", \"contraindications\": \"Severe hepatic impairment\", \"side_effects\": \"Dizziness, somnolence, headache\", \"interactions\": \"CNS depressants may enhance effects\", \"training_notes\": \"Requires baseline liver function tests\", \"approved_competitor_products\": [\"Lyrica\"], \"important_websites\": [\"https://www.lexpharma.com\"], \"current_approval_status\": \"Phase III completed (Q1 2025)\", \"expected_approval_date\": \"2025-12-01\" } ] }\n"
     ]
    }
   ],
   "source": [
    "resposne_json= response.json()\n",
    "import re\n",
    "import json\n",
    "import pandas as pd\n",
    "\n",
    "#response_dict = json.loads(response.text)\n",
    "response_json['choices'][0]['message']['content']\n",
    "\n",
    "\n",
    "def extract_table_from_response(response):\n",
    "    response_json = response.json()\n",
    "    assistant_text = response_json[\"choices\"][0][\"message\"][\"content\"]\n",
    "    cleaned_text = re.sub(r'<think>.*?</think>', '', assistant_text, flags=re.DOTALL)\n",
    "\n",
    "    lines = cleaned_text.splitlines()\n",
    "    header_pattern = re.compile(r\"^\\|\\s*Brandname\\s*\\|\", re.IGNORECASE)\n",
    "\n",
    "    def parse_row(line):\n",
    "        cells = [cell.strip() for cell in re.split(r\"\\s*\\|\\s*\", line.strip())]\n",
    "        if cells and cells[0] == '':\n",
    "            cells = cells[1:]\n",
    "        if cells and cells[-1] == '':\n",
    "            cells = cells[:-1]\n",
    "        return cells\n",
    "\n",
    "    all_data = []  \n",
    "    global_header = None\n",
    "    i = 0\n",
    "    while i < len(lines):\n",
    "        line = lines[i]\n",
    "        if header_pattern.match(line):\n",
    "            current_header = parse_row(line)\n",
    "            if global_header is None:\n",
    "                global_header = current_header\n",
    "            elif current_header != global_header:\n",
    "                print(\"DEBUG: Unterschiedlicher Header gefunden: \", current_header)\n",
    "            i += 1\n",
    "            if i < len(lines) and re.match(r\"^\\|[-\\s|]+$\", lines[i]):\n",
    "                i += 1  \n",
    "            while i < len(lines) and lines[i].strip() != \"\" and not header_pattern.match(lines[i]):\n",
    "                if \"|\" in lines[i]:\n",
    "                    row = parse_row(lines[i])\n",
    "                    if len(row) == len(global_header):\n",
    "                        all_data.append(row)\n",
    "                    else:\n",
    "                        print(f\"DEBUG: Überspringe Zeile (Spalten: {len(row)} vs. Header: {len(global_header)}): {row}\")\n",
    "                i += 1\n",
    "        else:\n",
    "            i += 1\n",
    "\n",
    "    if global_header is None:\n",
    "        print(\"DEBUG: Keine Headerzeile gefunden!\")\n",
    "        print(\"DEBUG: Bereinigter Text:\")\n",
    "        print(cleaned_text)\n",
    "        return None\n",
    "\n",
    "    if not all_data:\n",
    "        print(\"DEBUG: Keine passende Datenzeilen gefunden.\")\n",
    "        return None\n",
    "    df = pd.DataFrame(all_data, columns=global_header)\n",
    "    citations_list = response_json.get(\"citations\", [])\n",
    "    df[\"All_Citations\"] = \", \".join(citations_list)\n",
    "    \n",
    "    return df\n",
    "\n",
    "df = extract_table_from_response(response)\n",
    "df\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [],
   "source": [
    "# save df to excel\n",
    "df.to_excel(\"output_deepresearch_deepseekr1.xlsx\", index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "**Hinweis:** Die folgende Tabelle ist ein **Beispiel** basierend auf öffentlich zugänglichen Daten bis Oktober 2023. Da viele FDA-Entscheidungen für 2025 noch nicht finalisiert sind, werden **Platzhalter** für unbestätigte Informationen verwendet. Aktualisierungen erfordern eine Überprüfung durch aktuelle Quellen.\n",
      "\n",
      "---\n",
      "\n",
      "### **FDA-Entscheidungen 2025: Arzneimittelliste (nach Indikation und Datum sortiert)**  \n",
      "| **Indikation**                     | **Erwartetes Zulassungsdatum** | **Brandname (Wirkstoff)**             | **Produkteigenschaften**                                                                 | **Applikationsformen**        | **Lagerungsbedingungen**           | **Relevante Patientengruppen**                | **Informationen für Ärzte/Apotheken/Patienten**                                                                 | **Wirkmechanismus, Kontraindikationen, Nebenwirkungen, Interaktionen, Schulung**                                                                                     | **Zugelassene Konkurrenzprodukte**       | **Quellen**                                                                 |\n",
      "|-------------------------------------|-------------------------------|----------------------------------------|------------------------------------------------------------------------------------------|-------------------------------|-------------------------------------|-----------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|-----------------------------------------------------------------------------|\n",
      "| **Alzheimer-Krankheit (frühes Stadium)** | Q1 2025                       | **Donanemab** (Donanemab)             | Monoklonaler Antikörper gegen Amyloid-β; Priority Review                                 | Intravenöse Infusion          | 2–8°C (gekühlt)                    | Erwachsene mit früher Alzheimer-Demenz        | **Ärzte:** MRI-Überwachung für ARIA (Amyloid-bedingte Bildgebungsanomalien). **Patienten:** Infusionsprotokoll. | **MoA:** Bindet lösliches Amyloid. **NW:** Kopfschmerzen, ARIA, Infusionsreaktionen. **KI:** Schwere Hirnblutungen. **Schulung:** ARIA-Management.                   | Lecanemab (Leqembi), Aducanumab (Aduhelm) | [Eli Lilly Pressemitteilung](https://investor.lilly.com/news-releases)      |\n",
      "| **Paroxysmale nächtliche Hämoglobinurie (PNH)** | Q2 2025                       | **Iptacopan** (Iptacopan)             | Orale Komplementfaktor-B-Inhibitorin; Breakthrough Therapy Designation                   | Filmtablette                  | Raumtemperatur                      | Erwachsene mit PNH und Hämolyse               | **Ärzte:** Überwachung der Hämolyse-Parameter. **Patienten:** Tägliche Einnahme.                              | **MoA:** Hemmt Faktor B. **NW:** Kopfschmerzen, Übelkeit. **KI:** Schwere Infektionen. **Interaktionen:** CYP3A4-Inhibitoren.                                         | Ravulizumab (Ultomiris), Eculizumab (Soliris) | [Novartis Pipeline Update](https://www.novartis.com/pipeline)              |\n",
      "| **Pulmonale arterielle Hypertonie (PAH)** | März 2025                     | **Sotatercept** (Sotatercept)          | Aktivin-Rezeptor-Fusionprotein; Priority Review                                          | Subkutane Injektion           | 2–8°C (gekühlt)                    | Erwachsene mit PAH WHO-Klasse I–III           | **Ärzte:** Hämatologische Überwachung. **Patienten:** Selbstinjektion möglich.                                | **MoA:** Moduliert TGF-β-Signalweg. **NW:** Thrombozytopenie, Nasenbluten. **KI:** Aktive Blutungen. **Schulung:** Injektionstechnik.                                | Riociguat (Adempas), Selexipag (Uptravi) | [Merck Press Release](https://www.merck.com/news/)                          |\n",
      "| **Multiples Myelom**                | November 2025                 | **Linvoseltamab** (Linvoseltamab)      | BCMA-gerichteter bispezifischer Antikörper; Orphan Drug-Status                           | Intravenöse Infusion          | 2–8°C (gekühlt)                    | Erwachsene mit rezidiviertem/refraktärem MM   | **Ärzte:** Zytokin-Freisetzungssyndrom (CRS)-Management. **Patienten:** Stationäre Erstinfusion.               | **MoA:** Bindet CD3 und BCMA. **NW:** CRS, Neutropenie. **KI:** Schwere Hypersensitivität. **Interaktionen:** Immunsuppressiva.                                        | Teclistamab (Tecvayli), Belantamab (Blenrep) | [Regeneron Clinical Trials](https://clinicaltrials.gov/ct2/show/NCT05277636) |\n",
      "| **Morbus Crohn (schwere Fälle)**   | Q4 2025                       | **Mirikizumab** (Mirikizumab)          | IL-23-Inhibitor; Phase-III-Daten                                                        | Subkutane Fertigspritze       | 2–8°C (gekühlt)                    | Erwachsene mit refraktärem Morbus Crohn       | **Ärzte:** Screening auf TB vor Therapie. **Patienten:** Selbstinjektion nach Training.                        | **MoA:** Hemmt IL-23. **NW:** Infektionen, Injektionsstellenreaktionen. **KI:** Aktive Tuberkulose. **Schulung:** Injektionstechnik und Infektionszeichen.            | Ustekinumab (Stelara), Risankizumab (Skyrizi) | [Lilly Pipeline](https://www.lilly.com/pipeline)                            |\n",
      "\n",
      "---\n",
      "\n",
      "### **Unsichere Angaben/Platzhalter:**  \n",
      "- **Erwartetes Zulassungsdatum:** Basierend auf PDUFA-Zielterminen; Verschiebungen möglich.  \n",
      "- **Lagerungsbedingungen:** Bei Biologika oft Kühlung erforderlich (ggf. nach FDA-Label bestätigen).  \n",
      "- **Konkurrenzprodukte:** Abhängig von der finalen Indikationsgenehmigung.  \n",
      "\n",
      "### **Datenquellen-Checklist:**  \n",
      "1. **FDA-Datenbanken:** [Drugs@FDA](https://www.accessdata.fda.gov/scripts/cder/daf/), [PDUFA-Daten](https://www.fda.gov/patients/nda-and-bla-approvals).  \n",
      "2. **Unternehmens-Pipelines:** Eli Lilly, Novartis, Merck, Regeneron.  \n",
      "3. **Klinische Studienregister:** [ClinicalTrials.gov](https://clinicaltrials.gov/).  \n",
      "4. **Nachrichten:** BioPharma Dive, FiercePharma.  \n",
      "\n",
      "Für eine **vollständige Liste** sind regelmäßige Updates bis 2025 erforderlich, da sich Zulassungstermine und Daten ändern können.\n"
     ]
    }
   ],
   "source": [
    "\n",
    "client = OpenAI(api_key=config[\"DEEPSEEK\"],base_url=\"https://api.deepseek.com\")\n",
    "\n",
    "response = client.chat.completions.create(\n",
    "  model=\"deepseek-reasoner\",\n",
    "  max_tokens=8000,\n",
    "  messages=[{\"role\": \"user\",\"content\":\"Erstelle vollständige Tabelle aller Moleküle von allen Indikationen für die im Jahr 2025 eine Entscheidung der US-amerikanischen Food and Drug Administration (FDA) erwartet wird inklusive FDA Priority Review. Die Liste ist nach Indikation und erwartetem Zulassungsdatum sortiert. Die Liste umfasst im Weiteren: Brandname, Wirkstoff, Produkteigenschaften, Applikationsformen (einschließlich Darreichungsformen wie Pen, Fertigspritze, Filmtablette, Kapsel usw.), Lagerungsbedingungen (insbesondere ob eine Kühlung erforderlich ist), spezielle Patientengruppen, Informationen für Ärzte, Apotheken und Patienten, inklusive Wirkmechanismus, Kontraindikationen, Nebenwirkungen, Interaktionen und Schulungshinweisen, zugelassene Konkurrenzprodukte\\nAlles klar. Ich stelle eine vollständige Liste aller Arzneimittel (Moleküle) zusammen, für die im Jahr 2025 eine FDA-Entscheidung erwartet wird – einschließlich aller Indikationen und sowohl regulärer als auch Priority Reviews.\\nDie Übersicht wird nach Indikation und erwartetem Zulassungsdatum sortiert. Zu jedem Produkt werde ich die folgenden Informationen angeben:\\n·         Brandname und Wirkstoff\\n·         Produkteigenschaften\\n·         Applikationsformen (inkl. Darreichungsformen wie Pen, Fertigspritze, Filmtablette usw.)\\n·         Lagerungsbedingungen (v. a. ob Kühlung erforderlich ist)\\n·         Relevante Patientengruppen\\n·         Informationen für Ärzte, Apotheken und Patienten\\n·         Wirkmechanismus, Kontraindikationen, Nebenwirkungen, Interaktionen und Schulungshinweise\\n·         Zugelassene Konkurrenzprodukte\\nIch melde mich, sobald ich die Ergebnisse für dich zusammengestellt habe.\"\n",
    "        }\n",
    "      ],\n",
    "  stream =False) \n",
    "print(response.choices[0].message.content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "ename": "BadRequestError",
     "evalue": "Error code: 400 - {'error': {'message': \"Missing required parameter: 'tools[0].function'.\", 'type': 'invalid_request_error', 'param': 'tools[0].function', 'code': 'missing_required_parameter'}}",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mBadRequestError\u001b[0m                           Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[166], line 20\u001b[0m\n\u001b[0;32m     12\u001b[0m      config \u001b[38;5;241m=\u001b[39m yaml\u001b[38;5;241m.\u001b[39msafe_load(file)\n\u001b[0;32m     15\u001b[0m client \u001b[38;5;241m=\u001b[39m OpenAI(api_key\u001b[38;5;241m=\u001b[39mconfig[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mOPENAI_KEY_TEST\u001b[39m\u001b[38;5;124m\"\u001b[39m],)\n\u001b[1;32m---> 20\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[43mclient\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mchat\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcompletions\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcreate\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m     21\u001b[0m \u001b[43m  \u001b[49m\u001b[43mmodel\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mgpt-4o\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     22\u001b[0m \u001b[43m  \u001b[49m\u001b[43mmax_tokens\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;241;43m16384\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     23\u001b[0m \u001b[43m  \u001b[49m\u001b[43mmessages\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m[\u001b[49m\n\u001b[0;32m     24\u001b[0m \u001b[43m    \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     25\u001b[0m \u001b[43m      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msystem\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     26\u001b[0m \u001b[43m      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\n\u001b[0;32m     27\u001b[0m \u001b[43m        \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     28\u001b[0m \u001b[43m          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtext\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mYou are a pharmaceutical data expert and data extraction specialist. Your task is to compile a comprehensive list of all drug molecules for which an FDA decision is expected in 2025, including those with FDA Priority Review. This list must be detailed and organized by indication and expected approval date.\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43mGather the following details for each molecule:\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Indication**\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Expected Approval Date**\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Brand Name and Active Ingredient**\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Product Attributes**\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Application Forms** (e.g., pen, prefilled syringe, film-coated tablet, capsule, etc.)\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Storage Conditions** (especially whether cooling is required)\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Relevant Patient Groups**\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Information for Doctors, Pharmacies, and Patients**\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Mechanism of Action, Contraindications, Side Effects, Interactions, and Training Notes**\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Approved Competitive Products**\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Sources**\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43mEnsure accuracy by cross-checking data from reputable sources and note any uncertainties encountered during the information collection process.\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m# Steps\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m1. Extract a list of molecules with an FDA decision expected in 2025.\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m2. Organize the data by indication and expected approval date.\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m3. Collect and compile detailed information for each molecule as listed above.\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m4. Use placeholders for data specific to individual drugs where necessary.\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m5. Validate the collected data against credible sources to ensure accuracy.\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m# Output Format\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43mPresent the results in a detailed table format, where each row represents a molecule, and the columns align with the aforementioned data fields.\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m# Examples\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Indication:** [Example Indication]\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Expected Approval Date:** [Date]\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Brand Name and Active Ingredient:** [Brand Name] (Active Ingredient)\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Product Attributes:** [Attributes]\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Application Forms:** [Forms]\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Storage Conditions:** [Conditions]\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Relevant Patient Groups:** [Groups]\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Information for Doctors, Pharmacies, Patients:** [Information]\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Mechanism of Action, Contraindications, Side Effects, Interactions, and Training Notes:** [Details]\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Approved Competitive Products:** [Products]\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- **Sources:** [Source Information]\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m(Note: These are placeholders. Real examples should be completed with accurate and specific data.)\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m# Notes\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- Pay particular attention to any molecules marked for FDA Priority Review, as these often have implications for earlier approval.\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- If data discrepancies arise, ensure to document sources and note the details of any uncertainties.\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m- Ensure that the information is up-to-date and reflects the most recent submissions and reviews from the FDA.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     29\u001b[0m \u001b[43m          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtext\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m     30\u001b[0m \u001b[43m        \u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m     31\u001b[0m \u001b[43m      \u001b[49m\u001b[43m]\u001b[49m\n\u001b[0;32m     32\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     33\u001b[0m \u001b[43m    \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     34\u001b[0m \u001b[43m      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     35\u001b[0m \u001b[43m      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\n\u001b[0;32m     36\u001b[0m \u001b[43m        \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     37\u001b[0m \u001b[43m          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtext\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mCreate a complete table of all molecules for all indications for which a decision by the US Food and Drug Administration (FDA) is expected in 2025, including FDA Priority Review. The list is sorted by indication and expected approval date. Furthermore, the list includes: brand name, active ingredient, product properties, forms of application (including dosage forms such as pen, prefilled syringe, film-coated tablet, capsule, etc.), storage conditions (especially whether cooling is required), special patient groups, and information for physicians, pharmacies, and patients, including mechanism of action, contraindications, side effects, interactions and training instructions, and approved competitor products.\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43mAll right. I will compile a complete list of all medications (molecules) for which an FDA decision is expected in 2025 – including all indications and both regular and Priority Reviews.\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43mThe overview will be sorted by indication and expected approval date. For each product, I will provide the following information: · Brand name and active ingredient · Product properties · Forms of application (including dosage forms such as pen, prefilled syringe, film-coated tablet, etc.) · Storage conditions (especially whether cooling is required) · Relevant patient groups · Information for physicians, pharmacies, and patients · Mechanism of action, contraindications, side effects, interactions, and training instructions · Approved competitor products\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43mI will get back to you as soon as I have compiled the results for you.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     38\u001b[0m \u001b[43m          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtext\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m     39\u001b[0m \u001b[43m        \u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m     40\u001b[0m \u001b[43m      \u001b[49m\u001b[43m]\u001b[49m\n\u001b[0;32m     41\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     42\u001b[0m \u001b[43m    \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     43\u001b[0m \u001b[43m      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43massistant\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     44\u001b[0m \u001b[43m      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\n\u001b[0;32m     45\u001b[0m \u001b[43m        \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     46\u001b[0m \u001b[43m          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtext\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     47\u001b[0m \u001b[43m          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtext\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mFor example :  As of March 31, 2025, the U.S. Food and Drug Administration (FDA) has approved several novel drugs and vaccines, with additional decisions anticipated throughout the year. Below is a comprehensive table of these medications, organized by indication and expected approval date. Each entry includes detailed information on the brand name, active ingredient, product properties, forms of application, storage conditions, special patient groups, and pertinent information for healthcare providers and patients.\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m| Indication | Expected Approval Date | Brand Name | Active Ingredient | Product Properties | Forms of Application | Storage Conditions | Special Patient Groups | Mechanism of Action | Contraindications | Side Effects | Interactions | Training Instructions | Approved Competitor Products |\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m|------------|------------------------|------------|-------------------|--------------------|----------------------|--------------------|------------------------|---------------------|-------------------|--------------|-------------|----------------------|------------------------------|\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m| **Tenosynovial Giant Cell Tumor** | February 14, 2025 | Romvimza | Vimseltinib | Switch-control kinase inhibitor targeting CSF1R | Oral capsules | Store at room temperature | Adults with symptomatic tenosynovial giant cell tumor | Inhibits CSF1R to reduce tumor growth | Hypersensitivity to vimseltinib | Fatigue, nausea, liver enzyme elevation | Potential interactions with CYP3A4 inhibitors | Patients should be monitored for liver function | None approved |\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m| **Neurofibromatosis Type 1 with Symptomatic Plexiform Neurofibromas** | February 11, 2025 | Gomekli | Mirdametinib | MEK inhibitor | Oral capsules | Store at room temperature | Pediatric and adult patients with NF1 and inoperable tumors | Inhibits MEK1/2 to reduce tumor size | Hypersensitivity to mirdametinib | Rash, diarrhea, elevated creatine phosphokinase | Avoid concomitant use with strong CYP3A4 inhibitors | Regular monitoring of cardiac function recommended | None approved |\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m| **Moderate to Severe Acute Pain** | January 30, 2025 | Journavx | Suzetrigine | Non-opioid analgesic, sodium channel blocker | Oral tablets (50 mg) | Store at room temperature | Adults requiring short-term pain management | Selectively inhibits NaV1.8 sodium channels to block pain signals | Hypersensitivity to suzetrigine | Dizziness, headache, gastrointestinal discomfort | Caution with other CNS depressants | Patients should be advised on potential CNS effects | Opioid analgesics (e.g., hydrocodone) |\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m| **Acute Myeloid Leukemia and Myelodysplastic Syndrome** | January 21, 2025 | Grafapex | Treosulfan | Alkylating agent used in conditioning regimens | Intravenous infusion | Refrigerate; protect from light | Patients undergoing allogeneic hematopoietic stem cell transplantation | Cross-links DNA to inhibit cell division | Hypersensitivity to treosulfan | Myelosuppression, mucositis, hepatotoxicity | Increased toxicity with other myelosuppressive agents | Healthcare providers should monitor blood counts and organ function | Busulfan |\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m| **Unresectable or Metastatic HR-Positive, HER2-Negative Breast Cancer** | January 17, 2025 | Datroway | Datopotamab deruxtecan-dlnk | Antibody-drug conjugate targeting TROP2 | Intravenous infusion | Refrigerate; protect from light | Adults with prior endocrine-based therapy and chemotherapy | Delivers cytotoxic agent to TROP2-expressing cancer cells | Hypersensitivity to components | Nausea, neutropenia, interstitial lung disease | Caution with other immunosuppressants | Patients should be monitored for pulmonary symptoms | Sacituzumab govitecan |\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m| **Meningococcal Disease Prophylaxis** | February 14, 2025 | Penmenvy | Meningococcal groups A, B, C, W, and Y vaccine | Lyophilized powder for injection | Intramuscular injection | Refrigerate; do not freeze | Individuals aged 10 through 25 years | Induces immunity against Neisseria meningitidis serogroups A, B, C, W, and Y | Severe allergic reaction to vaccine components | Injection site reactions, fever, headache | None significant | Healthcare providers should be prepared for anaphylaxis management | Menveo, Bexsero |\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m| **Chikungunya Disease Prevention** | February 14, 2025 | Vimkunya | Chikungunya vaccine, recombinant | Injectable suspension | Intramuscular injection | Refrigerate; do not freeze | Individuals aged 12 years and older | Induces immunity against chikungunya virus | Severe allergic reaction to vaccine components | Injection site reactions, fever, myalgia | None significant | Patients should be monitored for allergic reactions post-vaccination | None approved |\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m| **Diabetes Mellitus** | February 14, 2025 | Merilog | Insulin aspart-szjj | Rapid-acting human insulin analog biosimilar to NovoLog | Subcutaneous injection | Refrigerate; do not freeze | Adults and pediatric patients with diabetes mellitus | Facilitates glucose uptake by cells | Hypoglycemia, hypersensitivity to insulin aspart | Hypoglycemia, weight gain, injection site reactions | Caution with other glucose-lowering agents | Patients should be trained on injection technique and hypoglycemia management | NovoLog |\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m| **Uncomplicated Urinary Tract Infections** | March 26, 2025 (expected) | Gepotidacin | Gepotidacin | First-in-class oral antibiotic | Oral tablets | Store at room temperature | Female adults and adolescents with uUTIs | Inhibits bacterial DNA replication | Hypersensitivity to gepotidacin | Nausea, diarrhea, headache | Potential interactions with other antibiotics | Patients should complete the full course as prescribed | Nitrofurantoin, trimethoprim-sulfamethoxazole |\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m| **Hereditary Angioedema Attacks** | June 17, 2025 (expected) | Sebetralstat | Sebetralstat | Oral plasma kallikrein inhibitor | Oral disintegrating tablets | Store at room temperature | Patients aged 12 years and older with HAE | Inhibits plasma kallikrein to reduce bradykinin production | Hypersensitivity to sebetralstat | Nausea, headache, dizziness | Caution with other kallikrein inhibitors | Patients should be trained on recognizing and managing HAE attacks | Icatibant (injection) |\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m| **Vasomotor Symptoms Associated with Menopause** | July 26, 2025 (expected) | Elinzanetant | Elinzanetant | Dual NK-1 and NK-3 receptor antagonist | Oral tablets | Store at room temperature | Women experiencing moderate to severe VMS | Modulates KNDy neurons to reduce hot flashes | Hypersensitivity to elinzanetant | Nausea, headache, fatigue | Potential interactions with CYP3A4 inhibitors | Patients should be informed about the non-hormonal nature of the treatment | Hormone replacement therapy |\u001b[39;49m\u001b[38;5;130;43;01m\\n\u001b[39;49;00m\u001b[38;5;124;43m| **H3 K27M-Mutant Diffuse Glioma** | August 18, 2025 (expected \u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m     48\u001b[0m \u001b[43m        \u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m     49\u001b[0m \u001b[43m      \u001b[49m\u001b[43m]\u001b[49m\n\u001b[0;32m     50\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     51\u001b[0m \u001b[43m    \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     52\u001b[0m \u001b[43m      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     53\u001b[0m \u001b[43m      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\n\u001b[0;32m     54\u001b[0m \u001b[43m        \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     55\u001b[0m \u001b[43m          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtext\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     56\u001b[0m \u001b[43m          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtext\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mThis is too short... it need to be logner-\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m     57\u001b[0m \u001b[43m        \u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m     58\u001b[0m \u001b[43m      \u001b[49m\u001b[43m]\u001b[49m\n\u001b[0;32m     59\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     60\u001b[0m \u001b[43m    \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     61\u001b[0m \u001b[43m      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     62\u001b[0m \u001b[43m      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\n\u001b[0;32m     63\u001b[0m \u001b[43m        \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     64\u001b[0m \u001b[43m          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtext\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     65\u001b[0m \u001b[43m          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtext\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mretry: Erstelle vollständige Tabelle aller Moleküle von allen Indikationen für die im Jahr 2025 eine Entscheidung der US-amerikanischen Food and Drug Administration (FDA) erwartet wird inklusive FDA Priority Review. Die Liste ist nach Indikation und erwartetem Zulassungsdatum sortiert. Die Liste umfasst im Weiteren: Brandname, Wirkstoff, Produkteigenschaften, Applikationsformen (einschließlich Darreichungsformen wie Pen, Fertigspritze, Filmtablette, Kapsel usw.), Lagerungsbedingungen (insbesondere ob eine Kühlung erforderlich ist), spezielle Patientengruppen, Informationen für Ärzte, Apotheken und Patienten, inklusive Wirkmechanismus, Kontraindikationen, Nebenwirkungen, Interaktionen und Schulungshinweisen, zugelassene Konkurrenzprodukte\u001b[39;49m\u001b[38;5;130;43;01m\\\\\u001b[39;49;00m\u001b[38;5;124;43mnAlles klar. Ich stelle eine vollständige Liste aller Arzneimittel (Moleküle) zusammen, für die im Jahr 2025 eine FDA-Entscheidung erwartet wird – einschließlich aller Indikationen und sowohl regulärer als auch Priority Reviews.\u001b[39;49m\u001b[38;5;130;43;01m\\\\\u001b[39;49;00m\u001b[38;5;124;43mnDie Übersicht wird nach Indikation und erwartetem Zulassungsdatum sortiert. Zu jedem Produkt werde ich die folgenden Informationen angeben:\u001b[39;49m\u001b[38;5;130;43;01m\\\\\u001b[39;49;00m\u001b[38;5;124;43mn·         Brandname und Wirkstoff\u001b[39;49m\u001b[38;5;130;43;01m\\\\\u001b[39;49;00m\u001b[38;5;124;43mn·         Produkteigenschaften\u001b[39;49m\u001b[38;5;130;43;01m\\\\\u001b[39;49;00m\u001b[38;5;124;43mn·         Applikationsformen (inkl. Darreichungsformen wie Pen, Fertigspritze, Filmtablette usw.)\u001b[39;49m\u001b[38;5;130;43;01m\\\\\u001b[39;49;00m\u001b[38;5;124;43mn·         Lagerungsbedingungen (v. a. ob Kühlung erforderlich ist)\u001b[39;49m\u001b[38;5;130;43;01m\\\\\u001b[39;49;00m\u001b[38;5;124;43mn·         Relevante Patientengruppen\u001b[39;49m\u001b[38;5;130;43;01m\\\\\u001b[39;49;00m\u001b[38;5;124;43mn·         Informationen für Ärzte, Apotheken und Patienten\u001b[39;49m\u001b[38;5;130;43;01m\\\\\u001b[39;49;00m\u001b[38;5;124;43mn·         Wirkmechanismus, Kontraindikationen, Nebenwirkungen, Interaktionen und Schulungshinweise\u001b[39;49m\u001b[38;5;130;43;01m\\\\\u001b[39;49;00m\u001b[38;5;124;43mn·         Zugelassene Konkurrenzprodukte\u001b[39;49m\u001b[38;5;130;43;01m\\\\\u001b[39;49;00m\u001b[38;5;124;43mnIch melde mich, sobald ich die Ergebnisse für dich zusammengestellt habe.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m     66\u001b[0m \u001b[43m        \u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m     67\u001b[0m \u001b[43m      \u001b[49m\u001b[43m]\u001b[49m\n\u001b[0;32m     68\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m     69\u001b[0m \u001b[43m  \u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     70\u001b[0m \u001b[43m  \u001b[49m\u001b[43mresponse_format\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m{\u001b[49m\n\u001b[0;32m     71\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mjson_schema\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     72\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mjson_schema\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     73\u001b[0m \u001b[43m      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mname\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mfda_drug_approvals_2025\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     74\u001b[0m \u001b[43m      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mschema\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     75\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mobject\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     76\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrequired\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmolecules\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     77\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mproperties\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmolecules\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43marray\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mitems\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mobject\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrequired\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\n\u001b[0;32m     78\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mindication\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     79\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mexpected_approval_date\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     80\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mbrand_name\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     81\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mactive_ingredient\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     82\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mproduct_properties\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     83\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcompetitor_products\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     84\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msources\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     85\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mproperties\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     86\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mbrand_name\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     87\u001b[0m \u001b[43m                  \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstring\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     88\u001b[0m \u001b[43m                  \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mdescription\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mThe brand name of the medication.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m     89\u001b[0m \u001b[43m                \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     90\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mindication\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     91\u001b[0m \u001b[43m                  \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstring\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     92\u001b[0m \u001b[43m                  \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mdescription\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mThe medical indication for which the drug is intended.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m     93\u001b[0m \u001b[43m                \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     94\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msources\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     95\u001b[0m \u001b[43m                  \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstring\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     96\u001b[0m \u001b[43m                  \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mdescription\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mSource urls for the information provided.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m     97\u001b[0m \u001b[43m                \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     98\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mactive_ingredient\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     99\u001b[0m \u001b[43m                  \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstring\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    100\u001b[0m \u001b[43m                  \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mdescription\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mThe active ingredient contained in the medication.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m    101\u001b[0m \u001b[43m                \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    102\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mproduct_properties\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    103\u001b[0m \u001b[43m                  \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mobject\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    104\u001b[0m \u001b[43m                  \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrequired\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\n\u001b[0;32m    105\u001b[0m \u001b[43m                    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mformulations\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    106\u001b[0m \u001b[43m                    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstorage_conditions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    107\u001b[0m \u001b[43m                    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mspecial_patient_groups\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    108\u001b[0m \u001b[43m                    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43minfo_for_healthcare\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m    109\u001b[0m \u001b[43m                  \u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    110\u001b[0m \u001b[43m                  \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mproperties\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    111\u001b[0m \u001b[43m                    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mformulations\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    112\u001b[0m \u001b[43m                      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43marray\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    113\u001b[0m \u001b[43m                      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mitems\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    114\u001b[0m \u001b[43m                        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstring\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m    115\u001b[0m \u001b[43m                      \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    116\u001b[0m \u001b[43m                      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mdescription\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mDifferent formulations of the product.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m    117\u001b[0m \u001b[43m                    \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    118\u001b[0m \u001b[43m                    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstorage_conditions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    119\u001b[0m \u001b[43m                      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstring\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    120\u001b[0m \u001b[43m                      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mdescription\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mConditions under which the medication should be stored, including cooling requirements.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m    121\u001b[0m \u001b[43m                    \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    122\u001b[0m \u001b[43m                    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43minfo_for_healthcare\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    123\u001b[0m \u001b[43m                      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mobject\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    124\u001b[0m \u001b[43m                      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrequired\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\n\u001b[0;32m    125\u001b[0m \u001b[43m                        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmechanism_of_action\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    126\u001b[0m \u001b[43m                        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontraindications\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    127\u001b[0m \u001b[43m                        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mside_effects\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    128\u001b[0m \u001b[43m                        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43minteractions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    129\u001b[0m \u001b[43m                        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtraining_instructions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m    130\u001b[0m \u001b[43m                      \u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    131\u001b[0m \u001b[43m                      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mproperties\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    132\u001b[0m \u001b[43m                        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43minteractions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    133\u001b[0m \u001b[43m                          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43marray\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    134\u001b[0m \u001b[43m                          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mitems\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    135\u001b[0m \u001b[43m                            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstring\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m    136\u001b[0m \u001b[43m                          \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    137\u001b[0m \u001b[43m                          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mdescription\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mKnown interactions with other drugs or substances.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m    138\u001b[0m \u001b[43m                        \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    139\u001b[0m \u001b[43m                        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mside_effects\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    140\u001b[0m \u001b[43m                          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43marray\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    141\u001b[0m \u001b[43m                          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mitems\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    142\u001b[0m \u001b[43m                            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstring\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m    143\u001b[0m \u001b[43m                          \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    144\u001b[0m \u001b[43m                          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mdescription\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mPotential adverse effects of the drug.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m    145\u001b[0m \u001b[43m                        \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    146\u001b[0m \u001b[43m                        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontraindications\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    147\u001b[0m \u001b[43m                          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43marray\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    148\u001b[0m \u001b[43m                          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mitems\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    149\u001b[0m \u001b[43m                            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstring\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m    150\u001b[0m \u001b[43m                          \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    151\u001b[0m \u001b[43m                          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mdescription\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mConditions or factors that would make the drug unsafe or inappropriate to use.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m    152\u001b[0m \u001b[43m                        \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    153\u001b[0m \u001b[43m                        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmechanism_of_action\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    154\u001b[0m \u001b[43m                          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstring\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    155\u001b[0m \u001b[43m                          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mdescription\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mHow the drug works in the body.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m    156\u001b[0m \u001b[43m                        \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    157\u001b[0m \u001b[43m                        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtraining_instructions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    158\u001b[0m \u001b[43m                          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstring\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    159\u001b[0m \u001b[43m                          \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mdescription\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mInstructions for training on how to use the medication.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m    160\u001b[0m \u001b[43m                        \u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m    161\u001b[0m \u001b[43m                      \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    162\u001b[0m \u001b[43m                      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mdescription\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mInformation for healthcare professionals and patients.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    163\u001b[0m \u001b[43m                      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43madditionalProperties\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\n\u001b[0;32m    164\u001b[0m \u001b[43m                    \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    165\u001b[0m \u001b[43m                    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mspecial_patient_groups\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    166\u001b[0m \u001b[43m                      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43marray\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    167\u001b[0m \u001b[43m                      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mitems\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    168\u001b[0m \u001b[43m                        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstring\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m    169\u001b[0m \u001b[43m                      \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    170\u001b[0m \u001b[43m                      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mdescription\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mGroups of patients for whom special considerations may apply.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m    171\u001b[0m \u001b[43m                    \u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m    172\u001b[0m \u001b[43m                  \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    173\u001b[0m \u001b[43m                  \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mdescription\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mProperties of the product that are relevant for understanding its characteristics.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    174\u001b[0m \u001b[43m                  \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43madditionalProperties\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\n\u001b[0;32m    175\u001b[0m \u001b[43m                \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    176\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcompetitor_products\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    177\u001b[0m \u001b[43m                  \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43marray\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    178\u001b[0m \u001b[43m                  \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mitems\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    179\u001b[0m \u001b[43m                    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstring\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m    180\u001b[0m \u001b[43m                  \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    181\u001b[0m \u001b[43m                  \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mdescription\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mOther approved products that serve as competitors.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m    182\u001b[0m \u001b[43m                \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    183\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mexpected_approval_date\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    184\u001b[0m \u001b[43m                  \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstring\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    185\u001b[0m \u001b[43m                  \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mdescription\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mThe anticipated date of FDA approval.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m    186\u001b[0m \u001b[43m                \u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m    187\u001b[0m \u001b[43m              \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    188\u001b[0m \u001b[43m              \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43madditionalProperties\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\n\u001b[0;32m    189\u001b[0m \u001b[43m            \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    190\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mdescription\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mA list of all molecules for which FDA decisions are expected in 2025, sorted by indication and expected approval date.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m    191\u001b[0m \u001b[43m          \u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m    192\u001b[0m \u001b[43m        \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    193\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43madditionalProperties\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\n\u001b[0;32m    194\u001b[0m \u001b[43m      \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    195\u001b[0m \u001b[43m      \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstrict\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mTrue\u001b[39;49;00m\n\u001b[0;32m    196\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m    197\u001b[0m \u001b[43m  \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    198\u001b[0m \u001b[43m  \u001b[49m\u001b[43mtools\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m[\u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mweb_search\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    199\u001b[0m \u001b[43m  \u001b[49m\u001b[43mstore\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43;01mTrue\u001b[39;49;00m\n\u001b[0;32m    200\u001b[0m \u001b[43m)\u001b[49m\n",
      "File \u001b[1;32mc:\\Users\\FahRe\\AppData\\Local\\Programs\\Python\\Python312\\Lib\\site-packages\\openai\\_utils\\_utils.py:279\u001b[0m, in \u001b[0;36mrequired_args.<locals>.inner.<locals>.wrapper\u001b[1;34m(*args, **kwargs)\u001b[0m\n\u001b[0;32m    277\u001b[0m             msg \u001b[38;5;241m=\u001b[39m \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mMissing required argument: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mquote(missing[\u001b[38;5;241m0\u001b[39m])\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m    278\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mTypeError\u001b[39;00m(msg)\n\u001b[1;32m--> 279\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mfunc\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[1;32mc:\\Users\\FahRe\\AppData\\Local\\Programs\\Python\\Python312\\Lib\\site-packages\\openai\\resources\\chat\\completions\\completions.py:914\u001b[0m, in \u001b[0;36mCompletions.create\u001b[1;34m(self, messages, model, audio, frequency_penalty, function_call, functions, logit_bias, logprobs, max_completion_tokens, max_tokens, metadata, modalities, n, parallel_tool_calls, prediction, presence_penalty, reasoning_effort, response_format, seed, service_tier, stop, store, stream, stream_options, temperature, tool_choice, tools, top_logprobs, top_p, user, web_search_options, extra_headers, extra_query, extra_body, timeout)\u001b[0m\n\u001b[0;32m    871\u001b[0m \u001b[38;5;129m@required_args\u001b[39m([\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmessages\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmodel\u001b[39m\u001b[38;5;124m\"\u001b[39m], [\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmessages\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmodel\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mstream\u001b[39m\u001b[38;5;124m\"\u001b[39m])\n\u001b[0;32m    872\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mcreate\u001b[39m(\n\u001b[0;32m    873\u001b[0m     \u001b[38;5;28mself\u001b[39m,\n\u001b[1;32m   (...)\u001b[0m\n\u001b[0;32m    911\u001b[0m     timeout: \u001b[38;5;28mfloat\u001b[39m \u001b[38;5;241m|\u001b[39m httpx\u001b[38;5;241m.\u001b[39mTimeout \u001b[38;5;241m|\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;241m|\u001b[39m NotGiven \u001b[38;5;241m=\u001b[39m NOT_GIVEN,\n\u001b[0;32m    912\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m ChatCompletion \u001b[38;5;241m|\u001b[39m Stream[ChatCompletionChunk]:\n\u001b[0;32m    913\u001b[0m     validate_response_format(response_format)\n\u001b[1;32m--> 914\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_post\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m    915\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43m/chat/completions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    916\u001b[0m \u001b[43m        \u001b[49m\u001b[43mbody\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmaybe_transform\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m    917\u001b[0m \u001b[43m            \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    918\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmessages\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmessages\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    919\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmodel\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmodel\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    920\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43maudio\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43maudio\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    921\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mfrequency_penalty\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfrequency_penalty\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    922\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mfunction_call\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfunction_call\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    923\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mfunctions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfunctions\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    924\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mlogit_bias\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mlogit_bias\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    925\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mlogprobs\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mlogprobs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    926\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmax_completion_tokens\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_completion_tokens\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    927\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmax_tokens\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_tokens\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    928\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmetadata\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    929\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmodalities\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmodalities\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    930\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mn\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mn\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    931\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mparallel_tool_calls\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mparallel_tool_calls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    932\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprediction\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprediction\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    933\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mpresence_penalty\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mpresence_penalty\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    934\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mreasoning_effort\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mreasoning_effort\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    935\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mresponse_format\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mresponse_format\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    936\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mseed\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mseed\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    937\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mservice_tier\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mservice_tier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    938\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstop\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstop\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    939\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstore\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstore\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    940\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstream\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    941\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstream_options\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    942\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtemperature\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtemperature\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    943\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtool_choice\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtool_choice\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    944\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtools\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtools\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    945\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtop_logprobs\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_logprobs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    946\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtop_p\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_p\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    947\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43muser\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    948\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mweb_search_options\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mweb_search_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    949\u001b[0m \u001b[43m            \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    950\u001b[0m \u001b[43m            \u001b[49m\u001b[43mcompletion_create_params\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mCompletionCreateParams\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    951\u001b[0m \u001b[43m        \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    952\u001b[0m \u001b[43m        \u001b[49m\u001b[43moptions\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmake_request_options\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m    953\u001b[0m \u001b[43m            \u001b[49m\u001b[43mextra_headers\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_headers\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mextra_query\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_query\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mextra_body\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_body\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtimeout\u001b[49m\n\u001b[0;32m    954\u001b[0m \u001b[43m        \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    955\u001b[0m \u001b[43m        \u001b[49m\u001b[43mcast_to\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mChatCompletion\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    956\u001b[0m \u001b[43m        \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[0;32m    957\u001b[0m \u001b[43m        \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mStream\u001b[49m\u001b[43m[\u001b[49m\u001b[43mChatCompletionChunk\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    958\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[1;32mc:\\Users\\FahRe\\AppData\\Local\\Programs\\Python\\Python312\\Lib\\site-packages\\openai\\_base_client.py:1242\u001b[0m, in \u001b[0;36mSyncAPIClient.post\u001b[1;34m(self, path, cast_to, body, options, files, stream, stream_cls)\u001b[0m\n\u001b[0;32m   1228\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mpost\u001b[39m(\n\u001b[0;32m   1229\u001b[0m     \u001b[38;5;28mself\u001b[39m,\n\u001b[0;32m   1230\u001b[0m     path: \u001b[38;5;28mstr\u001b[39m,\n\u001b[1;32m   (...)\u001b[0m\n\u001b[0;32m   1237\u001b[0m     stream_cls: \u001b[38;5;28mtype\u001b[39m[_StreamT] \u001b[38;5;241m|\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[0;32m   1238\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m ResponseT \u001b[38;5;241m|\u001b[39m _StreamT:\n\u001b[0;32m   1239\u001b[0m     opts \u001b[38;5;241m=\u001b[39m FinalRequestOptions\u001b[38;5;241m.\u001b[39mconstruct(\n\u001b[0;32m   1240\u001b[0m         method\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mpost\u001b[39m\u001b[38;5;124m\"\u001b[39m, url\u001b[38;5;241m=\u001b[39mpath, json_data\u001b[38;5;241m=\u001b[39mbody, files\u001b[38;5;241m=\u001b[39mto_httpx_files(files), \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39moptions\n\u001b[0;32m   1241\u001b[0m     )\n\u001b[1;32m-> 1242\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m cast(ResponseT, \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcast_to\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mopts\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream_cls\u001b[49m\u001b[43m)\u001b[49m)\n",
      "File \u001b[1;32mc:\\Users\\FahRe\\AppData\\Local\\Programs\\Python\\Python312\\Lib\\site-packages\\openai\\_base_client.py:919\u001b[0m, in \u001b[0;36mSyncAPIClient.request\u001b[1;34m(self, cast_to, options, remaining_retries, stream, stream_cls)\u001b[0m\n\u001b[0;32m    916\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[0;32m    917\u001b[0m     retries_taken \u001b[38;5;241m=\u001b[39m \u001b[38;5;241m0\u001b[39m\n\u001b[1;32m--> 919\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_request\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m    920\u001b[0m \u001b[43m    \u001b[49m\u001b[43mcast_to\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mcast_to\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    921\u001b[0m \u001b[43m    \u001b[49m\u001b[43moptions\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43moptions\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    922\u001b[0m \u001b[43m    \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    923\u001b[0m \u001b[43m    \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream_cls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    924\u001b[0m \u001b[43m    \u001b[49m\u001b[43mretries_taken\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mretries_taken\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    925\u001b[0m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[1;32mc:\\Users\\FahRe\\AppData\\Local\\Programs\\Python\\Python312\\Lib\\site-packages\\openai\\_base_client.py:1023\u001b[0m, in \u001b[0;36mSyncAPIClient._request\u001b[1;34m(self, cast_to, options, retries_taken, stream, stream_cls)\u001b[0m\n\u001b[0;32m   1020\u001b[0m         err\u001b[38;5;241m.\u001b[39mresponse\u001b[38;5;241m.\u001b[39mread()\n\u001b[0;32m   1022\u001b[0m     log\u001b[38;5;241m.\u001b[39mdebug(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mRe-raising status error\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m-> 1023\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_make_status_error_from_response(err\u001b[38;5;241m.\u001b[39mresponse) \u001b[38;5;28;01mfrom\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[0;32m   1025\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_process_response(\n\u001b[0;32m   1026\u001b[0m     cast_to\u001b[38;5;241m=\u001b[39mcast_to,\n\u001b[0;32m   1027\u001b[0m     options\u001b[38;5;241m=\u001b[39moptions,\n\u001b[1;32m   (...)\u001b[0m\n\u001b[0;32m   1031\u001b[0m     retries_taken\u001b[38;5;241m=\u001b[39mretries_taken,\n\u001b[0;32m   1032\u001b[0m )\n",
      "\u001b[1;31mBadRequestError\u001b[0m: Error code: 400 - {'error': {'message': \"Missing required parameter: 'tools[0].function'.\", 'type': 'invalid_request_error', 'param': 'tools[0].function', 'code': 'missing_required_parameter'}}"
     ]
    }
   ],
   "source": [
    "from openai import OpenAI\n",
    "from openai import OpenAI\n",
    "import pandas as pd\n",
    "import json\n",
    "from dotenv import load_dotenv\n",
    "import os\n",
    "import yaml\n",
    "\n",
    "load_dotenv()\n",
    "\n",
    "with open(\"config.yaml\", \"r\") as file:\n",
    "     config = yaml.safe_load(file)\n",
    "\n",
    "\n",
    "client = OpenAI(api_key=config[\"OPENAI_KEY_TEST\"],)\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "response = client.chat.completions.create(\n",
    "  model=\"gpt-4o\",\n",
    "  max_tokens=16384,\n",
    "  messages=[\n",
    "    {\n",
    "      \"role\": \"system\",\n",
    "      \"content\": [\n",
    "        {\n",
    "          \"text\": \"You are a pharmaceutical data expert and data extraction specialist. Your task is to compile a comprehensive list of all drug molecules for which an FDA decision is expected in 2025, including those with FDA Priority Review. This list must be detailed and organized by indication and expected approval date.\\n\\nGather the following details for each molecule:\\n\\n- **Indication**\\n- **Expected Approval Date**\\n- **Brand Name and Active Ingredient**\\n- **Product Attributes**\\n- **Application Forms** (e.g., pen, prefilled syringe, film-coated tablet, capsule, etc.)\\n- **Storage Conditions** (especially whether cooling is required)\\n- **Relevant Patient Groups**\\n- **Information for Doctors, Pharmacies, and Patients**\\n- **Mechanism of Action, Contraindications, Side Effects, Interactions, and Training Notes**\\n- **Approved Competitive Products**\\n- **Sources**\\n\\nEnsure accuracy by cross-checking data from reputable sources and note any uncertainties encountered during the information collection process.\\n\\n# Steps\\n\\n1. Extract a list of molecules with an FDA decision expected in 2025.\\n2. Organize the data by indication and expected approval date.\\n3. Collect and compile detailed information for each molecule as listed above.\\n4. Use placeholders for data specific to individual drugs where necessary.\\n5. Validate the collected data against credible sources to ensure accuracy.\\n\\n# Output Format\\n\\nPresent the results in a detailed table format, where each row represents a molecule, and the columns align with the aforementioned data fields.\\n\\n# Examples\\n\\n- **Indication:** [Example Indication]\\n- **Expected Approval Date:** [Date]\\n- **Brand Name and Active Ingredient:** [Brand Name] (Active Ingredient)\\n- **Product Attributes:** [Attributes]\\n- **Application Forms:** [Forms]\\n- **Storage Conditions:** [Conditions]\\n- **Relevant Patient Groups:** [Groups]\\n- **Information for Doctors, Pharmacies, Patients:** [Information]\\n- **Mechanism of Action, Contraindications, Side Effects, Interactions, and Training Notes:** [Details]\\n- **Approved Competitive Products:** [Products]\\n- **Sources:** [Source Information]\\n\\n(Note: These are placeholders. Real examples should be completed with accurate and specific data.)\\n\\n# Notes\\n\\n- Pay particular attention to any molecules marked for FDA Priority Review, as these often have implications for earlier approval.\\n- If data discrepancies arise, ensure to document sources and note the details of any uncertainties.\\n- Ensure that the information is up-to-date and reflects the most recent submissions and reviews from the FDA.\",\n",
    "          \"type\": \"text\"\n",
    "        }\n",
    "      ]\n",
    "    },\n",
    "    {\n",
    "      \"role\": \"user\",\n",
    "      \"content\": [\n",
    "        {\n",
    "          \"text\": \"Create a complete table of all molecules for all indications for which a decision by the US Food and Drug Administration (FDA) is expected in 2025, including FDA Priority Review. The list is sorted by indication and expected approval date. Furthermore, the list includes: brand name, active ingredient, product properties, forms of application (including dosage forms such as pen, prefilled syringe, film-coated tablet, capsule, etc.), storage conditions (especially whether cooling is required), special patient groups, and information for physicians, pharmacies, and patients, including mechanism of action, contraindications, side effects, interactions and training instructions, and approved competitor products.\\nAll right. I will compile a complete list of all medications (molecules) for which an FDA decision is expected in 2025 – including all indications and both regular and Priority Reviews.\\nThe overview will be sorted by indication and expected approval date. For each product, I will provide the following information: · Brand name and active ingredient · Product properties · Forms of application (including dosage forms such as pen, prefilled syringe, film-coated tablet, etc.) · Storage conditions (especially whether cooling is required) · Relevant patient groups · Information for physicians, pharmacies, and patients · Mechanism of action, contraindications, side effects, interactions, and training instructions · Approved competitor products\\nI will get back to you as soon as I have compiled the results for you.\",\n",
    "          \"type\": \"text\"\n",
    "        }\n",
    "      ]\n",
    "    },\n",
    "    {\n",
    "      \"role\": \"assistant\",\n",
    "      \"content\": [\n",
    "        {\n",
    "          \"type\": \"text\",\n",
    "          \"text\": \"For example :  As of March 31, 2025, the U.S. Food and Drug Administration (FDA) has approved several novel drugs and vaccines, with additional decisions anticipated throughout the year. Below is a comprehensive table of these medications, organized by indication and expected approval date. Each entry includes detailed information on the brand name, active ingredient, product properties, forms of application, storage conditions, special patient groups, and pertinent information for healthcare providers and patients.\\n\\n| Indication | Expected Approval Date | Brand Name | Active Ingredient | Product Properties | Forms of Application | Storage Conditions | Special Patient Groups | Mechanism of Action | Contraindications | Side Effects | Interactions | Training Instructions | Approved Competitor Products |\\n|------------|------------------------|------------|-------------------|--------------------|----------------------|--------------------|------------------------|---------------------|-------------------|--------------|-------------|----------------------|------------------------------|\\n| **Tenosynovial Giant Cell Tumor** | February 14, 2025 | Romvimza | Vimseltinib | Switch-control kinase inhibitor targeting CSF1R | Oral capsules | Store at room temperature | Adults with symptomatic tenosynovial giant cell tumor | Inhibits CSF1R to reduce tumor growth | Hypersensitivity to vimseltinib | Fatigue, nausea, liver enzyme elevation | Potential interactions with CYP3A4 inhibitors | Patients should be monitored for liver function | None approved |\\n| **Neurofibromatosis Type 1 with Symptomatic Plexiform Neurofibromas** | February 11, 2025 | Gomekli | Mirdametinib | MEK inhibitor | Oral capsules | Store at room temperature | Pediatric and adult patients with NF1 and inoperable tumors | Inhibits MEK1/2 to reduce tumor size | Hypersensitivity to mirdametinib | Rash, diarrhea, elevated creatine phosphokinase | Avoid concomitant use with strong CYP3A4 inhibitors | Regular monitoring of cardiac function recommended | None approved |\\n| **Moderate to Severe Acute Pain** | January 30, 2025 | Journavx | Suzetrigine | Non-opioid analgesic, sodium channel blocker | Oral tablets (50 mg) | Store at room temperature | Adults requiring short-term pain management | Selectively inhibits NaV1.8 sodium channels to block pain signals | Hypersensitivity to suzetrigine | Dizziness, headache, gastrointestinal discomfort | Caution with other CNS depressants | Patients should be advised on potential CNS effects | Opioid analgesics (e.g., hydrocodone) |\\n| **Acute Myeloid Leukemia and Myelodysplastic Syndrome** | January 21, 2025 | Grafapex | Treosulfan | Alkylating agent used in conditioning regimens | Intravenous infusion | Refrigerate; protect from light | Patients undergoing allogeneic hematopoietic stem cell transplantation | Cross-links DNA to inhibit cell division | Hypersensitivity to treosulfan | Myelosuppression, mucositis, hepatotoxicity | Increased toxicity with other myelosuppressive agents | Healthcare providers should monitor blood counts and organ function | Busulfan |\\n| **Unresectable or Metastatic HR-Positive, HER2-Negative Breast Cancer** | January 17, 2025 | Datroway | Datopotamab deruxtecan-dlnk | Antibody-drug conjugate targeting TROP2 | Intravenous infusion | Refrigerate; protect from light | Adults with prior endocrine-based therapy and chemotherapy | Delivers cytotoxic agent to TROP2-expressing cancer cells | Hypersensitivity to components | Nausea, neutropenia, interstitial lung disease | Caution with other immunosuppressants | Patients should be monitored for pulmonary symptoms | Sacituzumab govitecan |\\n| **Meningococcal Disease Prophylaxis** | February 14, 2025 | Penmenvy | Meningococcal groups A, B, C, W, and Y vaccine | Lyophilized powder for injection | Intramuscular injection | Refrigerate; do not freeze | Individuals aged 10 through 25 years | Induces immunity against Neisseria meningitidis serogroups A, B, C, W, and Y | Severe allergic reaction to vaccine components | Injection site reactions, fever, headache | None significant | Healthcare providers should be prepared for anaphylaxis management | Menveo, Bexsero |\\n| **Chikungunya Disease Prevention** | February 14, 2025 | Vimkunya | Chikungunya vaccine, recombinant | Injectable suspension | Intramuscular injection | Refrigerate; do not freeze | Individuals aged 12 years and older | Induces immunity against chikungunya virus | Severe allergic reaction to vaccine components | Injection site reactions, fever, myalgia | None significant | Patients should be monitored for allergic reactions post-vaccination | None approved |\\n| **Diabetes Mellitus** | February 14, 2025 | Merilog | Insulin aspart-szjj | Rapid-acting human insulin analog biosimilar to NovoLog | Subcutaneous injection | Refrigerate; do not freeze | Adults and pediatric patients with diabetes mellitus | Facilitates glucose uptake by cells | Hypoglycemia, hypersensitivity to insulin aspart | Hypoglycemia, weight gain, injection site reactions | Caution with other glucose-lowering agents | Patients should be trained on injection technique and hypoglycemia management | NovoLog |\\n| **Uncomplicated Urinary Tract Infections** | March 26, 2025 (expected) | Gepotidacin | Gepotidacin | First-in-class oral antibiotic | Oral tablets | Store at room temperature | Female adults and adolescents with uUTIs | Inhibits bacterial DNA replication | Hypersensitivity to gepotidacin | Nausea, diarrhea, headache | Potential interactions with other antibiotics | Patients should complete the full course as prescribed | Nitrofurantoin, trimethoprim-sulfamethoxazole |\\n| **Hereditary Angioedema Attacks** | June 17, 2025 (expected) | Sebetralstat | Sebetralstat | Oral plasma kallikrein inhibitor | Oral disintegrating tablets | Store at room temperature | Patients aged 12 years and older with HAE | Inhibits plasma kallikrein to reduce bradykinin production | Hypersensitivity to sebetralstat | Nausea, headache, dizziness | Caution with other kallikrein inhibitors | Patients should be trained on recognizing and managing HAE attacks | Icatibant (injection) |\\n| **Vasomotor Symptoms Associated with Menopause** | July 26, 2025 (expected) | Elinzanetant | Elinzanetant | Dual NK-1 and NK-3 receptor antagonist | Oral tablets | Store at room temperature | Women experiencing moderate to severe VMS | Modulates KNDy neurons to reduce hot flashes | Hypersensitivity to elinzanetant | Nausea, headache, fatigue | Potential interactions with CYP3A4 inhibitors | Patients should be informed about the non-hormonal nature of the treatment | Hormone replacement therapy |\\n| **H3 K27M-Mutant Diffuse Glioma** | August 18, 2025 (expected \"\n",
    "        }\n",
    "      ]\n",
    "    },\n",
    "    {\n",
    "      \"role\": \"user\",\n",
    "      \"content\": [\n",
    "        {\n",
    "          \"type\": \"text\",\n",
    "          \"text\": \"This is too short... it need to be logner-\"\n",
    "        }\n",
    "      ]\n",
    "    },\n",
    "    {\n",
    "      \"role\": \"user\",\n",
    "      \"content\": [\n",
    "        {\n",
    "          \"type\": \"text\",\n",
    "          \"text\": \"retry: Erstelle vollständige Tabelle aller Moleküle von allen Indikationen für die im Jahr 2025 eine Entscheidung der US-amerikanischen Food and Drug Administration (FDA) erwartet wird inklusive FDA Priority Review. Die Liste ist nach Indikation und erwartetem Zulassungsdatum sortiert. Die Liste umfasst im Weiteren: Brandname, Wirkstoff, Produkteigenschaften, Applikationsformen (einschließlich Darreichungsformen wie Pen, Fertigspritze, Filmtablette, Kapsel usw.), Lagerungsbedingungen (insbesondere ob eine Kühlung erforderlich ist), spezielle Patientengruppen, Informationen für Ärzte, Apotheken und Patienten, inklusive Wirkmechanismus, Kontraindikationen, Nebenwirkungen, Interaktionen und Schulungshinweisen, zugelassene Konkurrenzprodukte\\\\nAlles klar. Ich stelle eine vollständige Liste aller Arzneimittel (Moleküle) zusammen, für die im Jahr 2025 eine FDA-Entscheidung erwartet wird – einschließlich aller Indikationen und sowohl regulärer als auch Priority Reviews.\\\\nDie Übersicht wird nach Indikation und erwartetem Zulassungsdatum sortiert. Zu jedem Produkt werde ich die folgenden Informationen angeben:\\\\n·         Brandname und Wirkstoff\\\\n·         Produkteigenschaften\\\\n·         Applikationsformen (inkl. Darreichungsformen wie Pen, Fertigspritze, Filmtablette usw.)\\\\n·         Lagerungsbedingungen (v. a. ob Kühlung erforderlich ist)\\\\n·         Relevante Patientengruppen\\\\n·         Informationen für Ärzte, Apotheken und Patienten\\\\n·         Wirkmechanismus, Kontraindikationen, Nebenwirkungen, Interaktionen und Schulungshinweise\\\\n·         Zugelassene Konkurrenzprodukte\\\\nIch melde mich, sobald ich die Ergebnisse für dich zusammengestellt habe.\"\n",
    "        }\n",
    "      ]\n",
    "    }\n",
    "  ],\n",
    "  response_format={\n",
    "    \"type\": \"json_schema\",\n",
    "    \"json_schema\": {\n",
    "      \"name\": \"fda_drug_approvals_2025\",\n",
    "      \"schema\": {\n",
    "        \"type\": \"object\",\n",
    "        \"required\": [\"molecules\"],\n",
    "        \"properties\": {\"molecules\": {\"type\": \"array\",\"items\": {\"type\": \"object\",\"required\": [\n",
    "                \"indication\",\n",
    "                \"expected_approval_date\",\n",
    "                \"brand_name\",\n",
    "                \"active_ingredient\",\n",
    "                \"product_properties\",\n",
    "                \"competitor_products\",\n",
    "                \"sources\"],\n",
    "        \"properties\": {\n",
    "                \"brand_name\": {\n",
    "                  \"type\": \"string\",\n",
    "                  \"description\": \"The brand name of the medication.\"\n",
    "                },\n",
    "                \"indication\": {\n",
    "                  \"type\": \"string\",\n",
    "                  \"description\": \"The medical indication for which the drug is intended.\"\n",
    "                },\n",
    "                \"sources\": {\n",
    "                  \"type\": \"string\",\n",
    "                  \"description\": \"Source urls for the information provided.\"\n",
    "                },\n",
    "                \"active_ingredient\": {\n",
    "                  \"type\": \"string\",\n",
    "                  \"description\": \"The active ingredient contained in the medication.\"\n",
    "                },\n",
    "                \"product_properties\": {\n",
    "                  \"type\": \"object\",\n",
    "                  \"required\": [\n",
    "                    \"formulations\",\n",
    "                    \"storage_conditions\",\n",
    "                    \"special_patient_groups\",\n",
    "                    \"info_for_healthcare\"\n",
    "                  ],\n",
    "                  \"properties\": {\n",
    "                    \"formulations\": {\n",
    "                      \"type\": \"array\",\n",
    "                      \"items\": {\n",
    "                        \"type\": \"string\"\n",
    "                      },\n",
    "                      \"description\": \"Different formulations of the product.\"\n",
    "                    },\n",
    "                    \"storage_conditions\": {\n",
    "                      \"type\": \"string\",\n",
    "                      \"description\": \"Conditions under which the medication should be stored, including cooling requirements.\"\n",
    "                    },\n",
    "                    \"info_for_healthcare\": {\n",
    "                      \"type\": \"object\",\n",
    "                      \"required\": [\n",
    "                        \"mechanism_of_action\",\n",
    "                        \"contraindications\",\n",
    "                        \"side_effects\",\n",
    "                        \"interactions\",\n",
    "                        \"training_instructions\"\n",
    "                      ],\n",
    "                      \"properties\": {\n",
    "                        \"interactions\": {\n",
    "                          \"type\": \"array\",\n",
    "                          \"items\": {\n",
    "                            \"type\": \"string\"\n",
    "                          },\n",
    "                          \"description\": \"Known interactions with other drugs or substances.\"\n",
    "                        },\n",
    "                        \"side_effects\": {\n",
    "                          \"type\": \"array\",\n",
    "                          \"items\": {\n",
    "                            \"type\": \"string\"\n",
    "                          },\n",
    "                          \"description\": \"Potential adverse effects of the drug.\"\n",
    "                        },\n",
    "                        \"contraindications\": {\n",
    "                          \"type\": \"array\",\n",
    "                          \"items\": {\n",
    "                            \"type\": \"string\"\n",
    "                          },\n",
    "                          \"description\": \"Conditions or factors that would make the drug unsafe or inappropriate to use.\"\n",
    "                        },\n",
    "                        \"mechanism_of_action\": {\n",
    "                          \"type\": \"string\",\n",
    "                          \"description\": \"How the drug works in the body.\"\n",
    "                        },\n",
    "                        \"training_instructions\": {\n",
    "                          \"type\": \"string\",\n",
    "                          \"description\": \"Instructions for training on how to use the medication.\"\n",
    "                        }\n",
    "                      },\n",
    "                      \"description\": \"Information for healthcare professionals and patients.\",\n",
    "                      \"additionalProperties\": False\n",
    "                    },\n",
    "                    \"special_patient_groups\": {\n",
    "                      \"type\": \"array\",\n",
    "                      \"items\": {\n",
    "                        \"type\": \"string\"\n",
    "                      },\n",
    "                      \"description\": \"Groups of patients for whom special considerations may apply.\"\n",
    "                    }\n",
    "                  },\n",
    "                  \"description\": \"Properties of the product that are relevant for understanding its characteristics.\",\n",
    "                  \"additionalProperties\": False\n",
    "                },\n",
    "                \"competitor_products\": {\n",
    "                  \"type\": \"array\",\n",
    "                  \"items\": {\n",
    "                    \"type\": \"string\"\n",
    "                  },\n",
    "                  \"description\": \"Other approved products that serve as competitors.\"\n",
    "                },\n",
    "                \"expected_approval_date\": {\n",
    "                  \"type\": \"string\",\n",
    "                  \"description\": \"The anticipated date of FDA approval.\"\n",
    "                }\n",
    "              },\n",
    "              \"additionalProperties\": False\n",
    "            },\n",
    "            \"description\": \"A list of all molecules for which FDA decisions are expected in 2025, sorted by indication and expected approval date.\"\n",
    "          }\n",
    "        },\n",
    "        \"additionalProperties\": False\n",
    "      },\n",
    "      \"strict\": True\n",
    "    }\n",
    "  },\n",
    "  reasoning={},\n",
    "  tools=[{\"type\": \"web_search\"}],\n",
    "  store=True\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'{\"molecules\": [{\"brand_name\": \"Vykat XR\", \"indication\": \"Prader-Willi-Syndrom\", \"sources\": \"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-greenlights-first-ever-treatment-rare-metabolic-disorder-2025-03-26/\", \"active_ingredient\": \"Diazoxid-Cholin\", \"product_properties\": {\"formulations\": [\"Retardtabletten\"], \"storage_conditions\": \"Bei Raumtemperatur lagern\", \"info_for_healthcare\": {\"interactions\": [\"Vorsicht bei gleichzeitiger Anwendung mit blutdrucksenkenden Medikamenten\"], \"side_effects\": [\"Übelkeit\", \"Schwindel\", \"Hypoglykämie\"], \"contraindications\": [\"Überempfindlichkeit gegen Diazoxid\"], \"mechanism_of_action\": \"Aktiviert ATP-sensitive Kaliumkanäle, reduziert die Sekretion appetitanregender Neuropeptide\", \"training_instructions\": \"Patienten sollten über die Erkennung und Behandlung von Hypoglykämie informiert werden\"}, \"special_patient_groups\": [\"Kinder ab 4 Jahren mit Prader-Willi-Syndrom\"]}, \"competitor_products\": [\"Keine zugelassenen Konkurrenzprodukte\"], \"expected_approval_date\": \"2025-03-26\"}, {\"brand_name\": \"Cardamyst\", \"indication\": \"Paroxysmale supraventrikuläre Tachykardie (PSVT)\", \"sources\": \"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-milestone-pharmas-heart-rhythm-nasal-spray-2025-03-28/\", \"active_ingredient\": \"Etripamil\", \"product_properties\": {\"formulations\": [\"Nasenspray\"], \"storage_conditions\": \"Bei Raumtemperatur lagern\", \"info_for_healthcare\": {\"interactions\": [\"Vorsicht bei gleichzeitiger Anwendung mit anderen Kalziumkanalblockern\"], \"side_effects\": [\"Nasenreizungen\", \"Schwindel\", \"Kopfschmerzen\"], \"contraindications\": [\"Überempfindlichkeit gegen Etripamil\"], \"mechanism_of_action\": \"Blockiert Kalziumkanäle, verlangsamt die AV-Überleitung\", \"training_instructions\": \"Patienten sollten in der korrekten Anwendung des Nasensprays geschult werden\"}, \"special_patient_groups\": [\"Erwachsene mit PSVT\"]}, \"competitor_products\": [\"Keine zugelassenen Konkurrenzprodukte\"], \"expected_approval_date\": \"2025-03-27\"}, {\"brand_name\": \"Zenocutuzumab\", \"indication\": \"NRG1-positive Krebserkrankungen\", \"sources\": \"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-extends-review-merus-gene-targeting-cancer-therapy-2024-11-05/\", \"active_ingredient\": \"Zenocutuzumab\", \"product_properties\": {\"formulations\": [\"Intravenöse Infusion\"], \"storage_conditions\": \"Kühl lagern; vor Licht schützen\", \"info_for_healthcare\": {\"interactions\": [\"Vorsicht bei gleichzeitiger Anwendung mit anderen monoklonalen Antikörpern\"], \"side_effects\": [\"Übelkeit\", \"Fatigue\", \"Infusionsreaktionen\"], \"contraindications\": [\"Überempfindlichkeit gegen Zenocutuzumab\"], \"mechanism_of_action\": \"Blockiert NRG1-Fusionen, hemmt Tumorwachstum\", \"training_instructions\": \"Gesundheitspersonal sollte in der Verabreichung und Überwachung von Infusionen geschult werden\"}, \"special_patient_groups\": [\"Erwachsene mit NRG1-positiven soliden Tumoren\"]}, \"competitor_products\": [\"Keine zugelassenen Konkurrenzprodukte\"], \"expected_approval_date\": \"2025-02-04\"}, {\"brand_name\": \"Apitegromab\", \"indication\": \"Spinale Muskelatrophie (SMA)\", \"sources\": \"https://www.reuters.com/business/healthcare-pharmaceuticals/scholar-rocks-genetic-disease-drug-meets-main-goal-late-stage-trial-2024-10-07/\", \"active_ingredient\": \"Apitegromab\", \"product_properties\": {\"formulations\": [\"Intravenöse Infusion\"], \"storage_conditions\": \"Kühl lagern; vor Licht schützen\", \"info_for_healthcare\": {\"interactions\": [\"Vorsicht bei gleichzeitiger Anwendung mit anderen Muskelrelaxantien\"], \"side_effects\": [\"Kopfschmerzen\", \"Infusionsreaktionen\", \"Übelkeit\"], \"contraindications\": [\"Überempfindlichkeit gegen Apitegromab\"], \"mechanism_of_action\": \"Hemmt Myostatin, fördert Muskelwachstum\", \"training_instructions\": \"Gesundheitspersonal sollte in der Verabreichung und Überwachung von Infusionen geschult werden\"}, \"special_patient_groups\": [\"Kinder und Erwachsene mit SMA\"]}, \"competitor_products\": [\"Spinraza\", \"Zolgensma\", \"Evrysdi\"], \"expected_approval_date\": \"2025-01-31\"}, {\"brand_name\": \"Revakinagene taroretcel (NT-501)\", \"indication\": \"Makuläre Teleangiektasie Typ 2\", \"sources\": \"https://primetherapeutics.com/fda-decisions-expected-march-2025\", \"active_ingredient\": \"Revakinagene taroretcel\", \"product_properties\": {\"formulations\": [\"Implantat\"], \"storage_conditions\": \"Kühl lagern; vor Licht schützen\", \"info_for_healthcare\": {\"interactions\": [\"Keine bekannten Wechselwirkungen\"], \"side_effects\": [\"Augenreizung\", \"Fremdkörpergefühl\", \"Sehverschlechterung\"], \"contraindications\": [\"Überempfindlichkeit gegen Revakinagene taroretcel\"], \"mechanism_of_action\": \"Kontinuierliche Freisetzung von CNTF zur Reduktion des Photorezeptorverlusts\", \"training_instructions\": \"Chirurgen sollten in der Implantationstechnik geschult werden\"}, \"special_patient_groups\": [\"Erwachsene mit Makulärer Teleangiektasie Typ 2\"]}, \"competitor_products\": [\"Keine zugelassenen Konkurrenzprodukte\"], \"expected_approval_date\": \"2025-03-18\"}, {\"brand_name\": \"Rivoceranib + Camrelizumab\", \"indication\": \"Nicht resezierbares oder metastasiertes hepatozelluläres Karzinom\", \"sources\": \"https://primetherapeutics.com/fda-decisions-expected-march-2025\", \"active_ingredient\": \"Rivoceranib und Camrelizumab\", \"product_properties\": {\"formulations\": [\"Orale Tabletten (Rivoceranib)\", \"Intravenöse Infusion (Camrelizumab)\"], \"storage_conditions\": \"Rivoceranib: Bei Raumtemperatur lagern; Camrelizumab: Kühl lagern; vor Licht schützen\", \"info_for_healthcare\": {\"interactions\": [\"Vorsicht bei gleichzeitiger Anwendung mit anderen Immuntherapien\"], \"side_effects\": [\"Hyper '"
      ]
     },
     "execution_count": 124,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "response = response.choices[0].message.content\n",
    "response\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 127,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "First 500 characters of cleaned output:\n",
      "{\"molecules\": [{\"brand_name\": \"Vykat XR\", \"indication\": \"Prader-Willi-Syndrom\", \"sources\": \"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-greenlights-first-ever-treatment-rare-metabolic-disorder-2025-03-26/\", \"active_ingredient\": \"Diazoxid-Cholin\", \"product_properties\": {\"formulations\": [\"Retardtabletten\"], \"storage_conditions\": \"Bei Raumtemperatur lagern\", \"info_for_healthcare\": {\"interactions\": [\"Vorsicht bei gleichzeitiger Anwendung mit blutdrucksenkenden Medikamenten\"], \n"
     ]
    }
   ],
   "source": [
    "import demjson3\n",
    "raw_output = response.strip()\n",
    "if raw_output.startswith(\"```\") and raw_output.endswith(\"```\"):\n",
    "    raw_output = raw_output.strip(\"```\")\n",
    "    if raw_output.lstrip().startswith(\"json\"):\n",
    "        raw_output = raw_output.lstrip()[len(\"json\"):].strip()\n",
    "print(\"First 500 characters of cleaned output:\")\n",
    "print(raw_output[:500])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 130,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Raw output saved to raw_output.txt\n",
      "Error parsing JSON: String literal is not terminated\n",
      "Failed to repair JSON: String literal is not terminated\n"
     ]
    }
   ],
   "source": [
    "import demjson3\n",
    "import json\n",
    "\n",
    "# Save raw output for inspection\n",
    "with open(\"raw_output.txt\", \"w\", encoding=\"utf-8\") as f:\n",
    "    f.write(raw_output)\n",
    "print(\"Raw output saved to raw_output.txt\")\n",
    "\n",
    "try:\n",
    "    # Try to parse with standard json first\n",
    "    data = json.loads(raw_output)\n",
    "except json.JSONDecodeError:\n",
    "    # If that fails, use demjson3 which is more tolerant\n",
    "    try:\n",
    "        data = demjson3.decode(raw_output)\n",
    "        print(\"Successfully parsed with demjson3\")\n",
    "    except demjson3.JSONDecodeError as e:\n",
    "        print(f\"Error parsing JSON: {e}\")\n",
    "        # Attempt to repair the JSON by adding closing brackets\n",
    "        repaired_json = raw_output\n",
    "        if '\"molecules\":' in raw_output and not raw_output.strip().endswith('}'):\n",
    "            # Check if we're missing closing brackets for array and/or object\n",
    "            if '[' in raw_output and ']' not in raw_output[-5:]:\n",
    "                repaired_json += \"]}\"\n",
    "            elif not repaired_json.strip().endswith('}'):\n",
    "                repaired_json += \"}\"\n",
    "            \n",
    "            try:\n",
    "                data = demjson3.decode(repaired_json)\n",
    "                print(\"Successfully parsed after repairing JSON\")\n",
    "            except Exception as e:\n",
    "                print(f\"Failed to repair JSON: {e}\")\n",
    "                # Create a minimal valid structure to avoid errors in subsequent cells\n",
    "                data = {\"molecules\": []}\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 131,
   "metadata": {},
   "outputs": [],
   "source": [
    "# dict to an excel file \n",
    "import pandas as pd\n",
    "df = pd.DataFrame(data[\"molecules\"])\n",
    "df.to_excel(\"FDA_2025_molecules.xlsx\", index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 162,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\FahRe\\AppData\\Local\\Temp\\ipykernel_12116\\1510796883.py:102: PydanticDeprecatedSince20: The `schema` method is deprecated; use `model_json_schema` instead. Deprecated in Pydantic V2.0 to be removed in V3.0. See Pydantic V2 Migration Guide at https://errors.pydantic.dev/2.11/migration/\n",
      "  \"schema\": ProductOverview.schema()\n"
     ]
    }
   ],
   "source": [
    "from openai import OpenAI\n",
    "from pydantic import BaseModel\n",
    "from typing import List\n",
    "import pandas as pd\n",
    "import json\n",
    "from dotenv import load_dotenv\n",
    "import os\n",
    "import yaml\n",
    "\n",
    "# Define Pydantic models with strict validation\n",
    "class ApprovedCompetingProduct(BaseModel):\n",
    "    product_name: str\n",
    "    source_url: str\n",
    "\n",
    "    class Config:\n",
    "        extra = \"forbid\"\n",
    "\n",
    "class InformationFor(BaseModel):\n",
    "    doctors: str\n",
    "    pharmacies: str\n",
    "    patients: str\n",
    "\n",
    "    class Config:\n",
    "        extra = \"forbid\"\n",
    "\n",
    "class ProductProperties(BaseModel):\n",
    "    description: str\n",
    "    application_forms: List[str]\n",
    "    storage_conditions: str\n",
    "    relevant_patient_groups: List[str]\n",
    "    information_for: InformationFor\n",
    "    mechanism_of_action: str\n",
    "    contraindications: str\n",
    "    side_effects: str\n",
    "    interactions: str\n",
    "    training_instructions: str\n",
    "    approved_competing_products: List[ApprovedCompetingProduct]\n",
    "\n",
    "    class Config:\n",
    "        extra = \"forbid\"\n",
    "\n",
    "class ProductOverview(BaseModel):\n",
    "    brand_name: str\n",
    "    product_properties: ProductProperties\n",
    "\n",
    "    class Config:\n",
    "        extra = \"forbid\"\n",
    "\n",
    "# Load configuration (API key etc.)\n",
    "load_dotenv()\n",
    "\n",
    "with open(\"config.yaml\", \"r\") as file:\n",
    "    config = yaml.safe_load(file)\n",
    "\n",
    "client = OpenAI(api_key=config[\"OPENAI_KEY_TEST\"])\n",
    "\n",
    "# Call the API with the desired input and output format\n",
    "response = client.responses.create(\n",
    "    model=\"gpt-4o-2024-11-20\",\n",
    "    input=[\n",
    "        {\n",
    "            \"role\": \"system\",\n",
    "            \"content\": [\n",
    "                {\n",
    "                    \"type\": \"input_text\",\n",
    "                    \"text\": (\n",
    "                        \"You are a pharmaceutical data expert and data extraction specialist. Your task is to compile a comprehensive list of all drug molecules for which an FDA decision is expected in 2025, including those with FDA Priority Review. This list must be detailed and organized by indication and expected approval date.\\n\\n\"\n",
    "                        \"Gather the following details for each molecule:\\n\\n\"\n",
    "                        \"- **Indication**\\n\"\n",
    "                        \"- **Expected Approval Date**\\n\"\n",
    "                        \"- **Brand Name and Active Ingredient**\\n\"\n",
    "                        \"- **Product Attributes**\\n\"\n",
    "                        \"- **Application Forms** (e.g., pen, prefilled syringe, film-coated tablet, capsule, etc.)\\n\"\n",
    "                        \"- **Storage Conditions** (especially whether cooling is required)\\n\"\n",
    "                        \"- **Relevant Patient Groups**\\n\"\n",
    "                        \"- **Information for Doctors, Pharmacies, and Patients**\\n\"\n",
    "                        \"- **Mechanism of Action, Contraindications, Side Effects, Interactions, and Training Notes**\\n\"\n",
    "                        \"- **Approved Competitive Products**\\n\"\n",
    "                        \"- **Sources**\\n\\n\"\n",
    "                        \"Ensure accuracy by cross-checking data from reputable sources and note any uncertainties encountered during the information collection process.\"\n",
    "                    )\n",
    "                }\n",
    "            ]\n",
    "        },\n",
    "        {\n",
    "            \"role\": \"user\",\n",
    "            \"content\": [\n",
    "                {\n",
    "                    \"type\": \"input_text\",\n",
    "                    \"text\": (\n",
    "                        \"Now give me a complete table of all molecules for all indications for which a decision by the US Food and Drug Administration (FDA) is expected in 2025, including FDA Priority Review. The list is sorted by indication and expected approval date. Furthermore, the list includes: brand name, active ingredient, product properties, forms of application (including dosage forms such as pen, prefilled syringe, film-coated tablet, capsule, etc.), storage conditions (especially whether cooling is required), special patient groups, and information for physicians, pharmacies, and patients, including mechanism of action, contraindications, side effects, interactions and training instructions, and approved competitor products.\\n\"\n",
    "                    )\n",
    "                }\n",
    "            ]\n",
    "        }\n",
    "    ],\n",
    "    text={\n",
    "        \"format\": {\n",
    "            \"type\": \"json_schema\",\n",
    "            \"name\": \"product_overview\",\n",
    "            \"strict\": True,\n",
    "            \"schema\": ProductOverview.schema()\n",
    "        }\n",
    "    },\n",
    "    reasoning={},\n",
    "    tools=[{\"type\": \"web_search\"}],\n",
    "    temperature=0.97,\n",
    "    max_output_tokens=9030,\n",
    "    top_p=1,\n",
    "    store=True\n",
    ")\n",
    "\n",
    "if response.status == \"incomplete\" and response.incomplete_details.reason == \"max_output_tokens\":\n",
    "    print(\"Ran out of tokens\")\n",
    "    if response.output_text:\n",
    "        print(\"Partial output:\", response.output_text)\n",
    "    else:\n",
    "        print(\"Ran out of tokens during reasoning\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 163,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\"brand_name\":\"Suzetrigine\",\"product_properties\":{\"description\":\"Suzetrigine is a non-opioid pain medication developed for the treatment of moderate-to-severe acute pain. It functions as an oral, selective inhibitor of NaV1.8, a voltage-gated sodium channel that plays a critical role in pain signaling in the peripheral nervous system.\",\"application_forms\":[\"Oral tablet\"],\"storage_conditions\":\"Store at room temperature; no special cooling required.\",\"relevant_patient_groups\":[\"Adults with moderate-to-severe acute pain\"],\"information_for\":{\"doctors\":\"Suzetrigine offers a non-opioid alternative for managing acute pain, potentially reducing the risk of addiction associated with opioid use.\",\"pharmacies\":\"Ensure proper dispensing and patient education regarding the non-opioid nature and administration of suzetrigine.\",\"patients\":\"Suzetrigine is a non-opioid medication designed to manage acute pain without the risks associated with opioids.\"},\"mechanism_of_action\":\"Suzetrigine selectively inhibits the NaV1.8 sodium channel, which is involved in transmitting pain signals in the peripheral nervous system.\",\"contraindications\":\"Patients with known hypersensitivity to suzetrigine or any of its components should avoid use.\",\"side_effects\":\"Common side effects may include nausea, dizziness, and headache. Consult a healthcare provider for a complete list.\",\"interactions\":\"Potential interactions with other medications have not been fully established; consult a healthcare provider for guidance.\",\"training_instructions\":\"Patients should be instructed on the proper oral administration of suzetrigine and advised to report any adverse effects to their healthcare provider.\",\"approved_competing_products\":[{\"product_name\":\"Acetaminophen\",\"source_url\":\"https://www.drugs.com/acetaminophen.html\"},{\"product_name\":\"Ibuprofen\",\"source_url\":\"https://www.drugs.com/ibuprofen.html\"}]}}   \n"
     ]
    }
   ],
   "source": [
    "print(response.output_text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[\n",
      "  {\n",
      "    \"id\": \"ws_67ea9eb223248191bc5bb250f6bfcd320348dd1be5657452\",\n",
      "    \"status\": \"completed\",\n",
      "    \"type\": \"web_search_call\"\n",
      "  },\n",
      "  {\n",
      "    \"id\": \"msg_67ea9eb50e248191955475841847cdc10348dd1be5657452\",\n",
      "    \"content\": [\n",
      "      {\n",
      "        \"annotations\": [],\n",
      "        \"text\": \"{\\\"brand_name\\\":\\\"Suzetrigine\\\",\\\"product_properties\\\":{\\\"description\\\":\\\"Suzetrigine is a non-opioid pain medication developed for the treatment of moderate-to-severe acute pain. It functions as an oral, selective inhibitor of NaV1.8, a voltage-gated sodium channel that plays a critical role in pain signaling in the peripheral nervous system.\\\",\\\"application_forms\\\":[\\\"Oral tablet\\\"],\\\"storage_conditions\\\":\\\"Store at room temperature; no special cooling required.\\\",\\\"relevant_patient_groups\\\":[\\\"Adults with moderate-to-severe acute pain\\\"],\\\"information_for\\\":{\\\"doctors\\\":\\\"Suzetrigine offers a non-opioid alternative for managing acute pain, potentially reducing the risk of addiction associated with opioid use.\\\",\\\"pharmacies\\\":\\\"Ensure proper dispensing and patient education regarding the non-opioid nature and administration of suzetrigine.\\\",\\\"patients\\\":\\\"Suzetrigine is a non-opioid medication designed to manage acute pain without the risks associated with opioids.\\\"},\\\"mechanism_of_action\\\":\\\"Suzetrigine selectively inhibits the NaV1.8 sodium channel, which is involved in transmitting pain signals in the peripheral nervous system.\\\",\\\"contraindications\\\":\\\"Patients with known hypersensitivity to suzetrigine or any of its components should avoid use.\\\",\\\"side_effects\\\":\\\"Common side effects may include nausea, dizziness, and headache. Consult a healthcare provider for a complete list.\\\",\\\"interactions\\\":\\\"Potential interactions with other medications have not been fully established; consult a healthcare provider for guidance.\\\",\\\"training_instructions\\\":\\\"Patients should be instructed on the proper oral administration of suzetrigine and advised to report any adverse effects to their healthcare provider.\\\",\\\"approved_competing_products\\\":[{\\\"product_name\\\":\\\"Acetaminophen\\\",\\\"source_url\\\":\\\"https://www.drugs.com/acetaminophen.html\\\"},{\\\"product_name\\\":\\\"Ibuprofen\\\",\\\"source_url\\\":\\\"https://www.drugs.com/ibuprofen.html\\\"}]}}   \",\n",
      "        \"type\": \"output_text\"\n",
      "      }\n",
      "    ],\n",
      "    \"role\": \"assistant\",\n",
      "    \"status\": \"completed\",\n",
      "    \"type\": \"message\"\n",
      "  }\n",
      "]\n"
     ]
    }
   ],
   "source": [
    "import json\n",
    "print(response.output_text)\n",
    "print(json.dumps(response.output, default=lambda o: o.__dict__, indent=2))"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
